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Abstract 
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system 
(CNS) that affects primarily young adults. The initial relapsing-remitting phase, characterized 
by transitory attacks of inflammatory demyelination, is treatable with immunomodulatory 
interventions while the later progressive stage of the disease is as yet untreatable. During 
disease progression the slow accumulation of cortical grey matter (GM) demyelination 
seems to reflect the nature of neurological symptoms and has been strongly associated with 
the presence of a compartmentalized immune response within the meninges. We 
hypothesized that a secluded chronic interaction of immune cells within the meningeal 
compartment is the mechanism underlying the accumulation of cortical damage during this 
phase. Our aims were to: characterize the phenotypes of immune cells contributing to 
meningeal inflammation; to describe their possible interactions; and to verify their 
association with GM pathology. This analysis, also performed in white matter, was aimed at 
comparing the inflammation in the two compartments. In parallel we correlated the 
pathological findings with clinical milestones to test the hypothesis of cortical pathology as a 
substrate for clinical progression. We performed a detailed quantitative 
immunohistochemical analysis on a cohort of 21 post-mortem progressive MS cases by 
sampling 483 brain tissue blocks provided by UK MS Tissue Bank.  
The proportion of demyelinated tissue in the GM was approximately four times greater than 
in WM and positively correlated with the presence in the subarachnoid space of a pro-
inflammatory lymphocyte subset identified by the expression of CD8+ and CD161+ and with 
the density of MHCII+ microglia in the cortex. We showed that the most frequent lymphocytic 
subsets quantified in the MS brain were, in decreasing order, CD8+ T cells, CD20+ B cells, 
CD4+ T and CD8+CD161+ T cells. Furthermore, we identified the presence of mucosal 
associated invariant T (MAIT) cells, a novel IL-17 secreting subset of CD161+ lymphocytes 
expressing CCR6 and invariant TCRVα7.2, within the subarachnoid space and in WM 
perivascular infiltrates. In addition we reported that a higher density of meningeal 
inflammation correlates with a younger age at death 
These findings showed the presence of a pro-inflammatory response compartmentalized 
within the meninges of the MS brain, which was associated with an exacerbated cortical 
pathology and a more severe disease course, in particular affecting its late progressive 
phase. These observations support our hypothesis of a role of meningeal inflammation in the 
accumulation of cortical pathology during progressive MS. This detrimental immune 
activation within the meninges is a potential target for localized therapeutic interventions 
aiming to prevent or arrest its development during the progressive phase of the disease. 
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1.1 Multiple sclerosis 
MS is the most common disease of the CNS to cause permanent disability in young adults, 
with 85,000 sufferers in the UK alone (Noseworthy et al., 2000). A variety of motor, sensor 
and cognitive dysfunctions characterize this disease depending on the presence of 
inflammatory foci of demyelination (lesions) that are found throughout the brain and the 
spinal cord (Compston and Coles, 2008). The causes of tissue damage are thought to be 
immune-mediated and currently there are no effective treatments for its progressive form.  
1.1.1 Epidemiology  
The prevalence of MS varies considerably around the world (Weinshenker, 1994). Therefore 
a classification of different regions according to prevalence has been proposed: a region is 
considered of low prevalence if there are less than 5 cases per 100,000 persons, while in 
regions with intermediate prevalence there are up to 30 cases per 100,000 persons. In 
regions, such as northern Europe, southern Australia and the middle part of North America, 
characterized by a high prevalence, observations report more than 30 cases per 100,000 
(Kurtzke, 1991). The number of women affected by MS is approximately double than the 
number of affected men (2008). The incidence of MS observed over the past 30 years has 
increased in Canadian women showing a significant change in the female to male ratio to 
more than 3:1 (Orton et al., 2006).   
1.1.2 Aetiology 
The reasons for the variability in MS prevalence worldwide are not fully understood but 
environmental and genetic explanations have been formulated. 
1.1.2.1 Environmental factors 
The environmental influence has been based on observed occurrence of rapid shifts in the 
prevalence of multiple sclerosis (Kurtzke and Hyllested, 1987) as well as the apparent 
change in its frequency among people (Alter et al., 1966, Dean, 1967) and their offspring 
(Elian et al., 1990) who migrated to and from high-prevalence regions. In particular the 
comparison of MS incidence between the migrating population and the population of origin 
has revealed that the risk of MS correlate with the place of residence in childhood (Dean and 
Kurtzke, 1971, Alter et al., 1962, Detels et al., 1977).  However, the environmental factors 
with the strongest evidence for involvement in MS have been shown to be the infection with 
Epstein - Barr virus (EBV), the exposure to smoking and the distance north or south of the 
equator which has been linked with sunlight exposure and vitamin D serum levels. 
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The role of EBV in the development of MS has been proposed on the basis of serological 
observations showing that nearly all individuals with MS (>99%) have been found to have 
been infected with EBV compared with approximately 94% of age-matched controls and that 
MS occurrence is very rare, although not impossible, in adults who have never been infected 
with EBV (Ascherio and Munger, 2007, Thacker et al., 2006).  Notably, individuals with a 
history of infectious mononucleosis have an increased risk of developing MS (Nielsen et al., 
2007, Ramagopalan et al., 2009) and also paediatric cases of EBV infection have been 
associated to the development of MS (Banwell et al., 2007). In addition people with high 
titres of anti-EBV antibodies, observed several years before the onset of the neurological 
symptoms, have a higher risk of developing MS compared with those with low titres 
(Sundstrom et al., 2004, Levin et al., 2005). This temporal sequence in both paediatric and 
adult onset of MS supports causality. However, these observations might also indicate that 
in MS patients an early EBV infection and mononucleosis are just evidences of an 
abnormality of the individual immune response. It is then this abnormal response that 
underlies MS risk rather than a viral reactivation per se. Furthermore reports on other factors 
such as geographical region and data from migration studies suggest that the timing of 
exposure is a crucial determinant of risk for MS, particularly for EBV infection that might 
happen very early in life. Since EBV infection is nearly ubiquitous in adults with MS, 
inhibiting EBV infection could be suggested as a potential option of preventive intervention. 
However, the implications of an EBV vaccination strategy at a population level are currently 
unknown and they need to be explored carefully.  
Another environmental factor is the geographical latitude. It has been shown that the more it 
increases the higher is the prevalence of MS within regions of temperate climate (Kurtzke, 
1980). The proposed explanation for this phenomenon is that insufficient sunlight exposure, 
together with low intake of dietary of Vitamin D, is associated with low serum levels of 25-
hydroxyvitamin D which in turn has been linked with increased susceptibility to MS (van der 
Mei et al., 2003, Munger et al., 2004). Besides epidemiological evidence, genetic findings 
also support a protective role of Vitamin D in MS. For example a rare loss-of-function 
mutation in CYP27B1, which encodes a vitamin D-activating enzyme, has recently been 
identified in patients with MS (Ramagopalan et al., 2011). More recently the effects of 
vitamin D on T cells have been investigated showing that vitamin D inhibits CD4+ T cells 
proliferation in RRMS patients and in controls as well as induces an increase in IL-10 
producing T cells and a decrease in IL-17 producing T cells (Correale et al., 2011). These 
observations indicate that vitamin D plays an important role in shaping T cell responses 
towards an immunosuppressive phenotype and that its decrease might impair mechanisms 
of immune regulation.  
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1.1.2.2 Genetics 
Evidence that genetic factors have a substantial effect on susceptibility to MS has been 
shown by genetic epidemiological studies (Dyment et al., 2004). Family studies assessing 
risk to relatives of MS probands have revealed a marked familial aggregation of the disease 
(Sadovnick et al., 1988, Robertson et al., 1996, Willer et al., 2003, Ebers et al., 2004) and 
first-degree relatives are generally at 10-25 times greater risk of developing MS than the 
general population. Concordance rates in monozygotic twins are commonly reported at 
around 30%, indicating both a partial genetic influence, but also substantial environmental 
influence on susceptibility (Dyment et al., 2004). In addition ethnic origin has also been 
shown to play a part in the development of MS: there is evidence of lower prevalence of MS 
in African Americans men (risk is 40% lower than White American men) and also Native 
Americans, Mexicans, Puerto Ricans, Japanese, Filipinos and Chinese exhibit a virtual 
absence of the disease (Kurtzke et al., 1979). MS is more frequent in women than in men 
(Orton et al., 2006, Wallin et al., 2004, Hirst et al., 2009) and since genome-wide studies did 
not provide any convincing support for any MS-associated genes on the X chromosome it is 
thought that the increased incidence of MS in women might be related to environmental and 
female-specific physiology (Whitacre, 2001).  
Genome wide studies have been performed in different MS subtypes (Martinelli-Boneschi et 
al., 2012) and populations (Marrosu et al., 2001, Dean et al., 2008), but no single major 
susceptibility polymorphism has been identified although the strongest association is found 
for one or more susceptibility genes in the area of the human leukocyte antigen (HLA) genes 
on chromosome 6 (Masterman et al., 2000, Jersild et al., 1973). The class II linkage in MS 
differs in various populations with the highest association with HLA-DR2 (BRB1*1501)/DQ6 
(DQB1*0602) (McDonald, 1984, Oksenberg et al., 1993). In addition a study by Dyment et 
al. has shown that DRB1*17 (DR3) allele is also associated with MS susceptibility (Dyment 
et al., 2005). Given that the association of HLA-DRB1 and MS susceptibility is definite, a 
number of studies have tried to investigate which HLA-DRB1 alleles may play a role in 
disease clinical outcome. However, the results have been inconsistent and contradictory: 
some alleles are associated with severe outcome (Barcellos et al., 2003), some with benign 
outcome (DeLuca et al., 2007, Silva et al., 2007) and some with no effects on disease 
severity (Barcellos et al., 2006, Smestad et al., 2007). Therefore it has been proposed that 
the disease outcome might be influenced by the complex interactions of a hierarchy of 
susceptibility and resistance “haplotypes” (Ramagopalan et al., 2008, Ramagopalan et al., 
2007). 
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Nevertheless genome-wide association studies managed to uncover other genes with a 
modest effect in MS but interestingly with a function in the immune response like interleukin-
7 receptor α (IL7RA), interleukin-2 receptor α (IL2RA), C-type lectin-domain family 16 
member A (CLEC16A), CD58 (formerly lymphocyte function-associated antigen 3), tumor-
necrosis-factor receptor superfamily member 1A (TNFRSF1A), interferon regulatory factor 8 
(IRF8) and CD6 (De Jager et al., 2009, Hafler et al., 2007, Patsopoulos et al., 2011, Sawcer 
et al., 2011, Kemppinen et al., 2011). These analyses also show that a striking number of 
immunologically-relevant genes, particularly those involved in the T helper differentiation 
pathway and acting as cell surface receptors, are significantly over-represented amongst 
those mapping close to the identified loci, supporting the idea that the immune system plays 
an essential role in the development of MS. 
1.1.3 The disease course of MS: the relapsing-remitting and the 
progressive forms 
The onset of neurological symptoms is characterized in the majority of MS patients by an 
episode, or relapse, of loss of one or more functions which are related to the central nervous 
system (CNS) region which has been affected (Compston and Coles, 2008). A period of 
recovery, or remission, from these dysfunctions follows during the early stages of the 
disease course, which is therefore termed the relapsing-remitting phase (RRMS) of MS. New 
attacks happen at random intervals but initially average about 1.5 per year, decreasing 
steadily with time. Longitudinal MRI and clinical data show that, if in the beginning these 
symptoms are accompanied by white matter abnormality at clinically unaffected sites, 
therefore fulfilling the criteria for relapsing-remitting multiple sclerosis (RRMS), patients are 
far more likely to convert to MS than those with a normal scan (82% vs 21%). Nevertheless it 
must be kept in consideration that the remaining 18% of those with abnormal scan at 
presentation did not develop MS (Fisniku et al., 2008). The phase during which periods of 
disease and amelioration alternate comes to an end when new disabilities start accumulating 
without signs of remission. This secondary phase is therefore called progressive (SPMS). 
However for the 20% of the patients progression characterizes the disease directly from 
onset and this MS course is thus named primary progressive (PPMS). Interestingly, both 
these courses have in common the age at which progression starts, at around 40 years of 
age (Confavreux and Vukusic, 2006). It has also been reported a progressive relapsing MS, 
which is a rare MS subtype characterized by neurological progression from onset, with 
superimposed relapses thereafter (Andersson et al., 1999) (Fig 1.1).  
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Figure 1.1 MS disease course: the relapsing-remitting and the progressive phase  
On top graph the EDSS scale on the Y axis indicates the level of disability in time (X axis): 
green columns represent relapses while remissions consist in the time of recovery between 
them. This phase of the disease is termed: relapsing-remitting. Usually around 40 years of 
age, symptoms start accumulating constantly without remission: this phase of the disease is 
termed secondary progressive. For about 20% of patients the disease course is 
characterized by progressive onset around the same age and therefore termed primary 
progressive. On bottom graph the red line shows the constant decrease of brain volume 
during the whole disease course: while RRMS is characterized by new inflammatory lesions 
(yellow), the SPMS and the PPMS are instead characterized by a constant and slow accrual 
of axonal loss (violet). Adapted from Compston and Coles, 2002. 
Whereas irreversible disability occurs sooner after clinical onset in primary progressive MS 
than in patients with an initial relapsing-remitting course, the time course from onset of 
progressive disability is similar in PPMS and SPMS (Confavreux et al., 2000). Disability in 
MS is quantified according to the Kurtzke Expanded Disability Status Scale (EDSS) that, by 
assigning a score to eight different functional systems, produces a scale ranging from 0 to 
10 units (Kurtzke, 1983). In RRMS cases the estimated median time to secondary 
progressive is 15 years and after 25 years from onset >80% of patients have entered the 
secondary progressive phase with a median EDSS level of 3. Further it is established that 
neither the risk of entering the secondary progressive phase nor the latency of onset of 
progression are related to the total number of attacks during the relapsing-remitting phase 
(Kremenchutzky et al., 2006, Scalfari et al., 2010). Half of all patients diagnosed with MS will 
not be able to walk unaided 15 years after diagnosis, with disability fixed and worsening 
during progressive disease (Weinshenker, 1994). The median duration of the disease is 
approximately 30 years from diagnosis, giving a reduction in life expectancy of 5-10 years 
compared with the general population. Death is attributable to complications of MS in 
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approximately 60% of cases (Bronnum-Hansen et al., 2004). Currently there is no effective 
treatment for progressive MS (Pender and Wolfe, 2002).  
1.1.4 The pathological features of multiple sclerosis: white matter 
demyelination 
More than a century has passed since the first description of the clinical and pathological 
characteristics of MS by Charcot, Carswell, Cruveilhier and others but this relapsing-
remitting and eventually progressive disorder of CNS continues to challenge investigators 
trying to understand its causes and pathogenesis to prevent the disease progression 
(Noseworthy, 1999). There is wide agreement that MS is an immune-mediated disorder that 
can be triggered by environmental factors in genetically susceptible people (Hohlfeld and 
Wekerle, 2001) however the sequence of events that initiate the disease remain largely 
unknown. Given the clinical and pathological diversity of this desease probably more than 
one pathogenic mechanisms contributes to tissue injury and therefore more than one 
therapeutical approach will need to be developed.  
The pathological hallmark of chronic MS, after which the disease has been named, is the 
presence of many demyelinated plaques disseminated in the white matter (WM) all over the 
CNS. Most common pathological findings defining a plaque are a well-demarcated 
hypocellular white matter area characterized by loss of myelin and axons and the formation 
of an astrocytic scar. Lesions can involve the optic nerves, periventricular areas, brain stem, 
cerebellum and spinal cord. Although lesions in tissue sections often appear with a round or 
oval shape, they often have a finger-like extension along the path of small or medium sized 
blood vessels (Dawson’s fingers). Another common observation is the presence of 
inflammatory cells that are typically found in perivascular spaces but also as diffuse 
infiltrates in the parenchyma. It seems that the composition of the inflammatory infiltrate 
varies depending on the developmental stage of the demyelinating lesion although, in 
general, T lymphocytes and macrophages prevail, with the latter seemingly characterizing 
active lesions. In order to draw meaningful conclusions regarding the earliest immunological 
and molecular events contributing to the formation of a lesion, only actively demyelinating 
plaques should be considered. Classically, the identification of myelin-degradation products 
inside macrophages, thus termed engulfed or “foamy” macrophages, is the most reliable 
methods to find an active lesion (Lassmann et al., 1998). However it must be noted that 
when stringent criteria are used to define lesional activity, the frequency of active plaques in 
patients with chronic multiple sclerosis is extremely low. The numerous activated 
macrophages and also microglial cells, commonly associated with demyelinated plaques, 
may mediate degradation through the production of soluble toxic factors, such as tumor 
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necrosis factor (TNF), interferon-γ (IFN-γ), reactive oxygen or nitrogen species, proteolytic 
and lypolitic enzymes and excitatory amino acids (Hanisch, 2002, Hanisch and Kettenmann, 
2007, Kreutzberg, 1996).  
Also B cells and antibodies play an essential role in the formation of the demyelinated 
plaque in WM. In fact antibodies against antigens located on the surface of the myelin 
sheath or oligodendrocytes can cause demyelination directly through the activation of 
complement (Piddlesden et al., 1993). In addition, antibodies against both myelin 
oligodendrocyte glycoprotein and myelin basic protein can be identified in the MS brain 
(Raine et al., 1999) and deposits of immunoglobulins and activated complement are a 
common finding in white matter lesions (Compston et al., 1989, Prineas et al., 2001). 
Evidence of an antibody–mediated demyelination is supported by a rat model of 
experimental autoimmune encephalomyelitis (EAE), an animal model of brain inflammation 
resembling CNS demyelinating diseases, in which an increased demyelination after the 
administration of antibody specific for myelin oligodendrocyte glycoprotein (MOG) has been 
observed (Linington et al., 1988). Taken together these observations are strongly suggestive 
that antibody-mediated mechanisms have an important role in the pathogenesis of white 
matter lesions.  
Although remyelination is minimal in lesions associated with chronic multiple sclerosis, 
plaques in acute and early phase of the disease course, can show extensive, although not 
completely reversed to normal, remyelination and therefore named “shadow plaques”. 
Remyelination has been shown to be reduced in aged animals in part due to changes in the 
environmental signals regulating it (Hinks and Franklin, 2000) and to be affected by 
epigenetic changes within aging oligodendrocyte precursor cells (OPCs), which decrease 
their ability to differentiate into remyelinating oligodendrocytes (Shen et al., 2008, Tang et 
al., 2000). These age-dependent effects might mirror, and may in part determine, a well-
recognized feature of many chronically demyelinated MS lesions, which is the presence 
OPCs (Wolswijk, 1998) that fail to differentiate into myelinating oligodendrocytes (Kuhlmann 
et al., 2008). Thus therapeutical strategies aiming at promoting endogenous remyelination 
need to be developed (Ruckh et al., 2012). Early symptoms of multiple sclerosis are widely 
believed to result from axonal demyelination that ultimately slows or blocks the conduction of 
the action potentials. The regression of symptoms, observed during remissions, has been 
attributed to the resolution of inflammatory oedema and to partial remyelination but other 
mechanisms, like the presence of cytokines and oxidative stress are likely intervene at this 
stage (Moreno et al., 2011, Smith, 2011). Irreversible axonal injury, gliotic scarring, and 
exhaustion of the oligodendrocyte progenitor pool may finally occur after repeated relapses 
and ultimately lead to loss of neurologic function. These events leading to axonal loss might 
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also be underlying the early episodes of inflammatory demyelination but the beginning of the 
MS pathogenesis is still unclear and debated (Trapp et al., 1998, Lucchinetti et al., 1999, 
Bitsch et al., 2000).  
1.2 Cortical pathology  
For many years, the observation of focal inflammatory demyelination in the white matter has 
been considered the pathological “hallmark” of multiple sclerosis. However, demyelination in 
the cerebral cortex had already been observed in early pathology studies by Sander 
(Sander, 1898), Dinkler (Dinkler, 1904), Schob (Schob, 1907) and Dawson (Dawson, 1916). 
After these initial, largely casual, reports of demyelination in the gray matter (GM) of MS 
patients, the topic has been largely disregarded (Brownell and Hughes, 1962). This was 
mostly due to difficulties involved in the visualization of cortical grey matter lesions in the 
post-mortem MS brain with the available immunostaining procedures as well as to the 
predominant attention for generally more eye-catching white matter plaques.  However in 
2003, when new immunohistochemical stainings techniques that sensitively improved the 
detection of GM damage became available, the presence and the extent of GM 
demyelination could be described in detail and the possible pathophysiological processes 
causing it became a central issue in MS research. The attention slowly shifted back from 
white matter to grey matter visualization also with modern magnetic resonance imaging 
(MRI) techniques.  
These observations were also accompanied by two emerging facts in MS pathology: first, 
the presence of substantial inflammatory infiltrates in the meninges and second, the 
emerging concept that the cerebrospinal fluid (CSF) and the meningeal space play a role in 
the immunopathogenesis of MS. In fact there is now extensive evidence, based on 
pathology reports, showing that the presence of immune cells infiltrates in the leptomeninges 
overlying the cerebrum is a common feature (Frischer et al., 2009, Guseo and Jellinger, 
1975, Kutzelnigg et al., 2005, Magliozzi et al., 2007). At the same time experiments on EAE, 
the animal model mimicking MS, have shown that the anatomic localization of initial T cell 
interaction with antigen presenting cells, leading to their activation within the CNS, occurs in 
the subarachnoid space before the onset of symptoms (Bartholomaus et al., 2009, Kivisakk 
et al., 2009). Taken together these observations contribute to describe the meninges as an 
immunologically specialized compartment where immune surveillance takes place under 
physiological conditions and where the immune system is reactivated during pathological 
processes occurring within the CNS. These concepts are thus contributing to the 
reassessment of the role played by the immune cells present in the meningeal compartment 
in the immunopathology of MS. 
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1.2.1 Magnetic Resonance Imaging and cortical pathology: the 
“clinico-radiological” paradox 
If the diagnosis of MS is not possible on the basis of clinical evidence then a MRI scan can 
show focal or confluent abnormalities in white matter in more than 95% of patients. However 
their presence alone does not make the diagnosis of multiple sclerosis since characteristic 
radiological lesions can also appear in people without clinical signs of disease (Compston 
and Coles, 2008). Therefore a MRI scan is repeated later on in order to fulfil one of 
diagnostic criteria for MS based on the principle of dissemination of lesions both in time and 
in space (Polman et al., 2005). In fact it is widely accepted that the presence of gadolinium 
(Gd-DTPA) enhancing lesions detected on MRI scan in white matter is associated with 
changes in blood brain barrier (BBB) permeability and with the presence of active 
macrophage infiltrates in relation to demyelination (Hawkins et al., 1990, Katz et al., 1993, 
Nesbit et al., 1991, Bruck et al., 1997). In MS, virtually all new and MRI-visible lesions go 
through a phase of Gd-DTPA enhancement persisting for two to eight weeks and the 
number of enhancing lesions correlates with a number of clinical measures, of which the 
occurrence of a relapse is the most evident. Such a sensitive disease measure might really 
be helpful to closely monitor disease progression during its whole duration, if it was not for a 
phenomenon that has been called the “clinico-radiological paradox” (Filippi et al., 1995a, 
Filippi et al., 1995b). In fact it has been observed that after the relapsing-remitting phase of 
the disease the patients’ clinical symptoms progressively worsen, while there is no 
corresponding change to the lesion load detected by the MRI scans.  
This evidence, taken together with the histological reports describing the extent of grey 
matter lesions, have pushed the research towards the development of MRI protocols 
sensitive enough to detect cortical pathology. On the contrary to what is described for white 
matter, the detection of grey matter pathology with conventional T2-weighted MRI has been 
much more difficult because of the intrinsically low density of myelin in the cortex that 
generates a little contrast between normal and demyelinated GM. Furthermore cortical 
lesions are small and partial volume effect with CSF in the sulci can interfere with reliable 
lesions detection (Kidd et al., 1999, Newcombe et al., 1991). In order to increase the 
sensitivity of the detection of cortical lesions on MRI, techniques such as fast fluid-
attenuated inversion recovery (FLAIR) MR sequence have been developed (Boggild et al., 
1996, Rovaris et al., 1997) showing an improvement when compared to the conventional 
MRI (Gawne-Cain et al., 1997, Filippi et al., 1996, Tubridy et al., 1999, Bakshi et al., 2001) 
although still reporting a lower prevalence of cortical damage than that reported in post-
mortem studies (Boggild et al., 1996). In 1994, a new MRI technique, the double inversion 
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recovery (DIR), was introduced providing the possibility to clearly distinguish the signal from 
the cerebral cortex and the WM in the healthy human subjects by suppression of the signal 
from WM and the CSF (Redpath and Smith, 1994) and was then applied to image GM 
pathology in MS brain several years later (Geurts et al., 2005b). 
A number of important scientific contributions by Calabrese and colleagues have 
subsequently confirmed histopathology studies on the grey matter by reporting that 
intracortical grey matter lesions, detected with DIR, are already present early in the disease 
course (Bagnato et al., 2006, Calabrese et al., 2010a, Calabrese et al., 2010b) and are 
found also in relapse onset and patients with PPMS (Calabrese et al., 2009). Observations 
made by this group showed further that SPMS male patients, notably those positive for IgG 
oliclonal bands in the CSF, exhibit cortical lesions more frequently (Calabrese et al., 2007b, 
Roosendaal et al., 2009) whereas patients with benign MS are relatively spared (Calabrese 
and Gallo, 2009). Measurements of cortical pathology have been then correlated with the 
clinical progression to show associations with clinical disability, brain volume loss and/or 
cognitive impairment (Calabrese et al., 2008, Calabrese et al., 2010d, Calabrese et al., 
2009). Analisys of patients has shown that cortical pathology increases in terms of size and 
number of lesions over time (Calabrese et al., 2010d). Whereas the detection of focal, and 
particularly subpial, lesions in the cortex is difficult using conventional MRI measures, 
another measure of cortical pathology, GM atrophy, has proven to be robust and reliable 
using the standard MRI sequences (Miller et al., 2002). A decreased volume, as well as 
cortical thinning, has been found to affect MS patients compared to healthy age-matched 
controls and has been also detected in the early phase of the disease course and across 
different MS types (Ge et al., 2001, Calabrese et al., 2007a, Calabrese et al., Sastre-Garriga 
et al., 2005, Tedeschi et al., 2005, Chard et al., 2004). During recent years MRI imaging has 
become more a widespread tool, not only for diagnostic purposes, but also to monitor the 
efficacy of therapies for MS. Therefore MRI imaging is becoming an increasingly relevant 
issue to understand the clinico-radiological paradox in MS.  
1.2.2 Meningeal inflammation and cortical pathology 
The pathology of GM lesions differs considerably from that of WM lesions: lymphocytic 
infiltration, both perivascular and parenchymal, complement deposition and BBB disruption 
have not been detected in the cortical pathology whereas WM lesions are frequently 
exhibiting substantial inflammation (Bo et al., 2003a, Brink et al., 2005, van Horssen et al., 
2007). The presence of abundant, sometimes florid, lymphocytic infiltrates in the meninges 
of the progressive MS brain had been described many years ago although not characterized 
in detail (Hassin, 1921). In more recent years a seminal study on 143 MS cases has 
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assessed the frequency of significant perivascular infiltrates in the meninges to reveal that 
they are a pathological finding in more than 40% of the progressive MS cases. For the first 
time this report also analyzed the relationship between the presence of active demyelination 
in the cortex and these infiltrates (Guseo and Jellinger, 1975) showing that, in the vast 
majority of the samples, lymphocytic extravasates in the meninges were spatially associated 
with active cortical demyelination. Notably in the same study the qualitative evaluation of 
inflammation in the meningeal compartment, as well as in the white matter, has been 
analyzed in parallel with clinical milestones, showing significant correlations between the 
increasing severity of active demyelination and lymphocytic infiltration with the decreasing 
duration of illness. Therefore this analytical approach has paved the way for future 
investigations on the nature of the immune cell within the meninges and their association 
with cortical pathology and disease course.  
Another early observation in the history of MS pathology, which has later induced the 
investigations to focus on meningeal inflammation, was made comparing the separation 
pattern of proteins, using electrophoresis, in the CSF and the blood serum of patients (Link 
and Huang, 2006). Kabat and his colleagues applied the electrophoresis technique to be 
able to separate proteins in serum and CSF showing that proteins migration patterns seen in 
healthy individuals are found to be similar in CSF and corresponding serum. In contrast, 
protein patterns that are observed in patients with neurosyphilis in particular, but also in MS, 
have revealed in CSF an increase in gamma globulin when compared to blood serum (Kabat 
et al., 1942). 70% of patients with MS have been found to have elevated proportions of 
proteins migrating as gamma globulin when related to total protein content, indirectly 
implicating that the source of this surplus must be located within the CNS (Yahr, 1954). 
Based on further results from purification of individual CSF and serum proteins with 
electrophoretic separation, it has been shown that the proteins in some of these bands 
consist of immunoglobulins G (IgG), while other bands co-migrating with IgG consist of other 
immunoglobulin classes or free light chains or CNS derived proteins (Link, 1967b, Link, 
1967a). These electrophoretic bands of proteins have been named oligoclonal bands 
(OCBs) based on the assumption that in inflammatory neurological diseases, like MS, a 
restricted number of B-cell clones, when compared to the periphery, occur to mature into Ig-
secreting plasma cells within the CNS and/or the CSF compartments. Clonally expanded  B 
cells in the CSF are strongly believed to be the source of the OCB (Obermeier et al., 2008) 
although this is still a complex and incompletely resolved issue. In regard to the specificity 
and the pathological significance of OCB in the CSF a recent study has shown that a 
significant proportion of these antibody response is directed against lipid antigens, in 
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particular sulphatide and heteromeric complexes containing sulfatide, a glycolipid highly 
enriched in the myelin membrane (Brennan et al., 2011).  
In keeping with these findings, suggestive of B cell somatic hypermutation and class switch 
recombination localized within the MS brain, a seminal pathological study has revealed the 
presence of ectopic follicle-like structures in the meninges (Serafini et al., 2004). Following 
this observation another pathological study on a wider cohort of MS cases has revealed a 
strong association between the presence of ectopic follicle-like structures in the meninges 
and more severe cortical pathology and disease course. In fact about 41% of the SPMS 
cases harbouring these organized inflammatory structures in the meninges are significantly 
different from those without in terms of a more pronounced demyelination, microglia 
activation and loss of neurites in the cortex. This study has also matched these pathological 
findings with clinical data for each patient showing that these cases have a younger age at 
onset and they reach irreversible disability and death earlier when compared to the follicle-
negative ones (Magliozzi et al., 2007). A more detailed analysis of the features of cortical 
pathology in follicle-positive cases has then revealed a gradient of neuronal loss, away from 
the first cortical layers into the deeper ones, accompanied by an opposite gradient of 
increased density of activated microglia (Magliozzi et al., 2010). A further study cemented 
the link between the inflammatory response occurring within the meninges and cortical 
pathology showing the analysis of 123 SPMS cases and reporting the presence of ectopic 
follicle like structures associated with an increase in widespread meningeal inflammation 
whose quantification correlates with the extent of grey matter demyelination and the degree 
of microglial acitvation (Howell et al., 2011).  
1.2.3 Antigen presentation in the meningeal compartment: the role of 
MHC class-II positive phagocytes   
The dynamics of immune cells interactions within the MS brain meningeal compartment, 
overlying cortical pathology, have become a matter of speculation and boosted further 
investigations using EAE. It has been shown that the triggering of an autoimmune response 
systemically may induce symptoms and demyelination patterns resembling MS and that 
activated T cells, specific for one or more neuroauto-antigens are induced to cross the BBB 
and penetrate the CNS where an amplification of the immune response, after the recognition 
of the cognate antigens presented by antigen-presenting cells, occurs (Zamvil and 
Steinman, 1990). A number of experiments have aimed at clarifying an enduring debate 
regarding the anatomic site responsible for the reactivation of encephalitogenic T cells and 
the development of the disease. In fact there are three major sites at which adoptively 
transferred encephalitogenic lymphocytes can encounter competent antigen-presenting cells 
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(APCs): the systemic immune compartment with its secondary lymphoid tissues, the CNS 
parenchyma harbouring microglia and astrocytes and the perivascular and meningeal space 
with its macrophages and dendritic cells (DCs). 
Therefore to seek proof whether macrophages and microglia are also capable of presenting 
antigen to auto-aggressive effector T cells in vivo, Greter and colleagues managed to create 
an adoptive transfer EAE model in which MHC class-II expression was restricted either to 
the CNS parenchyma or to the peripheral immune compartment and the blood-brain barrier 
and meninges. They have shown that the encephalitogenic T cell migration into the CNS is 
independent from lymphoid organs, that CNS-resident APCs, such as microglia or astrocytes 
are not required for T cells to recognize their cognate antigen in vivo and that instead it is the 
presence of MHC class-II positive DCs, although found in small numbers and associated 
with the BBB and meningeal blood vessels, that is necessary and sufficient to permit disease 
development (Greter et al., 2005). In addition another adoptive transfer EAE study, 
comparing different T cell lines stimulated with different myelin epitopes known to induce 
either mild or strong monophasic clinical EAE, has shown that the difference between highly 
and weakly pathogenic myelin-specific T cells was not related to their ability to enter the 
CNS, but to the degree these cells are reactivated after entry into the CNS (Kawakami et al., 
2004). In addition to this a previous EAE study had also shown that activated memory T cells 
enter the CSF from the systemic circulation through the choroid plexus and meningeal blood 
vessels to monitor the subarachnoid space as part of immune surveillance of the healthy 
CNS, in a P-selectin dependent manner (Kivisakk et al., 2003). A further study on this matter 
by the same research group, has analyzed the early phases of EAE, using flow cytometry, to 
show that CD4+ T cells accumulated and proliferated in the subarachnoid space before they 
could be detected in the spinal cord parenchyma (Kivisakk et al., 2009). In addition they 
have shown CD4+ T cells interacting with MHC class-II positive APCs in the subarachnoid 
space imaged using confocal time-lapse microscopy directly on ex-vivo leptomeningeal 
explants of mice before the onset of neurobehavioural signs of EAE. Another crucial 
evidence of antigen presentation occurring within the meningeal compartment by means of 
MHC class-II phagocytes in EAE model has been provided by Bartholomaus and his 
colleagues. Applying intravital two-photon imaging in a Lewis rat model of EAE, they 
presented the real time interactive processes of effector T cells on leptomeningeal vessels 
from their first arrival to manifest autoimmune disease. Interestingly, the incoming T cells 
adhere on meningeal vessels until complete arrest and then start scanning their luminal 
surface, crawling preferentially against the blood flow. After diapedesis, these cells keep on 
scanning the abluminal vascular surface and the underlying leptomeningeal (pial) 
membrane. There the T cells encounter phagocytes that effectively present antigens, foreign 
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as well as myelin proteins. These contacts stimulate the effector T cells to produce pro-
inflammatory mediators and provide a trigger to the formation of further inflammatory 
infiltration culminating in the onset of EAE (Bartholomaus et al., 2009). 
Only interstitial fluid (ISF) but no cells can drain from the brain along basement membranes  
between smooth muscles cells in the tunica media of arteries (Weller et al., 2009) and in the 
subarachnoid space (SAS) ISF is separated from CSF by just few layers of smooth muscles, 
adventitia and by a thin coating of pia-arachnoid. Therefore the pathways for the drainage of 
CSF and ISF show continuity at many places. The pia mater in fact consists of a very thin 
layer of cells (Alcolado et al., 1988, Feurer and Weller, 1991) and may be fully permeable to 
fluid and small molecules and, although it forms a barrier to particulate matter and 
erythrocytes, it does not appear to prevent the migration of macrophages (Krahn, 1981), 
which are able to have free mobility across it.  In keeping with these observations, by 30 min 
after injection of a fluorescent tracer into the caudate putamen of a mouse brain, the tracer is 
no longer present in the brain parenchyma or within the vascular basement membrane. 
However, the tracer can be found in perivascular macrophages on the outer aspects of 
artery walls in brain parenchyma and in the leptomeninges (Carare et al., 2008) (Fig 1.2 A, 
B).  
Taken together these evidences provide strong support that the subarachnoid space is 
indeed, at least in the EAE model, the place where antigen presentation and immune system 
activation takes place within the CNS. Whether these events could happen in a similar 
fashion in the human brain or whether meningeal inflammatory infiltrates even precede the 
formation of white matter lesions within the MS brain is still a matter of debate (Fig 1.2 C). 
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Figure 1.2 The role of perivascular meningeal macrophages: antigen uptake and 
immune cells (re)activation 
(A) A summary diagram showing how ISF and solutes (light green line) drain out of the brain 
along basement membranes between smooth muscle cells in the tunica media of arteries. 
Some smooth muscle cells (brown) in the tunica media (yellow) and perivascular 
macrophages on the outer aspect of the artery wall take up soluble tracer (cells coloured in 
light green) (Carare et al., 2008). Figure adapted from Weller 2009. (B) Diagram of the 
proposed route for the lymphatic drainage from the brain. ISF draining from the brain 
parenchyma along basement membranes of the leptomeningeal arteries is separated from 
the CSF by a layer of pia-arachnoid and continues through the base of the skull along the 
carotid artery to cervical lymph nodes. Figure adapted from Weller 2009. (C) Schematic 
picture of the possible invasion steps of autoreactive T cells into the CNS: (I) effector T cells 
(green) scan the luminal side of meningeal blood vessels (light blue), stop where adhesion 
molecules and chemokines are upregulated and by diapedesis (II) cross the blood vessels 
walls and start scanning the perivascular space (III) until they establish contact with 
perivascular/meningeal macrophages (orange-red) and become activated (yellow). Then 
they migrate into the CNS parenchyma to exert their effector functions. Figure adapted from 
Bartholomaus 2009. 
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1.2.4 The immunological specialization and compartmentalization of 
the immune response of the MS brain 
In the past the CNS has been traditionally described as an immunologically “privileged” site. 
This short definition is aimed at highlighting the immunological differences between the 
immune response observed within the brain and the other tissues. It is based on evidence 
showing that the rat sarcoma can grow well when injected into the mouse brain parenchyma 
but not when implanted subcutaneously or intramuscularly (Shirai, 1921). These results have 
then been confirmed over the years for tissue grafts (Medawar, 1948), bacteria (Matyszak 
and Perry, 1995), viruses (Stevenson et al., 1997) and vectors (Byrnes et al., 1996). Around 
the same time the blood-brain barrier was also being investigated and the two concepts 
developed together contributing to the idea that immune “privilege” of the brain was absolute 
and attributed wholly to the BBB. However, other experimental evidences revealed how 
rejection of a foreign tumor within the brain occured if it approached the ventricles (Murphy 
and Sturm, 1923) and if injection was directed into the ventricles (Mason et al., 1986). 
Therefore, as far as adaptive immunity is concerned, the privilege of the CNS is limited to 
the parenchyma and the immune reactivity of the ventricles, choroid plexus, meninges and 
circumventricular organs is similar to that of the periphery (Galea et al., 2007a). The CNS 
should rather be considered an immunologically “specialized” site where immune responses 
do occur but are strongly influenced by the local anatomical features.  
The anatomical substrate for these observations is to be found in the absence of 
conventional lymphatic drainage in the brain and in the ways in which lymphocytes can 
traffic to the CNS (Ransohoff et al., 2003). There are in fact three well-known and 
established routes for lymphocytes migration in to the CNS (Fig 1.3 A, B). The first route, 
from peripheral blood to CSF across the choroid plexus is likely the most common one under 
physiological conditions. In this migratory pathway, leukocytes can extravasate across the 
fenestrated endothelium of the choroid plexus stroma, then through the stromal core to the 
villi interacting also with these epithelial cells and finally enter the CSF at its site of formation. 
The CSF of an healthy individual contains about 3000 leukocytes per ml, 80% of which are T 
cells, in contrast to the maximum of 45% observed in blood, and notably less than 1% are B 
cells (Svenningsson et al., 1995). In the second route, from blood to subarachnoid space, 
leukocytes can traverse from the internal carotid artery, extravasating across postcapillary 
venules at the pial surface of the brain into the subarachnoid space and into the Virchow-
Robin perivascular spaces. This route is currently under investigation in various models of 
CNS inflammation using intravital microscopy (Gavins, 2011) . It has been shown that 
leukocytes rolling on these vessels are virtually absent in healthy conditions while after 
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application of different inflammatory stimuli their rolling is highly increased and is partially 
sensitive to antibody-mediated blockade of α4 integrin and absolutely dependent on P-
selectin (Kerfoot and Kubes, 2002). The third route, from blood to parenchymal perivascular 
space, is the one that allows the entry of inflammatory extravasates typically observed in 
white matter lesions. In this case leukocytes are required to cross the BBB and the 
endothelial basal lamina. Notably only activated T cell blasts can undergo this extravasation 
event which occurs independently from their antigen specificity (Hickey, 1999, Wekerle and 
Fierz, 1985).  The mechanisms of extravasation in this route have been recently investigated 
by intravital microscopy in an EAE model showing that highly activated neuroantigen-specific 
encephalitogenic lymphocytes failed to interact with parenchymal venules unless the vessels 
were previously activated by intravenous injection of lipopolysaccharide (LPS) or 
administration of TNF (Piccio et al., 2002). We must then consider the importance of 
leukocytes extravasation in the spinal cord since it is the pathology affecting this region that 
causes the most severe symptoms of MS. It seems that the mechanisms are similar to the 
ones observed in the cerebrum for the second and the third route although differences might 
arise depending on the molecular patterns of expression of adhesion molecules in the spinal 
blood vessels (Vajkoczy et al., 2001).  
These observations have wide-ranging and considerable clinical implications, particularly in 
MS because the CNS is not only the target of the pathological immune response but also 
becomes an immunological compartment itself during the progressive course of the disease. 
This phenomenon has been named compartmentalization of inflammation in the CNS and it 
has hypothesized to be a pathological mechanism driving progressive MS (Meinl et al., 
2008).  
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Figure 1.3 Three routes for leukocytes trafficking to the CNS and CSF flow 
(A) The arterial supply of the brain parenchyma is derived from terminal branches of the 
internal carotid arteries following the brain surface in the subarachnoid space (vessels 
highlighted in red). Arterial supply is also provided by other deep penetrating branches of the 
internal carotid artery. The three routes for leukocytes trafficking to the CNS are: (I) Route I- 
from blood to CSF across the choroid plexus, (II) Route II- from blood to the SAS, (III) Route 
III- from blood to perivascular parenchymal space (WM blood vessels sections are also 
indicated in red). The CSF is actively secreted by the choroid-plexus epithelium that is 
located in the ventricular system of the brain. The CSF flows from the ventricles to the SAS 
(arrows) and (B) is reabsorbed to the systemic circulation through the arachnoid villi that 
extend into the venous sinuses of the cerebral hemispheres.Adapted from Ransohoff et al. 
(2003).    
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The idea of an immunological compartmentalization of the CNS in respect to the periphery 
during chronic inflammation has been derived from different pathological observations made 
in the MS brain: intrathecal IgG production and detection of OCBs (Obermeier et al., 2008) 
accompanied by the detection of B cell follicle-like aggregates in the meninges (Magliozzi et 
al., 2007), an “anatomically friendly” environment fostering immune cells persistence (Meinl 
et al., 2006), inflammation accumulating beyond classical WM lesions accompanied by a 
generalized BBB disruption also far away from these active lesions (Kutzelnigg et al., 2005). 
It has also been hypothesized that the synergy of these immunopathological mechanisms 
might contribute to disease progession. Further an immune response secluded within the 
CNS might explain the fact that therapeutical interventions with a systemic action sort no 
beneficial effects for the patients entering the progressive phase of the disease. 
1.2.5 Role of microglia in cortical pathology 
Microglia cells, the resident immune cells of the brain, are named after their characteristic of 
being small (micro) and having a glue-like appearance (glia). Under physiological conditions, 
they are in a so-called “resting” state but constantly patrolling the cerebral microenvironment 
ready to respond to pathogens and disturbance of tissue homeostasis to shift their activity to 
what has been defined as “activated” state (Soulet and Rivest, 2008). Time-lapse imaging 
studies revealed the ability of microglia to undergo significant and rapid morphological 
changes, with de novo formation and withdrawal of processes as motile filopodium-like 
protrusion (Nimmerjahn et al., 2005). It is such a dynamic and careful reorganization of 
cellular ramifications that enable the otherwise stationary microglia to thoroughly scan their 
environment rapidly shifting towards the site of an injury when microlesions are induced. 
This response and its directional guidance apparently depend on purinoreceptor stimulation 
and may involve assistance from astrocytes (Davalos et al., 2005, Haynes et al., 2006). 
Therefore microglial activation can be identified by changes in shape, density and the 
upregulation of activation markers such as MHC class-II.  
These cells are present throughout the CNS, including the spinal cord, are isolated in the 
brain parenchyma by the BBB and their direct interaction with pathogens and other types of 
immune cells is therefore quite limited, at least in the intact brain.  Many molecules can 
trigger a transformation from the resting (or surveying) to the activated (alerted or reactive) 
state: like microbial structures, serum components, intracellular constituents, 
immunoglobulin-antigen complexes, opsonising complement, protein aggregates and pro-
inflammatory cytokines, which all have in common the fact that they indicate a threat to the 
structural and functional integrity of the CNS. Microglia cells change their response 
depending on the nature of noxious stimulus: when microglia are challenged by bacterial 
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invasion, phagocytosis occurs together with the release of inflammatory mediators (Hanisch 
et al., 2001, Hausler et al., 2002), by contrast when removing apoptotic cells or myelin 
debris, microglia relase anti-inflammatory factors (Magnus et al., 2001, Liu et al., 2006).  
A series of studies addressed the effects of adaptive immune responses on microglia 
focusing on reactions to INF-γ and IL-4, the T-cell master cytokines associated with T helper 
type 1 and 2 responses (Th1 and Th2): they have shown that microglial instruction with IL-4 
and low concentration of IFN-γ supports oligodendrogenesis and neuroprotection involving 
complex regulation of insulin-like growth factor (IGF)-I and TNF (Butovsky et al., 2006a) 
whereas high levels of INF-γ do not support cell renewal which can be restored by IL-4 
(Butovsky et al., 2006b). Furthermore, another in vitro experiment has examined the effect of 
IL-17, the signature cytokine of a T helper 17 immune response (Th17), on microglia 
showing that it can trigger the production of IL-6, inflammatory protein-2, nitric oxide, 
adhesion molecules and neurotrophic factors. They have also reported the production of IL-
17 by microglia itself suggesting the possibility of an autocrine inflammatory loop 
(Kawanokuchi et al., 2008). These observations show that microglia response can vary with 
the stimulus intensity, it is versatile and determined by the competition of different signals, it 
is affected by soluble messengers of adaptive immunity, such as cytokines, and by physical 
contact, such as through MHC class-II which presents antigens.  
In MS brain the evaluation of the pattern of the immunostaining for activated microglia, 
indicated by increased expression of MHC class-II and a ramified morphology, has become 
a pathological hallmark for the staging of lesions both in WM and in GM (Bo et al., 1994, 
Peterson et al., 2001) where it has been reported to be common and diffuse (Kutzelnigg et 
al., 2005). In keeping with these findings an EAE model mimicking grey matter pathology 
has shown a strong correlation between the density of activated microglia and the extent of 
demyelination in cortex (Merkler et al., 2006) and more recently MHC class-II has been 
found significantly increased in all regions of MS brain than control cortex (Gray et al., 2008).  
Observations in animal models of MS and in vitro experiments are strongly suggestive that 
the activation of microglia, triggered by soluble pro-inflammatory factors such as INF-γ in the 
meninges, is ultimately detrimental to the homeostasis of neurons and oligodendrocytes in 
the cortex (Gardner, 2009). 
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1.2.6 Different anatomical structure of microvasculature and arteries 
in cortical grey matter and subcortical white matter 
The density of the arteries and capillary networks has been reported to be 3 times greater in 
the cortex than in white matter (Ranson, 1959). Arterial blood vessels penetrate the cortex 
from the leptomeninges at almost right angles to the cortical surface (Fig 1.4 A). 
Interestingly, arteries that penetrate the walls of gyri make an almost right angle turn when 
reaching the subcortical white matter and at that point they begin to coil, loop and spiral. This 
is observed both in arteries penetrating the convexities of the gyri and those entering 
through the walls of sulci (Fig 1.4 B). Notably the trunks of the subcortical and deep white 
matter arteries that transverse the cortex are characterized by tight adhesion between the 
thin adventitial sheaths and the vascular walls (Fig 1.4 C) but, at the point where they enter 
the white matter, the spaces between the adventitial sheets and vascular walls widen exactly 
where they begin to coil, loop and spiral (Nonaka et al., 2003c, Nonaka et al., 2003b, 
Nonaka et al., 2003a) (Fig 1.4 D). In the compact cerebral cortex, with densely packed 
neuronal processes connected by synapses, the extracellular spaces are restricted to an 
interval of 10 to 20 nm whereas in the white matter parenchyma, consisting of parallel 
bundles of myelinated fibers, extracellular spaces are 80 nm or more (Nonaka et al., 2003b, 
Nonaka et al., 2003a). 
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Figure 1.4 Anatomical differences between GM cortical and subcortical WM blood 
vessels  
(A) Capillary networks are denser in the cortex than in white matter. The gyral white matter 
is rich in subcortical and deep white matter arteries, with concentrations of arteries 
penetrating from the summits and the lateral walls of the gyri. (B) The subcortical arteries 
penetrate the cortex in a straight line (I, red box). When they reach the subcortical white 
matter they begin to coil, loop and spiral (II, red box). (C) The trunk of a subcortical artery 
penetrates the cortex in a straight line, with tight adhesion of the adventitial sheath to the 
vascular wall. (D) Subcortical arteries coiling, looping and spiralling within the wide 
adventitial spaces in the subcortical white matter. Adapted from Nonaka, 2003. 
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1.3 Immunopathology of MS 
Although it may seem self-evident, given the enormous amount of pathological observations 
associating inflammation with tissue damage in the MS brain, the evidence of 
immunopathological mechanisms of acute disease activity has started to be well 
documented only during recent years when the effects of different immunosuppression 
strategies have been examined (Coles et al., 1999, Hartung et al., 2002). 
1.3.1 Therapeutic strategies 
Currently numerous studies are collecting observations on the effects of four monoclonal 
antibodies targeting selective molecules on immune cells and CNS-related inflammatory 
processes: alemtuzumab, natalizumab, daclizumab and rituximab (Bielekova and Becker, 
2010). Without directly indicating either CD4+ or CD8+ T cells, a treatment that removes 
lymphomononuclear cells by means of antibody to CD52 (Alemtuzumab) has produced a 
profound reduction in inflammatory activity and thus indicates the involvement of T cells in 
MS (Coles, 2007). Natalizumab is a selective adhesion molecule inhibitor whose target is the 
α4 subunit of VLA-4 receptor, whose interaction with vascular cell adhesion molecule-1 is 
necessary for immune cells to migrate across the BBB. Natalizumab binds to α4-integrin 
expressed on the surface of activated T cells and other mononuclear leukocytes, preventing 
their adhesion to endothelial cells and ultimately inhibiting their migration to the CNS (Muraro 
and Bielekova, 2007, Rudick and Sandrock, 2004, del Pilar Martin et al., 2008), which is 
likely to be the most important early therapeutic mechanism of this mAb (Niino et al., 2006). 
Treatment with Daclizumab, a mAb that binds to CD25, the IL-2 binding epitope of the α-
chain of the IL-2 receptor (IL-2R) upregulated on activated T cells, has not surprisingly lead 
to immediate depletion of CD25+ cells but instead to profound expansion of the regulatory 
CD56bright NK cells. Most importantly these regulatory cells, which are also present in 
lymphnodes where they can influence early T cell priming (Fehniger et al., 2003), migrate to 
inflammatory lesions and participate in termination of the immune response by killing 
autologous activated T cells. It remains unclear whether expansion and activation of 
CD56bright NK cells is the only mechanism of action of Daclizumab but this strongly correlates 
with clinical and MRI response (Bielekova et al., 2006, Bielekova et al., 2009).  
Further evidence has been provided by the analysis of the immunological changes in the 
peripheral blood of MS patients before and after undergoing autologous haematopoietic 
stem cell transplantation (AHSCT) (Mancardi and Saccardi, 2008).  Such transplantation in 
fact stops inflammatory disease activity in approximately 90% of patients and it is also safe 
with a transplant-related mortality of 1% since 2000 in European trials (Saccardi et al., 
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2006). Moreover, immunological studies of patients after transplantation have shown that the 
cellular immune system is extensively renewed by this procedure (Muraro et al., 2005). All of 
these observations in patients contribute to the understanding of the different roles of each 
immune cell subset in the immunopathogenesis of the complex inflammatory disease which 
is MS. In particular this knowledge is helping to unveil what elements can shape the immune 
response within and outside the CNS suggesting new targets for future therapeutical 
strategies. 
1.3.2 Role of B cells  
The substantial clinical benefit of B cell depletion in patients with MS using Rituximab 
(Hauser et al., 2008) has reassessed the role B cells in MS immunopathological 
mechanisms. The Fab domain of Rituximab binds to the CD20 antigen on B lymphocytes 
and the Fc domain recruits immune effector functions that mediate B cell death by antibody-
dependent cell-mediated cytotoxicity (Clynes et al., 2000) leading to a mean 95% reduction 
of B cells in the CSF (Piccio et al., 2010). Further evidences showing B cells contribution to 
the pathogenesis of MS are: the intrathecal IgG synthesis that is consistent with a clonal 
expansion of B cells within the CNS (Villar et al., 2005), the presence of B and plasma cells 
in active and chronic WM plaques (Esiri, 1977), the detection of B cell follicle-like structures 
in the meninges of the MS brain associated with a more severe cortical pathology (Magliozzi 
et al., 2007), the presence of related B cell clones in the meninges and WM lesions (Lovato 
et al., 2011), the matching between the IgG transcriptome of B cell with the corresponding 
IgG proteome in the CSF (Obermeier et al., 2008), the fact the prominent target of OCBs 
antibodies are myelin-derived lipids or lipids-complexes (Brennan et al., 2011).  
Different immunopathological mechanisms of B cells in MS have been proposed. In the first 
place, their traditional role of antibodies-secreting cells after their differentiation to plasma 
cells, which in turn may contribute to tissue injury via either the action of neutralizing 
antibodies or activating the complement cascade (Martin and Chan, 2006). Secondly, B cells 
may act as antigen-presenting cells owing to the expression of immunoglobulins in their 
surface that allows them to bind, neutralize, internalize, process and re-present on their 
surface part of the antigen attached to major histocompatibility complex proteins 
(Lanzavecchia, 1990). Thirdly, B cells can secrete pro-inflammatory cytokines such as TNF-
α, IL-6 and IL-4 which support the immune response of other mononuclear cells (Duddy et 
al., 2004). In addition B cells can differentiate to memory autoreactive cells that remain 
quiescent until re-exposure to the auto-antigen (Meinl et al., 2006) and are essential for the 
maintenance of ectopic lymphoid-like structures in the meninges (Serafini et al., 2004). After 
Rituximab infusion, CSF CXCL13 and CCL19 levels, essential chemokines involved in the 
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organization of lymphoid follicles, have been shown to be decreased and also a proportional 
decline in CSF T-cell levels has been reported. On the contrary the CSF IgG index, IgG 
concentration and OCBs number were unchanged after the treatment (Piccio et al., 2010). 
These findings are suggestive of a more important role of B cells in MS 
immunopathogenesis by sustaining a T cell response within the CNS by antigen-
presentation and cytokines secretion rather than by antibody production. 
1.3.3 Role of T cell subsets 
On the basis of observations showing that EAE could be transferred by in vitro reactivated 
myelin-specific CD4+ T cells (Zamvil and Steinman, 1990, Pettinelli and McFarlin, 1981)  
and that certain human leukocytes antigen class II alleles, whose gene products present 
antigen to CD4+ T cells, are the primary genetic association with MS (Hafler et al., 2007), 
the autoimmune pathogenesis of MS has been traditionally attributed to T helper cells. 
However the role of CD8+ T cells has also been considered since they have been reported 
to be predominant in white matter lesions (Hauser et al., 1986) and to be able to directly 
damage CNS target cells (Sobottka et al., 2009). Furthermore also MHC class I alleles, 
through which antigen is presented to the CD8+ T cells, have been associated with MS 
(Jersild et al., 1973) and EAE mediated by CD8+ T cells has been described (Ji and 
Goverman, 2007). In addition several clinical trials of monoclonal antibodies specifically 
against CD4+T cells, or the polarizing cytokines on which they depend, have failed to show 
any therapeutic benefit in MS (Coles et al., 2006). Experimental in vivo models of 
inflammatory demyelination show that the triggering of an autoimmune response 
systemically may induce symptoms and demyelination patterns resembling MS and that 
activated T cells, specific for one or more neuroauto-antigens are induced to cross the BBB 
and penetrate the CNS where an amplification of the immune response, after the recognition 
of the cognate antigens presented by antigen-presenting cells, occurs (Zamvil and 
Steinman, 1990).  Direct damage to neurons and oligodendrocytes might be mediated also 
by soluble T-cell products such as perforin and the interaction of Fas antigen with Fas 
ligand. There is also evidence of direct cytotoxicity mediated by the interaction of CD8+ T 
cells with class I major-histocompatibility-complex antigens on antigen-presenting cells and 
persistent viral infection (Lucchinetti et al., 1998). 
1.3.3.1 Role of CD4+ T cells 
The role of CD4+ T cells in MS induction and perpetuation has progressively been defined 
on the basis of the following observations on MS patients and EAE model. One of the first 
evidences about the role of CD4+ consisted of the detection of autoreactive, myelin basic 
protein (MBP) specific, CD4+ T cell clones both in MS patients and healthy controls (Burns 
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et al., 1983). This observation has indicated that the presence of MBP-reactive CD4+ T cells 
alone, is not sufficient to induce demyelination. Rather, it is the frequency of activated MBP-
reactive cells that is increased in MS patients in comparison to healthy individuals (Zhang et 
al., 1994). Therefore it has been investigated whether the mechanisms of central and 
peripheral tolerance were impaired in MS patients. It has been shown that, in the case of a 
dysfunction in the mechanisms of central tolerance, the thymic output will include T cells with 
T cell receptors alterations favouring autoimmunty (Wucherpfennig et al., 2009, Yin et al., 
2011). At the same time in MS CD4+ immunoregulatory T cells (Tregs), a subset 
characterized by CD25high , transcription factor Foxp3 expression (Hori et al., 2003a, Hori et 
al., 2003b) and the ability to suppress T cell proliferation by both cell-cell contact and 
cytokine-mediated mechanisms, have been shown to be decreased in number and 
functionally impaired (Viglietta et al., 2004). In addition, their frequency is increased during a 
clinical relapse (Dalla Libera et al., 2011).   
Another evidence of a skewed CD4+ T cell function associated with MS is that the 
requirement for costimulation, that is the interaction of CD80/86 on APCs with CD28 on T 
cells as well as the control via the negative costimulator CTLA-4, is perturbed in CD4+ T 
cells in MS (Scholz et al., 1998, Lovett-Racke et al., 1998, Chitnis and Khoury, 2003).  In 
addition CD4+ CD28- T cell subset in MS is characterized by a clear Th1 skew, a seemingly 
increased proliferative capacity and a relative enrichment for autoreactive T cells (Markovic-
Plese et al., 2001).  
Different experiments on EAE model have confirmed this finding showing that mice, 
expressing both MS-associated HLA-DR alleles and MS patient-derived MBP-specific TCR, 
spontaneously develop EAE (Madsen et al., 1999, Quandt et al., 2004). In addition a 
therapeutic trial has shown that the administration of an altered peptide ligand of MBP(83-99) 
induced cross-reactive CD4+ T cells with a Th1 phenotype  that has lead to disease 
exacerbations in MS patients (Bielekova et al., 2000). The cytotoxic activity of CD4+ T cells 
is relatively poorly understood compared with that of CD8+ T cells. However, it has been 
shown that CD4+ T cells restricted by HLA-DR2a can employ perforin-mediated killing while 
MBP-specific CD4+ T cells restricted by HLA-DR2b can exclusively exhibit Fas/Fas-L-
mediated cytolysis (Vergelli et al., 1997a, Vergelli et al., 1997b, Vergelli et al., 1996, 
Jaraquemada et al., 1990). Taken together these observations have shown that CD4+ T 
cells have a role both in the initiation of MS, by means of a higher frequency of autoreactive 
clones, and in its propagation, by means of a skewed phenotype.  
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1.3.3.2 Role of CD8+ T cells 
Although the interest of research on autoimmunity in the CNS has focused for long time 
almost exclusively on CD4+ T cells, on the basis that EAE could be transferred by CD4+T 
cells (Ben-Nun et al., 1981), the potential importance of CD8+ T cells in the 
immunopathology of MS has been reassessed on the basis of new data collected by clinical 
trials and EAE model (Goverman et al., 2005, Friese and Fugger, 2005). One compelling 
reason for this is that depletion of CD4+ T cells in patients with MS resulted in no 
improvement of disease (Coles et al., 2006). Other reasons for this shift in the research 
interest onto CD8+ T cells are that they outnumber CD4+ T cells in MS lesions (Hauser et 
al., 1986) and that clonal expansions are detected more frequently among CD8+ T cells 
isolated from MS white matter lesions than among CD4+ T cells (Junker et al., 2007). 
Prominent oligoclonal expansions of CD8+ memory T cells have also been found in the CSF 
(Jacobsen et al., 2002) and the persistence of CD8+ T cytotoxic cells (TCC) in CSF and 
blood has been shown (Skulina et al., 2004). At the same time the frequency of CD8+ T cells 
specific for CNS antigen-derived peptides has been shown in vitro to be higher in patients 
with MS compared with healthy individuals (Crawford et al., 2004) and also in the former the 
proliferation as well as INF-γ secretion by CD8+ T cells specific for MOG coincides with 
increased clinical disability and visualization of new white matter lesions by MRI (Arbour et 
al., 2003). More recently Ifergan and colleagues showed that both in human and in mouse 
the CD8+ T cells within the CNS are mostly effector memory lymphocytes providing 
evidence that they migrate through BBB endothelial cells, mainly via α4 integrin interactions, 
better than non-effector memory cells. Furthermore they showed that within the CNS this 
subset displays more aggressive functions, such as positivity to granzyme B and INF-γhigh, 
than CD4+ T cells (Ifergan et al., 2011).  
CD8+ T cells play an essential role the immunopathogenesis of CNS tissue damage since 
they exhibit more aggressive effector cytotoxic functions than CD4+ T cells. CD8+ T effector 
mechanisms include the production of soluble mediators and cell contact-mediated lysis. A 
role for the latter mechanism in MS pathology is supported by the findings that CD8+ T cells 
have been observed in MS lesions with their cytotoxic granules polarized towards 
oligodendrocytes and axons and that MBP-specific CD8+ T cells isolated from patients with 
MS specifically lyse freshly isolated human oligodendrocytes (Medana et al., 2001, 
Neumann et al., 2002). Moreover the extent of axonal damage correlates with the number of 
CD8+ T cells in the CNS (Bitsch et al., 2000, Kuhlmann et al., 2002). In regard to toxicity 
effects exerted by soluble mediators produced by CD8+ T cells, it has been shown that 
MBP-specific CD8+ T cells isolated from MS patients are able to secrete IFN-γ and TNF 
(Tzartos et al., 2008). The importance of soluble mediators was revealed when CD8+ MBP-
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specific T cell clones were transferred into mice that were also injected in the CNS with 
neutralizing agents for IFN-γ and TNF: neutralizing IFN-γ ameliorated the disease although 
TNF neutralization did not (Huseby et al., 2001). Another pathological mechanism through 
which an ongoing CD8+ T cell response within the CNS could contribute to tissue damage is 
the response to a virus. In this sense CD8+ virus-specific T cells can directly lyse neurons 
via Fas/Fas-L-mediated cytolysis (Medana et al., 2000). The observed association of EBV 
infection with MS, together with recent evidence of a dysregulated CD8+ T cell response to 
EBV in patients (Jilek et al., 2012, Jilek et al., 2008), could represent a further CD8-mediated 
indirect mechanism of toxicity within the CNS. 
1.3.3.3 Role of Th17 cells and Th17 surface markers 
Th17 cells have been established as an independent subset of T helper cells by the 
identification of unique signature interleukins, differentiation and transcription factors. Th17 
cells are characterized by the production of IL-17A, IL17F and IL-22 and the signals inducing 
naive T cell differentiation into Th17 lineage are mediated by transforming growth factor β 
(TGF-β), IL-23, IL-6, IL-1 and autocrine activity of IL-21 (Korn et al., 2009, Chung et al., 
2009). Support for a pathogenic role of T cell subsets secreting the cytokine IL-17 comes 
from EAE models and from studies of patients with MS. 
The transfer of T helper 17 (Th17) cells seemed to induce more severe EAE compared with 
transfer of Th1 cells. Furthermore, neutralizing IL-17 activity ameliorated EAE, thereby 
strengthening the notion that they are the “true” effector cells in CNS autoimmunity (Langrish 
et al., 2005, Park et al., 2005, Hofstetter et al., 2005, Komiyama et al., 2006). In regard to 
the comparison of the role of Th1 and Th17 responses in development of EAE striking 
discoveries have shown that mice deficient in IL-12, IFN-γ and TNF can still develop severe 
EAE (Steinman, 2007). By contrast, IL23-deficient mice are completely resistant to EAE 
(Cua et al., 2003) and IL-23 is essential for the development of pathogenic Th17 cells 
(McGeachy et al., 2009). The Th17 contribution to the inflammation in the CNS consists of 
the secretion of high levels of their signature pro-inflammatory cytokines IL-17A and IL-17F 
and also their ability to either directly synthesize or induce other cell types to produce other 
soluble pro-inflammatory mediators such as IL-6, granulocyes/macrophages colony-
stimulating factor (GM-CSF), matrix metalloproteinases and CXC chemokines including 
CXCL8, a potent neutrophil chemoattractant (Henningsson et al., 2011, van Hamburg et al., 
2011, Becher and Segal, 2011). In this sense it has been shown in EAE that IL-17 stimulates 
astrocytes to produce ELR+ CXC chemokines that could, in turn, attract neutrophils to the 
BBB and activate them to release vasoactive substances (Carlson et al., 2008). An essential 
experiment in EAE showed that CCR6, a chemokine receptor characteristic of Th17 cells, 
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can trigger the initiation of EAE by controlling the migration of a first wave of autoreactive 
Th17 cells into the uninflamed CNS. This conclusion has been derived by the fact that 
CCR6-knockout mice, after immunization by a standard protocol, developed Th17 responses 
but failed to develop EAE (Reboldi et al., 2009).  
Increased numbers of IL-17 transcripts have been detected in chronic multiple sclerosis 
lesions compared with either acute lesions or control tissue from individuals without CNS 
pathology (Lock et al., 2002). IL-17 has also been reported to be expressed at relatively high 
levels in circulating lymphocytes of MS patients (Durelli et al., 2009) and in the majority of 
CD8+ cells infiltrating MS brain lesions (Tzartos et al., 2008). Kebir and colleagues also 
reported that human Th17 cells migrate across BBB endothelial cell monolayers more 
efficiently than Th1 cells and that IL-17 and IL-22 directly stimulate CNS endothelial cells to 
express chemokines and downregulate tight junction proteins (Kebir et al., 2007).  The flow 
cytometric analysis on peripheral blood of healthy donors and MS and Rheumatoid Arthritis 
(RA) patients showed a significant excess of a T cell subset expressing CCR6, high levels of 
CD161 and including all circulating IL-17+CD8+ T cells (Annibali et al., 2010). In the same 
study the detailed analysis of CD161+CD8+ T cells has revealed that this subset comprises 
CCR6+, non-cytotoxic CD8 T lymphocytes with an effector-memory phenotype also 
characterized by the ability to secrete of INF-γ upon stimulation. This observation confirmed 
previous studies on peripheral blood showing different functional profiles between subsets of 
CD161 expressing lymphocytes: on one hand the CD8+CD161int subset containing 
predominantly effector and central memory T cells producing high levels of TNF and IFN-γ 
and showing vigorous proliferation after stimulation in vitro but no lytic activity, on the other 
hand CD8+CD161high subset being not proliferative, nor secreting cytokines or mediating NK 
lytic activity (Takahashi et al., 2006).  A study by Turtle et al. has characterized the 
CD161high subsets from peripheral blood of healthy donors and patients after HSCT showing 
that they express high levels of co-stimulatory and cytokines receptors and finding that 
signals provided to TCR ligation by αCD28, IL-12, IL-18, IL-23 and IL-1β can increase their 
proliferation and can influence the frequency of IL-17 secreting cells in this subset (Turtle et 
al., 2011). These observations have suggested that the expression of CD161, together with 
CCR6, might be an important marker for human Th17 detection and isolation (Cosmi et al., 
2008, Annunziato et al., 2008) although the meaning of CD161 levels of expression by 
human Th17 and its function are still unclear. 
1.3.3.4 Role of NK, NKT, NKT-like and MAIT cells 
The heterogeneity of MS among patients groups might also be linked to another immune cell 
subtype, Natural Killer cells (NK), whose fluctuations in activity and number has been 
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observed during the disease course. The association between NK cells and MS are based 
on the observed reduction of NK lysis prior and during acute exacerbations compared with 
chronic disease and normal during stable phases (Kastrukoff et al., 2003, Kastrukoff et al., 
1998). Flow cytometric analysis have shown that NK cells are significantly reduced in MS 
(Munschauer et al., 1995). Furthermore NK deficiencies exist in peripheral blood, placques 
and CSF of patients (Weber et al., 1987). NK cell depletion in two different EAE models 
exacerbates disease (Zhang et al., 1997, Matsumoto et al., 1998) and the transfer of in vitro 
generated NK cells decreases autoimmunity (Smeltz et al., 1999). More recently the first 
clinical trial with Daclizumab, an antibody against CD25, has shown a marked expansion of 
NK cells expressing CD56 at high levels. These cells, isolated from daclizumab-treated 
patients, have been shown to kill recently activated CD4+T cells not via perforin-mediated 
mechanism, but by as yet unknown receptor/ligand interactions (Bielekova et al., 2006).  
These observations indicate that NK cells may exert important immunoregulatory functions 
in MS.  
NKT cells share characteristics with T and NK cells and play a regulatory role in 
autoimmunity as well as in immune responses to tumors and infections via secretion of high 
levels of IL-4 and INF-γ. Both CD4- and CD4+ cells contain NKT cells and in humans these 
cells express a conserved canonical TCRα chain, Vα24JαQ, paired with a selected Vβ11 
segment. NKT cells recognize glycolipids presented by the nonclassical class I-like CD1d 
molecule (Park and Bendelac, 2000). A considerable reduction of Vα24JαQ+ cells among 
Vα24+ cells has been observed in MS blood (Illes et al., 2000) and confirmed by another 
group that also showed a reduced Vα24Vβ11+ NKT cells (van der Vliet et al., 2001). More 
recently a significant functional difference has been identified in the NKT cells of MS 
patients: while this subset in unfractionated peripheral blood from healthy subjects expanded 
in number and produced IFN-γ upon stimulation with alpha-galactosylceramide, NKT-cells 
from MS patients did not (O'Keeffe et al., 2008). 
Human CD161 (NKR-P1A) is a C-type lectin receptor originally found expressed by most NK 
cells and by CD1d-restricted NKT cells but also subsets of circulating and tissue-infiltrating T 
cells (Lanier et al., 1994, Exley et al., 1997). It has been shown that engagement of CD161 
on NK cells with Lectin-like Transcript 1 (LLT1), which is its ligand expressed on target cells, 
can inhibit cell-mediated cytotoxicity and INF-γ toxicity. Conversely, LLT1/CD161 interaction 
in the presence of a TCR signal enhanced INF-γ production by T cells (Aldemir et al., 2005). 
This observation, that has shown a different functional role of CD161 when it is expressed 
on NK and T cells, taken together with a microarray analysis that has provided evidence that 
human Th17 cells consistently express on their surface CD161 and CCR6 (Cosmi et al., 
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2008), have promoted a number of immunological studies aimed at describing the different 
subsets of cells expressing CD161 and their functional phenotype.  
First, a study on human umbilical cord and peripheral blood has shown that circulating 
CD161-expressing and IL-17 producing lymphocytes are not CD1d-restricted NK Cells but 
are NKT-like cells (Cosmi et al., 2008). Second a study by Dusseaux and colleagues has 
described another immune cell subset, Mucosal Associated Invariant T (MAIT) cells, as non-
cycling, tissue-targeted (CCR6+ expressing) cells that secrete IL-17 (Dusseaux et al., 2011) 
therefore sharing many similarities with the previously described CD8+CD161high (Annibali et 
al., 2010).  MAIT in humans are innate T cells restricted by MR1, a major histocompatibility 
complex class Ib molecule, and expressing a semi-invariant Vα7.2-Jα33 TCR α chain in 
preferential combination with Vβ2 and Vβ13 (Treiner et al., 2003). They can be identified in 
blood and tissue by the co-expression of CD161 and TCR Vα7.2 and they include most, if 
not all, the CD161high IL-17 secreting CD8 T cells previously described (Dusseaux et al., 
2011). MAIT cells are unconventional T cells that have been shown to reside in mucosal 
tissues and rapidly exert effector functions in absence of clonal expansions, therefore 
playing an important role in “first-line” immune responses (Le Bourhis et al., 2011). There is 
now growing evidence, both in humans and in mouse models of autoimmunity, of the 
immunopathological role of MAIT cells, in particular of their role in triggering a pro-
inflammatory environment within target organs such as the intestine (Kawachi et al., 2006), 
the joints (Chiba et al., 2011) and the MS brain (Illes et al., 2004). 
1.3.4 Evidence of INF and TNF involvement in MS pathology 
Many cytokines, mainly of Th1 type, such as INF and TNF have been implicated in MS 
(Pouly et al., 2000, Benvenuto et al., 1991, Calabresi et al., 1998, Hofman et al., 1989, 
Killestein et al., 2001, Selmaj et al., 1991, Selmaj and Raine, 1988). A role for INF-γ in MS 
pathology is suggested by the following three observations. First, administration of INF-γ to 
MS patients worsen the disease (Panitch et al., 1987); second, the proportion of CD4+ and 
CD8+ T cells from peripheral blood expressing INF-γ increases significantly in patients with 
progressive MS compared to control group (Becher et al., 1999). Finally, in MOG-
immunized, sub-clincal EAE, INF-γ injection in the subarachnoid space triggers 
demyelination in the cortical grey matter and spinal cord (Kerschensteiner et al., 2004, 
Merkler et al., 2006). Evidence supporting a role for TNF in MS pathology come from a 
number of studies that found it expressed by CSF-derived T cell clones by MS patients 
(Benvenuto et al., 1991, Calabresi et al., 1998) and identified it in the MS brain lesions 
(Hofman et al., 1989, Selmaj et al., 1991). In addition to these, in vitro studies found that 
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TNF can modulate oligodendrocytes Fas-mediated apoptosis (Pouly et al., 2000, Selmaj and 
Raine, 1988). 
1.3.5 The role of metalloproteinases in MS pathology 
Recent insights into the neuroinflammatory processes of demyelination, vascular cuffing, 
destruction of BBB, neuronal toxicity and the ensuing (re)activation of autoreactive 
lymphocytes indicate that, together with cytokines, also metalloproteinases (MMPs) play a 
pivotal role in MS (Opdenakker and Van Damme, 2011). MMPs constitute a family of 
enzymes that mediate the degradation and remodeling of extracellular matrix proteins 
(Goetzl et al., 1996). 
Among all known MMPs, MMP-9 might be particularly involved in BBB disruption degrading 
collagen IV, a major component of the basement membrane of the cerebral endothelium 
(Lukes et al., 1999). In fact the presence of MMP-9 in the CSF has been linked with MS, 
optic neuritis and other neuroinflammatory diseases (Gijbels et al., 1992, Hosokawa et al., 
2011) and it has been shown that MMP-9 can cleave myelin basic protein into 
immunodominant and encephalitogenic peptides (Proost et al., 1993, Gijbels et al., 1993). In 
addition MMP-9 knockout mice are partially resistant against the development of EAE 
(Dubois et al., 1999, Opdenakker et al., 2003) and completely resistant against MOG-
peptide-induced EAE when also MMP-2 is genetically knocked out (Agrawal et al., 2006). 
Depending on the kind of stimulation most cells within the CNS, i.e. endothelial cells, 
astrocytes, neurons and microglia, can generate MMP-2 and MMP-9 (Gottschall, 1996) and 
in autopsies from MS brains an enhanced MMP-9 expression has been confirmed in reactive 
microglia and astrocytes (Cuzner et al., 1996). Notably various cytokines can regulate gene 
expression of MMP-9 in cells (Pugin et al., 1999) and several chemokines such as IL-8 and 
other CXC-chemokines can stimulate secretion of MMP-9 from neutrophils (Opdenakker et 
al., 2001). In addition it has been shown that intact polyclonal immunoglubulins for 
intravenous use (IVIg) lead to increased secretion of MMP-9 in unstimulated microglia (Pul 
et al., 2009).  
1.3.6 The role of chemokines in CNS inflammation  
Chemokines were first classified as small, chemotactic cytokines that can selectively recruit 
subsets of leukocytes into different tissues. The chemokine family consists of more than 40 
members and is subdivided into four groups: α (CXC), β (CC), γ (C), δ (CX3C), according to 
the number of amino acids separating two cysteine residues within a highly conserved 
region of the chemokine. Chemokine receptors are classified similarly according to which 
group of chemokines they bind are designated by the same name followed by R (Horuk, 
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2001).  To date the majority of research investigating the role of chemokines in the CNS 
disease focused either on their secretion by parenchymal cells, including microglia and 
astrocytes or their leukocyte attractant properties (Ransohoff, 2009).  
Chemokine action causes cells initially to arrest rather than move during the multistep 
process of leukocyte extravasation (Butcher, 1991, Laudanna and Alon, 2006)  and most 
importantly mediate both clustering and conformational changes of integrins, leading to high-
affinity and avidity integrin interactions with cell adhesion molecules on vascular endothelial 
cells (Ransohoff, 2009). In the context of leukocytes trafficking, chemokines and their 
receptors are grouped as homeostatic (chemokines expressed constitutively in organs) or 
inflammatory (chemokines produced at sites of inflammation with cognate receptors 
expressed on infiltrating leukocytes (Charo and Ransohoff, 2006). For example, CXCL9, 
CXCL10 and CXCL11 are three CXC-family, INF-γ-inducible chemokines that signal through 
a single receptor CXCR3 which in turn is regulated by the Th1 (Thelper 1) cell-associated 
transcription factor T-bet (Muller et al., 2010). Interestingly, distribution of cells within 
inflamed CNS lesions is in part modulated by interactions between CXCL12, which is 
normally immobilized at the abluminal surface of cerebral microvessels, and CXCR4 on 
leukocytes (McCandless et al., 2006, McCandless et al., 2008b, McCandless et al., 2009). 
Fractalkine, or CX3CL1, is expressed as a transmembrane component that is regulated by 
cleavage and while its soluble form can act at distance as chemoattractant, its membrane-
bound form can serve as adhesion molecule for receptor-bearing cells (Clark and Malcangio, 
2012). Furthermore potent chemoattractants, such as CCL5 (RANTES), CCL4 and CXCL11, 
are expressed by microglia after IFN-γ stimulation (Rock et al., 2005). 
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1.4 Hypotheses 
During MS clinical course, the formation of GM and WM lesions might relate to different 
pathological mechanisms, possibly reflecting the different accumulation of GM and WM 
lesions during the early phase and the progressive phase of the disease.  
Here I test the hypotheses that: 
1. pro inflammatory lymphocytes contribute to meningeal inflammation and are 
associated with grey matter demyelination and microglial activation in the 
cortex of progressive MS brain 
2. immune cells interactions within the SAS are at the basis of the exacerbation 
of the immune response also triggering inflammatory waves into the white 
matter parenchyma 
3. there is a relationship between the production of chemokines in cortical 
lesions and the presence of inflammation in the overlying meninges  
4. the immune response in the meningeal compartment, together with the 
accrual of demyelination in GM, affects the clinical outcome of the 
progressive phase of the disease. 
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1.5 Aims 
This thesis aimed at the description of MS pathology focusing on cortical pathology and on 
characterization of immunopathological processes occurring in the overlying meningeal 
space. 
I) Quantify the extension of grey matter and white matter pathology in the 
progressive MS brain 
II) Characterize GM lesion types, microglial activation and parenchymal inflammation 
of cortical lesions 
III) Characterize the inflammatory infiltrates in the meninges quantifying the absolute 
and relative contribution of immune cell subsets to meningeal inflammation, 
focusing on the identification of novel pro-inflammatory subsets 
IV) Quantify the absolute and relative contribution of the same immune cell subsets to 
perivascular white matter inflammation in order to compare it with meningeal 
inflammation 
V) Verify the possible correlations between immune cells subsets in the meninges 
and the severity of cortical pathology, as well as the possible correlations between 
white matter lesions and inflammatory perivascular infiltrates 
VI) Assess the presence of immunopathological processes in the meninges, such as 
leakage of MOG and cell-to-cell contact between T cells and macrophages 
VII) Characterize the expression levels of chemokines  in the parenchyma of GM 
lesions 
VIII) Characterize chemokines receptors on lymphocytes infiltrating the CNS 
IX) Assess in lymphocytes infiltrating the CNS the expression of T cell lineage-specific 
nuclear transcription factors 
X) Correlate MS clinical milestones with the extent of GM and WM lesions, with GM 
lesion types, with the density of inflammation in the cortical parenchyma and in the 
meninges   
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2.1 UK MS Tissue Bank: preparation, screening and selection 
of cases 
2.1.1 Dissection and preparation of human post-mortem brain tissue 
Brain tissue samples were obtained from the UK Multiple Sclerosis Tissue Bank, Imperial 
College, London. All tissues were collected with fully informed consent via a prospective 
donor scheme with ethical approval by National Research Ethics Committee 
(08/MRE09/31).The diagnosis of multiple sclerosis was confirmed based on the patient 
history, summarized by Dr. Richard Nicholas, and a detailed neuropathological analysis 
provided by Dr Bishan Radotra, Dr Federico Roncaroli and Prof. Steve Gentleman. After 
dissection of cerebellum and spinal cord, the whole cerebrum is sliced into 1 cm thick slices 
that are sampled anterior and posterior to the first cut, taking the central sulcus and 
mamillary bodies as anatomical references (Fig 2.1 A). Brain coronal full hemispheric slices 
are then cut into 2x2 cm blocks, each one identified by a letter and number according to a 
grid photographed during dissection (Fig 2.1 B). Coronal slices are then alternatively snap 
frozen in isopentane on dry ice (snap frozen, SF) or fixed in 4% paraformaldehyde (mean 
fixation time = 17 ± 6 days), cryoprotected in 30% sucrose, frozen in cooled isopentane 
(fixed frozen, FF) and both stored at -80 ºC. Dissection takes place with average post-
mortem delay of 18 ± 1 hours (mean ± SEM). Blocks taken for routine neuropathological 
assessment are fixed in 4% paraformaldehyde and embedded in paraffin.  
2.1.2 Screening for inflammation and brain sampling strategy 
All MS cases that were affected by other confounding pathologies were excluded from this 
cohort. Twenty-one cases, including SP and PP MS, were selected to ensure a wide age 
range at death (median age at death = 60, age range 40–83 years) in order to reflect the 
entire MS cohort in the UK Multiple Sclerosis Tissue Bank (median age = 60, range 30–96 
years, n = 450). Initially, at least 8 paraffin-embedded slides per case, taken as part of the 
routine neuro-pathological assessment and stained with Luxol Fast Blue (LFB) and Cresyl 
Fast Violet (CFV) and with Haematoxylin and Eosin (H&E), were all examined for the 
presence of inflammation both in the meninges and in white matter parenchymal vessels. On 
the basis of this screening, an index of inflammation was assigned to each case based on 
the presence and the extent of meningeal and/or perivascular inflammation. Cases without a 
single example of a moderate meningeal or perivascular infiltrate (equivalent of <5 cells per 
infiltrate in any portion of perivascular or meningeal space using a 20X objective) were noted 
in the analysis of histological sections as “low inflammation”. For cases presenting at least a 
single example of moderate and/or abundant cellular infiltration (equivalent to an infiltrate of 
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10-50 or more loosely packed cells in perivascular of meningeal areas) were noted as “high 
inflammation” (Howell et al., 2011). 
 
 
Fig 2.1 Brain dissection and sampling strategy (A) An example of brain dissection into 
coronal slices 1 cm thick. (B) Each section is then cut into blocks of 2x2 cm and 
photographed on a grid to name each block accordingly. Blocks are alternatively fixed in 4% 
paraformaldehyde or snap frozen in ice-cold isopentane and immediately stored at -80 °C. 
(C) We sampled at least one tissue block from each coronal slice in order to cover the 
following brain regions:  frontal cortex (FC), superior frontal cortex (SFC), cyngulate cortex 
(CC), parietal cortex (PC), occipital cortex (OC) and temporal cortex (TC). Adapted from 
Atlas of the human brain, Academic Press, Mai, Voss, Paxinos, third edition, 2008, ISBN-13: 
978-0-12-373603-1. 
  
60 
 
An initial sampling of FF blocks was based on this analysis and starting from anterior to 
posterior, sampling included at least one block from each brain FF slice so that the cerebrum 
of each case was sampled as widely as possible in order to avoid sampling bias. The 
following regions were always included for each case: frontal cortex, temporal cortex, 
superior frontal cortex, parietal cortex, cingulate cortex, occipital cortex and periventricular 
areas (Fig 2.1 C). Since each block was then identified by a letter and number according to a 
grid photographed during dissection, a further criteria for the selection of tissue blocks 
included the presence of macroscopically visible lesions/plaques. In the event that stained 
slides lacked preserved meninges, additional sections cut from the same block were 
sampled. In all instances, only slides containing an intact meningeal compartment were 
considered for assessment of infiltrates. The same sampling method was followed for snap 
frozen blocks. In the end a total of 504 blocks were sampled from 21 cases (~20 blocks/case 
of fixed frozen tissue and 4 blocks/case of snap frozen tissue) (Traugott et al., 1983a, Moll et 
al., 2008). The analysis of all tissue blocks showed in chapters 3 to 6 includes always the 
same 21 MS cases and 4 non neurological controls. 
2.1.3 White matter lesion classification 
The extent of demyelination and degree of lesion activity were evaluated by combining LFB, 
myelin oligodendrocyte glycoprotein (MOG) and major histocompatibility complex (MHC) 
class II immunostaining on sequential sections for each block. The inflammatory activity of 
WML was defined by the pattern of MHC class II staining: active lesions contained numerous 
MHC class II cells in the lesion core and at the lesion border (Bruck et al., 1995); chronic 
active lesions had a border of MHC class II cells and a lower number in the core (Fig 2.2) 
(Magliozzi et al., 2007); chronic inactive lesions had a very low MHC class II cell density 
throughout the lesion (Kutzelnigg et al., 2005). Then a further pathology criterion to stage 
WM lesions was based on the qualitative observation of the distribution of CD3+ T cells. In 
chronic active lesions the centre contained few T cells while there were more around blood 
vessels near to the border of the lesion. Chronic inactive lesions were those with few or no T 
cells both in the centre or the periphery of the lesion (Ferguson et al., 1997). Four chronic 
active lesions were selected from fixed frozen blocks and in snap frozen blocks from each 
case. 
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Fig 2.2 Chronic active white matter lesions An example of chronic active lesion in 
white matter defined on sequential sections by (A) LFB, (B) MHC class-II and (C) MOG 
staining. All images acquired at 100X. Scale bars = 70µm 
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2.1.4 Grey matter lesion classification 
A qualitative index of microglial activation in the cortex was assigned to each fixed frozen 
block based on the density and morphology of MHC class-II positive cells: chronic inactive 
cortical lesions showed no clear border of MHC class-II positive cells, similar to normal 
appearing cortex. On the contrary chronic active cortical lesions were defined by a denser 
border of MHC class-II in the deeper layers or, much more frequently, by a higher density in 
the first cortical layers on a homogeneous background of high density MHC class-II positive 
cells in all cortical layers. Cortical lesions were classified, based on the extension of grey 
matter pathology within or beyond the delimitation of the cortex, according to the system 
used by Peterson et al. (Peterson et al., 2001): Type I lesions, also named leukocortical 
lesions, encompassed both white matter and the cortex, Type II lesions resided entirely 
within the cortex, Type III lesions, also called subpial, extended from the pial surface into the 
deeper cortex, usually to layers 3 or 4 and often extending over several gyri. The lesions that 
exhibited the features of both Type III and Type I, which is extending from the pial surface to 
cover the whole cortex and some subcortical WM, were defined as TypeI/III. 
2.1.5 Demographic and clinical data 
This study was performed on post-mortem brain tissue from 21 MS cases (17 SP-MS and 4 
PP-MS), of which 13 were females and 8 males. Control post-mortem brain tissues from four 
patients without evidence of neurological disease or neuropathological alterations were also 
used in this study. The same MS cases and controls were used consistently in all 
experiments in Chapters 3 to 6. The full lifetime clinical histories were available for each 
case and a summary of features of the MS clinical course was prepared by a consultant 
neurologist. All clinical demographics detailes are reported in table 2.5.  
2.2 Immunohistochemistry 
2.2.1 Antigen retrieval 
All the antibodies used in this study for immunohistochemistry were initially tested to find the 
optimal staining conditions. On fixed frozen tissue blocks the first step was to optimize 
antigen retrieval which can change depending on the antigen to be detected. Fixed frozen 
sections were removed from -80 °C, air-dried and washed in PBS. For MOG and MHC-II no 
antigen retrieval was used, instead sections were washed in ice cold methanol for 10 min in 
order to remove lipids from the tissue. When staining without antigen retrieval was negative, 
different buffer solutions for heat-induced antigen retrieval were tested in parallel: Sodium 
Citrate 10mM at pH 6.0, EDTA 1mM at pH 8.0, Tris-EDTA at pH 9.0 and DAKO target 
retrieval solution (Dako; S1699). Antigen retrieval consists of unmasking the epitope of the 
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antigen by breaking the chemical bonds created in the tissue by the fixation process. The 
amount of chemical bonds broken in this process is directly dependent on the pH of the 
solution and the time of retrieval, therefore we tested different conditions for these two 
variables. Furthermore, heat-induced antigen retrieval was performed for most antibodies 
with a vegetable steamer instead of a microwave to avoid boiling of buffers leading to 
mechanical stress on the samples and uneven temperatures that ultimately can disrupt the 
meningeal structures. The temperature of the buffer solution was constantly monitored with a 
thermometer. The final optimized protocol consisted in 3 cycles of 1.5 min each in buffer 
solution at 95 °C, alternated by 3 cycles of 1.5 min each in the same buffer solution at room 
temperature. After the last cycle at 95°C the samples were then removed from the steamer 
and left cool down to room temperature in order to allow the refolding of antigen structures 
that are disrupted at 95°C (Table 2.1).  
Table 2.1 Antigen retrieval methods for each antibody used for immunohistochemistry on 
fixed frozen tissue 
Antigen Cell specificity Antigen retrieval conditions  
MOG Myelin and Oligodendrocytes Ice cold methanol, 10 min 
MHC-II Activated microglia, 
macrophages, APCs 
Ice cold methanol, 10 min 
CD20 B lymphocytes Sodium Citrate 10mM at pH 
6.0, 3 X 1.5 min at 95°C in 
steamer 
CD3 T lymphocytes Sodium Citrate 10mM at pH 
6.0, 3 X 1.5 min at 95°C in 
steamer 
CXCL12 Lymphocytes 
chemoattractant 
Sodium Citrate 10mM at pH 
6.0, 3 X 1.5 min at 95°C in 
steamer 
CD31 endothelial cell marker Sodium Citrate 10mM at pH 
6.0, 3 X 1.5 min at 95°C in 
steamer 
 
2.2.2 Single immunohistochemistry: primary antibodies 
concentration, blocking and detection  
Once the optimal antigen retrieval method was established on fixed frozen tissue, the 
primary antibody concentration could be fine-tuned. The concentration provided by the 
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company producing the antibody was the first one to be tested in parallel with other dilutions 
ranging from 0.5µg/mL to 5µg/mL. This protocol was also followed for snap frozen tissue 
with the omission of antigen retrieval and the inclusion of 10 min incubation in ice-cold 
methanol. Before incubation with primary antibody all sections were incubated for 30 min 
with 0.1% H2O2 in PBS to eliminate endogenous peroxidise activity followed by 1h incubation 
in PBS containing 10% normal horse or goat serum to block nonspecific binding of the 
corresponding species of secondary antibodies. All antibodies were incubated at +4°C 
overnight diluted in PBS containing 0.1% Triton X-100 and 1% normal sera. Negative 
internal control (no primary antibody), isotype controls (mouse IgG1k isotype control, clone 
MOPC-31C, BD; mouse IgG2B, clone 73009, R&D Systems; rat IgG2a, eBioscience) were 
also tested for all the antibodies. When appropriate, primary antibodies were also tested on 
human spleen or tonsils as positive control. The sections were then incubated with 
biotinylated secondary Abs for 1 hr at room temp (horse anti-mouse IgG, goat anti-rabbit 
IgG, or horse anti-goat IgG, from Jackson Immunnoresearch Laboratories, diluted 1:200 in 
PBS containing 0.1% Triton X-100 and 1% normal sera), binding being visualized with the 
avidin–biotin horseradish peroxidase complex technique (ABC Vectastain Elite kit; Vector 
Laboratories), followed by 3,3’-diamino-benzidine (DAB) (Sigma Chemical Co.) as the 
substrate. Washing steps were performed in between each incubation with PBS. All sections 
were counterstained with Haematoxylin, sealed with Depex Polystyrene (DPX). All antibody 
details used in this thesis, including concentration,clone and source, are listed in Table 2.2. 
A number of antibodies were tested following the same methods but did not work on FF and 
SF brain tissue (Table 2.3). 
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Table 2.2 Details of the primary antibodies used for single immunohistochemistry and 
double immmunofluorescence on snap (SF) and fixed frozen (FF) tissue 
Antigen Cell specificity Clone 
 
Tissue 
fixation 
Dilution Source 
MOG Myelin and 
Oligodendrocytes 
Z12 
 
FF,SF 1:50 Kind gift of S. 
Piddlesden, 
Cardiff, UK 
MHC class-II Microglia, APCs LN3 FF,SF 1:100 Abcam 
CD20 B lymphocytes L26 FF Pre-diluted Immunotech 
CD3 T lymphocytes Rabbit 
polyclonal 
FF 1:500 DAKO 
CD4 Th RPA-T4 SF 1:100 BD 
CD8 CTLs, NKs HIT8a SF 1:100 BD 
CD8 CTLs, NKs Rabbit 
polyclonal 
SF 1:100 ThermoScientific 
CD161 Th17,Tc17, 
NK,NKT,MAIT 
B199.2 SF 1:100 AbDserotec 
TCRVα7.2 MAIT and some 
CTLs 
3C10 SF 1:100 Biolegend 
CCR6 Tc17, MAIT 53103 SF 1:100 R&D Systems 
CXCR5 Lymphocytes 
homing B cells 
RF8B2 (rat) SF 1:50 BD 
CXCR3 Receptor for 
CXCL-9-10-11 
1C6/CXR3 SF 1:200 BD 
MRP14 Macrophages 
and neutrphils 
S32.2 SF 1:400 Bachem 
Laminin Basement 
membrane 
Rabbit 
polyclonal 
SF 1:100 Sigma 
CXCL12 lymphocyte 
chemoattractant 
clone 79018 FF 1:50 R&D Systems 
CD31  endothelial cell 
marker 
clone 
EPR3094 
(rabbit) 
FF 1:100 Epitomics 
APC, antigen presenting cell; Th, T helper cell; CTL, cytotoxic T cell; NK, natural killer cell; 
Tc17, T cytotoxic cell secreting IL-17; NKT, natural killer T cells; MAIT, mucosal associated 
invariant T Cell; CCR6, C-C chemokine receptor type 6; SF, snap frozen; FF, fixed frozen. 
All antibodies listed in the table are mouse monoclonals except where noted. 
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Table 2.3 Primary antibodies tested for immunohistochemistry and immunofluorescence on 
snap and fixed frozen tissue. This table includes the details of the antibodies that did 
not show any signal on SF and FF brain tissue. 
Antigen Description Clone 
 
Source 
CXCR3 Receptor for CXCL-9-10-11, on 
Th1 cells 
2Ar1 Abcam 
CXCR4 Receptor for CXCL12, on B and 
T cells 
44716 R&D systems 
CCR4 Receptor for CCL2-4-5-17-22, 
on Th1 cells, 
Goat 
polyclonal 
Abcam 
CCR5 Receptor for MIP-1α, MIP1-β, 
MCP-2, RANTES 
45523 R&D systems 
T-bet Th1 transcription factor 4B10 Santa Cruz 
RORγT Th17 transcription factor (rat) 
AFKJS-9 
eBioscience 
RORγT Th17 transcription factor Rabbit 
polyclonal 
Abcam 
Foxp3 Tregs transcription factor PCH101 eBioscience 
IL-10 Interleukin 10 Rabbit 
polyclonal 
Abcam 
IL-17  Interleukin 17 Goat 
polyclonal 
R&D systems 
CCL20 Ligand for CCR6 Goat 
polyclonal 
R&D systems 
LLT1 Ligand for CD161 4CT Abnova 
All antibodies listed in the table are mouse monoclonals except where noted.  
2.2.3 Sequential double immunohistochemistry 
In order to identify redistribution of CXCL12 in meningeal vessels, a sequential double 
immunohistochemistry was performed with antibodies to both CD31 and CXCL12 as 
described above, but with the omission of the haematoxylin counterstain. First, horseradish 
peroxidase labelling for CD31 was visualized with DAB, then immunohistochemistry for 
CXCL12 was performed after blocking with 10% normal horse serum. The labelling for 
CXCL12 was visualized with VIP blue substrate containing levamisole (Vector Laboratories). 
2.3 Double immunofluorescence 
2.3.1 Snap frozen tissue: cutting and fixation 
All sections were cut 10µm thick and kept inside the cryostat until cutting session was over, 
then immediately stored at -80 °C. Sections were cut just before the staining session to 
avoid a long time in storage and decay of snap frozen tissue sections. Snap frozen tissue 
sections were then taken out from -80°C, directly submerged in ice-cold methanol, taken 
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directly from -20C freezer, and incubated to for 10 min. This fixation protocol dehydrates the 
tissue and allows a better antigen exposure in the lipid-rich brain tissue. 
2.3.2 Sequential double immunofluorescence    
Sections were incubated overnight at +4°C with the first primary antibody (CCR6, CD161, 
TCRVα7.2). Binding of biotinylated secondary antibody was visualized with the avidin-biotin 
horseradish peroxidase complex followed by 30 min incubation with Tyramine (Sigma) in 
PBS (1:1000) containing 0.03% H2O2 according to a modified version of a method described 
by Adams (Adams, 1992). After washing away the Tyramine excess, a 1h incubation with 
Alexa Fluor®-546 Streptavidin (Invitrogen, Carlsbad, CA) followed. Sections were then 
washed, blocked with normal serum and incubated overnight at 4°C with the second primary 
antibody (CD8 rabbit polyclonal, CD161), which was then visualized with an Alexa Fluor®-
488 secondary antibody. Sections were then counterstained with 4’,6-diamidino-2-
phenylindole (DAPI, Sigma) for the localization of the nuclei and coverslipped with aqueous 
mounting medium Vectashield (Vector Laboratories) (Fig 2.3). 
2.4 Imaging and quantification 
2.4.1 Light microscopy 
All sections were viewed with a Nikon eclipse i50 microscope. Images were captured 
through a QICAM digital camera (QImaging Inc.) using a motorised stage (PRIOR Inc.) 
controlled by Image-Pro 5.1.2. image analysis software that is able to generate tiled images 
of whole sections or areas of interest. Whole section images were acquired at 40X 
magnification and used to measure the extent of demyelination in GM and WM. Images of 
areas of interest were acquired at 200X and used to measure immune cell subsets as well 
as MRP14+ and MHC-II microglia in the cortex. All images were acquired using optimized 
settings for light intensity, exposure and white balance depending on the objective and kept 
the same during every acquisition session. Images were saved as .TIFF file with spatial 
reference information settings for each objective based on calibration images. 
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Fig 2.3 Sequential double immunofluorescence: Tyramine amplification (A) The 
antigen A is detected with the first primary Ab (light red) and a secondary biotinilated (B, 
blue). Avidin (av) is conjugated with Horse-radish peroxidase (HRP) which catalyses the 
formation of reactive biotinylated tyramine () that covalently binds to proteins via electron 
rich moieties such as the amino acids tryptophan and tyrosine, resulting in the deposition of 
biotin at the reaction site. (B) Subsequent application of fluorescently labelled streptavidin 
(green triangles) binds to the newly deposited biotin. (C) The antigen B is detected with the 
second primary Ab (light blue) and a secondary Ab (violet) directly conjugated with a 
fluorochrome (red triangles). 
 
2.4.2 Fluorescence microscopy 
All sections were viewed with a Nikon eclipse i50 microscope using Lumen200 fluorescent 
illumination system (Prior Scientific) with filter sets to detect 488nm (green), 546nm (red) and 
310nm (DAPI) excitation wavelength. Images were captured with a QIACAM digital camera 
(QImaging Inc.) and using Image Pro Plus software 7.0 (Media Cybernetics Inc.) to control 
an OASIS turbo scan system that could create tiled images of areas of interest. Images were 
saved as .TIFF file with spatial reference information settings for each objective based on 
calibration images. 
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2.4.3 Quantification of areas and cells in tissue sections 
For each fixed frozen section immunostained for MOG an image was acquired at 4x 
magnification (a total of 399 blocks for 21 cases). The areas of demyelination and the total 
area of WM and GM were manually outlined for each section using Image Pro Plus software 
and then expressed as a percentage of the total area. Each fixed frozen tissue section with 
lymphocytic nuclei in the meninges (counterstained with haematoxylin) was then stained for 
CD20+ B-cells and CD3+ T-cells on sequential sections in order to quantify their density/mm 
of underlying cortex on at least 4 images acquired at 20X magnification; the number of 
images acquired varied depending on the localization and the number of infiltrates in the 
meninges. Each image consisted in different number of 20X fields tiled together in a single 
TIFF file. The absolute quantification of immune cells subsets in the meninges consisted in 
counting their number then dividing it by the length of the cortex (mm) underlying the 
counted cells in each image acquired; in case of a sulcus only one side of the pial surface of 
the cortex was included in the measure. The relative quantification was calculated as the 
percentage of positive cells on the total lymphocytic nuclei counted in the same section. 
Quantification of double immunofluorescence for CD8+CD161+ and CD161+TCRVα7.2+ in 
the meninges was done following the same method. The assessment of CCR6+ CD8+ cells 
was qualitative and done only for the 9 MS cases for which MAIT cells were quantified. After 
the selection of four fixed frozen and four snap frozen blocks per case containing a WM 
chronic active lesion, the density in WML lymphocyte subsets was measured on 20X images 
of four perivascular infiltrates within each lesion on sequential sections. The cell density was 
defined as cell number counted per area of interest (mm2), outlined to include the 
perivascular cuff of each vessel/arteriole.  
MHC class-II positive cells in the cortical GM were counted on one image, acquired at 20x, 
covering all cortical layers on the same four snap frozen tissue blocks in order to correlate 
with the counts of immune cell subsets within the meninges. The image of the cortex was 
then divided into areas delimiting each cortical layer as described previously (Magliozzi et 
al., 2010). Microglial density was defined as a ratio of positive cells in parenchyma and 
around blood vessels (count included both round and ramified MHC class-II positive cells) 
and area of each cortical layer in mm2. The density in layers I-III is the average of the 
densities of the first three cortical layers.  
The density of MRP14+ cells in the cortex was calculated on the same 4 snap frozen blocks 
used for the quantification of MHC-II. The density was first calculated for each tissue block 
dividing the total number of MRP14+ in the cortex by the total area of the cortex in that 
tissue block. Then the density of MRP14+ cells in each cortical layer was quantified but on 
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images acquired at 20X, covering all cortical layers and overlapping with the same cortical 
region used for quantification of MHC-II. The density of MRP14+ in each cortical layer was 
calculated as a ratio between the cells counted in each layer and the area of the layer 
outlined as described previously (Magliozzi et al., 2010). 
I performed all the quantifications and counts on acquired images that are saved on the 
Neuroscience hard disk. All the immunostained sections are labelled and classified by case 
and are stored in UK MS tissue bank. A limitation of this quantification method is the lack of 
another observer performing the counts and quantification in parallel. Given the time limits in 
this project and at the same time considering the large amount of samples used it was not 
possible to quantify the samples twice. However, it has been shown previously that 
quantification of pathology on acquired images shows an inter-individual variability <2% 
(Magliozzi et al., 2007). 
2.4.4 Quantification of CXCL12 redistribution in meningeal vessels 
To determine distribution of CXCL12 in the meningeal vessels, two FF tissue blocks 
containing intact meninges were double immunostained for CXCL12 and the CD31 from 
following MS cases: MS237, MS247, MS330, MS371, MS376, MS377, MS383, MS387. In 
addition, one tissue block from four control cases (C28, C32, C41, C46, details in Table 2.4) 
was examined. Sections were then viewed at 20x and 40x magnifications and both the total 
numbers, and the number of vessels with redistribution of CXCL12 present, were counted. 
Blood vessels with redistribution of CXCL12 were then expressed as a percentage of the 
total number of vessels, Due to a degree of tissue degradation, a meningeal vessel was only 
counted if it had a fully intact endothelial wall and visible lumen. A vessel was considered to 
have a redistribution of CXCL12 if there was obvious staining of the whole vessel lumen with 
the vector blue substrate. Images of the redistributed vessels were acquired at 40x 
magnification.  
Table 2.4 Individual clinical and autopsy details of the control cases 
Case ID Gender Age at Death 
(years) 
Cause of Death Post-mortem 
Delay (hours) 
C 28 Female 60 Ovarian cancer 13 
C 32 Male 88 Prostate cancer 22 
C 41 Male 54 Lung cancer 20 
C 46 Male 75 Renal Failure 24 
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Case MS 
subtype 
Sex 2 yrs 
relapse 
rate 
Age at 
onset 
Age at 
progression 
Age at 
wheelchair 
Age at 
death 
Disease 
duration 
PMD Cause of death 
MS426 SP F 2 18 28 34 48 30 21 Multiple sclerosis 
MS387 SP F 6 32 35 36 43 11 13 Multiple sclerosis 
MS379 
SP 
F 
ND 32 ND ND 49 17 21 Multiple sclerosis, 
Pulmonary embolism 
MS377 SP F 1 27 ND ND 50 23 22 Aspiration pneumonia 
MS376 SP F 3 37 40 44 58 21 19 Multiple sclerosis 
MS371 SP M 1 24 33 36 40 16 27 Bronchopneumonia 
MS364 
SP 
F 
1 22 32 34 56 34 14 Bronchopneumonia, 
multiple sclerosis 
MS363 
SP 
M 
ND 15 ND 30 42 27 20 End stage of multiple 
sclerosis, respiratory failure 
MS335 
SP 
M 
2 24 36 39 62 38 13 Recurrent aspiration 
pneumonia, multiple 
sclerosis, renal failure 
MS306 
SP 
M 
1 35 50 57 78 43 17 Clostridium difficile 
diarrhoea, multiple sclerosis 
MS241 
SP 
F 
ND 43 58 62 83 40 15 Septicaemia, 
bronchopneumonia, MS, 
diabetes mellitus 
Table 2.5 Clinical demographics describing the MS subtype and the main clinical milestones defining disease progression, including cause 
of death and the post mortem delay before the brain was dissected. 
72 
 
PMD, post-mortem delay; ND, no data; YRS, years; SP, secondary progressive; PP, primary progressive 
 
Case MS 
subtype 
Sex 2 yrs 
relapse 
rate 
Age at 
onset 
Age at 
progression 
Age at 
wheelchair 
Age at 
death 
Disease 
duration 
PMD Cause of death 
MS237 SP M 1 37 64 72 77 40 19 Pneumonia, heart attack 
MS181 SP F 4 39 ND 69 71 32 20 Pneumonia, MS 
MS179 
SP 
F 
1 44 ND 48 70 26 20 Aspiration pneumonia, 
sepsis, multiple sclerosis 
MS147 
SP 
F 
3 38 49 52 60 22 27 Pneumonia, multiple 
sclerosis 
MS143 
SP 
F 
ND 59 ND 65 77 18 13 Pulmonary embolism, 
multiple sclerosis 
MS120 
SP 
F 
2 37 41 60 72 35 21 Metastatic liver disease, 
multiple sclerosis 
MS383 
PP 
M 
0 34 34 36 42 8 17 Aspiration pneumonia, 
multiple sclerosis 
MS378 PP M 0 41 41 46 53 12 15 Pneumonia 
MS313 
PP 
M 
0 37 37 58 66 29 16 Gastrointestinal bleeding 
caused by peptic ulcer 
disease,MS 
MS247 
PP 
F 
0 60 60 66 67 7 12 Multiple sclerosis, 
respiratory failure 
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2.5 Statistical analysis 
Data was analysed and compared using GraphPad PRISM (Ver. 5.0, GraphPad Inc., CA). 
All measures were expressed as median ± interquartile range (IQR) or mean ± SEM and 
noted in the results. Statistical comparisons were made using the non-parametric Mann-
Whitney test or unpaired t-test as detailed in the results section. Testing for correlation 
between two groups used the Spearman’s test. A p-value of ≤0.05 was considered as 
statistically significant. 
2.6 Molecular analysis of cortical lesions 
2.6.1 Selection of the area to sample and dissection 
Each snap frozen block was analyzed by light microscopy to manually draw a “map” of 
MOG, MRP14 and MHC class-II staining localization. Areas of the cortex negative for MOG 
and positive for MRP14 and MHC class-II staining were outlined as (active) lesions. This 
map was kept as reference to identify the cortical area, whose dimensions were usually 
5x3mm, to be dissected when tissue block was in the cryostat. After immersion of a razor 
blade in RNase free ethanol, the edge of the selected area was delimited by 1 or 2mm deep 
cut.  Areas to sample were often localized deep in cerebral sulci were more often immune 
cells aggregation has been observed. Attention was paid to sample as much as possible 
from the first cortical layers avoiding to collect any material in the meninges, and from the 
deepest cortical layers, avoiding to collect tissue from the undelying white matter. Therefore, 
the cortical layers sampled included the second to the fifth cortical layer. An autoclaved 
0.5mL Eppendorf tube was then placed in the cryostat and filled with 0.5mL of Trizol using 
DNase, RNase free filter tips. Working as fast as possible, at least 20 sections, 10μm thick, 
were collected into Trizol with a small clean paintbrush in order to collect more than 10mg 
(minimum amount for RNA extraction) and less than 100mg (maximum amount for saturation 
of the extraction kit) of tissue. The Eppendorf tube lid was then closed, labelled, wrapped it 
in Para-film (Brand, Camlab, UK) and immediately stored at -80 °C. 
2.6.2 RNA extraction 
Ribonucleic acid (RNA) was extracted from brain tissue using the RNA Mini Lipid Tissue Kit 
(Qiagen) according to the manufacturer’s instructions. Each time extraction was performed 
on 4 samples to keep the timing of incubations, temperature conditions and centrifugations 
according to the protocol and therefore minimize RNA decay and/or loss. Samples were 
defrosted and left 5 min at room temperature to promote the dissociation of nucleoprotein 
complexes and then transferred to a 1.5mL tube. 200µl Chloroform was added to each tube 
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that was flipped upside-down by hand for 15 seconds and incubated at room temperature for 
2 minutes before being centrifuged at 12,000rpm for 15 minutes at 4˚C (Spectrafuge-24D, 
Jencons-PLS, UK). The upper aqueous phase was then carefully removed, placed in a new 
tube where an equal volume of 70% ethanol was added before quickly and thoroughly 
mixing by vortexing. Samples were transferred to filtration columns and washed in sequence 
with 700µL of buffer RW1 once and 500µL of buffer RPE twice (both are ethanol based 
solution provided by QIAGEN extraction kit). All these centrifugation steps are performed at 
12,000rpm for 15s at room temperature. A last 1 min centrifugation without any solution was 
performed to remove any ethanol left that may interfere with downstream reactions. RNeasy 
column was then placed on a new (autoclaved) 1.5mL tube and incubated for 45s, before 
centrifugation, with 30µL of RNase-free water. This final elution step was repeated three 
times to maximize the RNA yield in a final volume of about 80µL/sample. Samples were 
immediately stored on ice, measured on nanodrop before storing them at -20°C.  
2.6.3 Two-step quantitative Real-Time PCR 
Samples were kept on ice, before reverse transcription of RNA using the QuantiTect 
Reverse Transcription Kit (Qiagen). Contaminating genomic deoxyribonucleic acid (gDNA) 
was removed by incubating samples for 2 minutes at 42˚C in gDNA wipeout buffer. Reverse 
transcription (RT) was then performed by incubating the RNA of each sample at 42˚C for 15 
minutes with RT master mix containing Quantiscript Reverse Transcriptase, RT buffer, and 
RT primer mix. RT was de-activated by heating the sample to 95˚C for 3 minutes. cDNA was 
then measured on nanodrop, diluted 2 to 5 folds to have a final concentration of about 
0.5µg/µL then stored at -80 °C until required. Detection of gene specific cDNA was carried 
out using the Quantitect SYBR Green quantitative polymerase chain reaction (qPCR) kit 
(Qiagen), together with Quantitect Primer Assays for genes of interest. Briefly, 1µl 
complementary DNA (cDNA) was added to each reaction, together with SYBR green master 
mix, and 2.5µl primer (Table 2.5). The final reaction volume was 25µl. qPCR was then 
performed in triplicate for each sample on a Stratagene MXP4000 system (according to 
parameters in Table 2.6). 
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Table 2.6 Details of primers used for qPCR. All primers were obtained from Qiagen. 
Protein Name Assay Name Cat. Number 
GADPH Hs_GADPH_2_SG QT01192646 
macrophage inflammatory protein 2-
alpha, CXCL2 
Hs_CXCL2_1_SG QT00013104 
Fractalkine, CX3CL1 Hs_CX3CL1_1_SG QT00098490 
macrophage inflammatory protein 1-β, 
CCL4 
Hs_CCL4_1_SG QT01008070 
RANTES, CCL5 Hs_CCL5_1_SG QT00090083 
interferon-inducible T-cell alpha 
chemoattractant, CXCL11 
Hs_CXCL11_1_SG QT00233387 
CXCL12 receptor, CXCR4 Hs_CXCR4_2_SG QT02311841 
Interleukin-23 subunit alpha, IL23A Hs_IL23A_1_SG QT00204078 
Interleukin-17A, IL17A Hs_IL17A_1_SG QT00009233 
Chemokine receptor CXCR3 Hs_CXCR3_1_SG QT00213493 
Monokine induced by gamma 
interferon (MIG), CXCL9 
Hs_CXCL9_1_SG QT00013461 
Interferon gamma-induced protein 10 
(IP-10), CXCL10 
Hs_CXCL10_1_SG QT01003065 
C-C chemokine receptor type 3, 
CCR3 
Hs_CCR3_1_SG QT00087038 
C-C chemokine receptor type 2, 
CCR2 
Hs_CCR2_2_SG QT01665769 
monocyte chemotactic protein-1 
(MCP-1), CCL2 
Hs_CCL2_1_SG QT00212730 
Interleukin-8, IL8 Hs_IL8_1_SG QT00000322 
Chemokine (C-X-C motif) ligand 1, 
CXCL1 
Hs_CXCL1_1_SG QT00199752 
Chemokine (C-C motif) ligand 21, 
CCL21 
Hs_CCL21_3_SG QT01157366 
C-C motif chemokine 19, CCL19 Hs_CCL19_3_SG QT01157359 
 
Table 2.7 Thermal cycling parameters used for qPCR, conducted on a Stratagene MXP4000 
system. 
Step Time Temperature (˚C) Ramp rate (˚C/min) 
PCR Activation 15 min 95 20 
Denaturation 15s 94 20 
Annealing 30s 55 20 
Extension 30s 72 2 
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2.6.4 Data analysis and gene expression   
GADPH was chosen as the reference gene given that its expression level was constant 
across all samples. The samples analyzed were 21 MS cases and three controls with no 
neurological disease. In order to use the normalized expression ratio method a calibrator 
sample was created by pooling the cDNA from the 3 controls. Ct values for each sample 
were obtained where fluorescence was increasing in a logarithmic way, a threshold value 
was kept constant for all samples, and only when the dissociation curve was consistent 
between samples for each set of primers. Data was exported to Microsoft Excel and the 
average Ct for each sample was calculated. We performed downstream analysis according 
to the Livak Method (also known as the  method). This method assumes that both 
target and reference gene are amplified with efficiencies near 100% and within 5% of each 
other and is used to determine the expression level of the target gene in the test sample 
relative to the calibrator sample. I did not check primers efficiency using a dilution curve 
method, I assumed they had a near 100% efficiency according to the manufacturer 
instructions (QIAGEN). I first normalised the CT of the target gene to that of GADPH, for both 
the test sample (MS cases and controls) and the calibrator sample (a pool of the cDNA from 
all controls run in triplicate): 
 
Then I normalized the CT of the test sample to the CT of the calibrator: 
 
Then I calculated the normalized expression ratio 
 
The Normalized expression ratio is the ratio of the target gene in the test sample to the 
calibrator sample, normalised to the expression of the reference gene. Normalising the 
expression of the target gene to that of the reference gene compensates for any difference 
in the amount of sample tissue (Livak and Schmittgen, 2001). 
2.7 Laser capture of single CD8+ T cells from brain tissue 
Snap frozen sections were cut 10µm thick and collected on PET membrane slides (Carl 
Zeiss, Germany) (Fig 2.4 A), which were previously irradiated with UV light at 245nm for 30 
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min to make the membranes more hydrophilic, thus facilitating the adherence of snap frozen 
sections and sterilising them to destroy any potentially contaminating nucleic acids. Then 
sections were processed, as previously described for immunofluorescence, for the detection 
of CD8+T cells using mouse monoclonal Antibody (clone HIT8a, BD). No nuclei 
counterstaining with DAPI was performed. Then sections were washed with sterile molecular 
biology water (Fig 2.4 B) and single CD8+ T cells were manually outlined (Fig 2.4 C) and 
then laser captured (LCM) using the PALM system (Carl Zeiss, Germany) (Fig 2.4 D) into 
the cap of a plastic tube already containing 15 µL of a digesting solution made of 1X TE, 
0.005% TWEEN and 100µg/mL proteinase K (pK). The tube was then removed from the 
LCM and spun with a bench centrifuge. A digestion for 30 min at 55 °C was then performed 
in order to remove most of the proteins followed by 15 min incubation at 75 °C to inactivate 
pK. The tube was then spun again with a bench centrifuge and kept on ice before multiplex 
PCR. Spleen tissue was used a control in parallel with brain tissue. 
2.7.1 PCR on genomic DNA 
To verify the presence of intact genomic DNA after LCM, 7µL of the solution containing the 
digested CD8+ T cells, were add to a standard PCR mix with 2 primers designed to amplify 
a single gene, CACNA1E, from genomic DNA. Human genomic DNA, both untreated and 
digested under the same conditions, was used in parallel as positive control. PCR master 
mix conditions were the same as the ones for the multiplex PCR: 1 x ABI buffer II, 1.5 mM 
MgCl2 200 µM, 10 pmol of each primer, 200 uM dNTP and 2U AmpliTaq gold (Applied 
Biosystems, Foster City, CA, USA). Thermal cycling conditions were: 95 °C for 7 min; 38 
cycles at 94 °C for 30s, 58 °C for 30s, 72 °C for 30s and a final extension of 72 °C for 6 min. 
2.7.2 TCR BV BJ amplification with multiplex PCR 
TCR BV-BJ rearrangements were PCR amplified from genomic DNA using BIOMED-2 
multiple primers as described (van Dongen et al., 2003). Two BIOMED-2 multiplex primers 
sets were prepared: multiplex primer tube 1 containing 23 TCR BV and six JB1 gene-specific 
primers; and tube 2 containing the same TCR BV primers and seven JB2 gene-specific 
primers (van Dongen et al., 2003). Final PCR conditions were optimized to: 1 x ABI buffer II, 
1.5 mM MgCl2 200 µM (multiplex primer tube 1), 2 mM MgCl2 200 µM (multiplex primer tube 
2), 10 pmol of each primer, 200 uM dNTP and 2U AmpliTaq gold (Applied Biosystems, 
Foster City, CA, USA). Thermal cycling conditions were: 95 °C for 7 min; 40 cycles at 95 °C 
for 30s, 60 °C for 30s, 72 °C for 30s and a final extension of 72 °C for 10 min (Dubinsky et 
al., 2009). 
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Fig 2.4 Laser capture of single CD8+ T cells from brain tissue (A) PET membrane slides 
are used to collect snap frozen 10 µm thick brain sections. (B) Single immunofluorescence 
for CD8+ T cells (green) is the performed to localize them and manually outline the areas to 
laser capture (red circle) (C). A pulse of laser is then used to cut the cells from the tissue and 
eject them into a collection cap just above the tissue (D). A single laser captured cell is 
photographed (green) (E). Inside the collection cap a solution was previously added to allow 
the landing of the cells which are then spun to the bottom of the tube for digestion (F). The 
solution containing the digested cells and their genomic DNA is then used as a template for 
multiplex PCR (G). 
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Chapter 3 
 
Characterization of WM and GM lesions: parenchymal 
inflammation  
 
 
 
 
 
 
80 
 
3.1 Introduction 
3.1.1 The detection of lesions in grey matter 
Demyelinated lesions have been classically detected in MS white matter while, due to the 
reduced density of myelinated fibres in the GM traditional staining methods could not reveal 
them with the same sensitivity. Since the introduction of myelin immunohistochemistry,  
demyelination in cortical gray matter regions has been detected and reported to be a 
common finding that can be extensive (Bo et al., 2003b, Peterson et al., 2001). GM 
demyelination can also be found in other grey matter areas such as the thalamus, basal 
ganglia, hypothalamus, hippocampus, cerebellum and spinal cord (Huitinga et al., 2001, 
Geurts et al., 2007, Vercellino et al., 2005, Gilmore et al., 2006). Therefore we wanted to 
detect demyelination in the MS brain using MOG immunohistochemistry and quantify its 
extent in WM and GM. 
3.1.2 The features of grey matter pathology  
3.1.2.1 Grey matter lesions classification 
A classification of the lesions, based on the extent of grey matter demyelination within or 
beyond the delimitation of the cortex, has been proposed (Peterson et al., 2001): Type I 
lesions, also named leukocortical lesions, encompass both white matter and the cortex, 
Type II lesions reside entirely within the cortex, Type III lesions, also called subpial, extend 
from the pial surface into the deeper cortex, usually to layers 3 or 4 and often extending over 
several gyri. Type IV lesions, extending throughout the full width of the cerebral cortex but 
never reaching into the adjacent subcortical white matter, have also been described (Bo et 
al., 2003b). Our aim was to analyze the frequency of GM lesion types in the MS brain. 
3.1.2.2 Microglial activation  
The transition of microglia from a resting to an activated state is documented by increased 
expression of “activation” markers and changes in morphology (Farber and Kettenmann, 
2005) and increased numbers of activated microglia in presence of neuronal and astrocyte 
loss have been reported in the outer cortical layers of GM lesions (Magliozzi et al., 2010). 
There is strong evidence from in vitro experiments that activated microglia can produce 
substances that can produce neuronal and tissue damage, such as free oxygen radicals 
(Thery et al., 1991), nitric oxide (Chao et al., 1992) and cytokines (Rock et al., 2005). An 
EAE model of CNS inflammation has shown that the switch in the microglia phenotype is 
accompanied by inducible nitric oxide synthase (iNOS) and interleukin-1β (IL-1β) expression 
and increased axonal injury (Moreno et al., 2011). Furthermore microglia is able to 
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communicate directly with cellular carriers of adaptive immunity by exchanging soluble 
messengers and by physical contact, such as through MHC class-II, which presents 
antigens (Hanisch and Kettenmann, 2007). Therefore we wanted to measure the activation 
of microglia in the cortex in order to correlate it with the extent of tissue damage measured 
by demyelination extent. 
3.1.2.3 Paucity of perivascular inflammation  
The grey matter pathology is characterized by hypocellular lesions, showing a paucity of 
CD3+ lymphocytes and CD68+ microglia/macrophages when compared to white matter 
lesions (Kidd et al., 1999, Peterson et al., 2001).  In fact cortical lesions may not be 
classified on the basis of inflammatory activity or the presence of myelin proteins within 
macrophages because of the very low extent of inflammation and technical difficulties in 
detecting and sensibly quantifying the much lower amount of phagocytosed myelin within 
macrophages (Bo et al., 2003a). However, different studies have already reported a very low 
extent of inflammation in the grey matter parenchyma where perivascular infiltrates are rare 
and the density of infiltrating lymphocyte subsets (CD20+ B cell, CD4+ and CD8+ T cell) is 
not increased compared to normal controls and normal appearing GM (Vercellino et al., 
2005, Kidd et al., 1999, Magliozzi et al., 2007, Bo et al., 2003a).  
3.1.2.4 The role of macrophages 
There is extensive evidence of monocytes and macrophages in WM inflammatory infiltrates 
(Hauser et al., 1986, Adams et al., 1989) and parenchyma where they are suggested to play 
a direct role in myelin removal, while their role in the subarachnoid space and grey matter 
lesions is less defined.  A study on the expression of markers of macrophage activation in 
time and aimed at providing the parameters for defining the activity of white matter plaques, 
showed that MRP14, a 14-KD calcium-binding protein found in complex with MRP8, is 
expressed by monocytes/macrophages and identified it as a pathological marker of early 
active lesions (Bruck et al., 1995). Since MRP14 is not expressed by resident microglia and 
is absent from mature resident macrophages, in MS brain tissue clearly indicates acute 
inflammatory activity. In inflamed tissues the MRP14/8 complex is specifically released 
during the activation of phagocytes (Rammes et al., 1997, Frosch et al., 2000) and is 
deposited onto the endothelium of venules associated with extravasating lymphocytes (Hogg 
et al., 1989) where it has also been shown to induce a thrombogenic inflammatory response 
by inducing at the same time an increase in expression of pro-inflammatory chemokines and 
adhesion molecules and a decrease in the expression of cell junction proteins and molecules 
involved in monolayer integrity (Viemann et al., 2005).  It has also been shown that MRP14/8 
complexes can induce nitric oxide (NO) production in macrophages as potently as IFN-γ and 
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that in combination, these cytokines, further synergize the NO secretion from macrophages 
(Pouliot et al., 2008). In MS elevated serum levels have been found in patients during 
relapse when compared to patients in remission (Bogumil et al., 1998) while the expression 
and the release of MRP14/8 complexes by phagocytes correlates with disease activity in 
other inflammatory disorders like rheumatoid arthritis (Foell and Roth, 2004) and psoriasis 
(Benoit et al., 2006).  
The role of macrophages in cortical pathology has been reported in a study in which the 
induction of EAE in the common marmoset, a non-human-primate model for MS, has 
allowed the detailed analysis of the cellular composition of early cortical inflammatory 
demyelinating pathology, showing that inflammatory infiltrates were predominantly 
composed by CD3+ T cells and MRP14+ macrophages, a marker only expressed in early 
differentiation stages of monocytes and neutrophils. Interestingly the density of MRP14+ 
cells was higher in WM subcortical lesions than in GM lesions (Merkler et al., 2006). 
Therefore we wanted to investigate the presence of macrophages in cortical lesions and 
quantify their density. 
3.1.3 The features of white matter pathology 
The hallmark of MS pathology is the presence in the white matter of visible and sometimes 
extensive plaques of demyelinated sclerotic tissue. Histological analysis has shown that 
white matter pathology is characterized by multiple foci of inflammation consisting of 
abundant perivascular and sometimes parenchymal lymphocytic infiltrates, consisting of T 
cell (Friese and Fugger, 2009, Babbe et al., 2000), B cell and plasma cell (Prineas and 
Wright, 1978) and monocytes/macrophages (Bruck et al., 1995). These inflammatory 
infiltrates are accompanied by loss of oligodendrocytes and demyelination.  In conclusion the 
pathology of WM lesions differs from that of GM lesions in that significant lymphocyte 
infiltration, both in parenchyma and in perivascular space, complement deposition (Brink et 
al., 2005) and macrophages have been detected, whereas GM lesions are characterized by 
low inflammation. Therefore we wanted to characterize the inflammatory infiltrates in WM 
lesions and verify a possible correlation with the extent of demyelination. 
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3.1.4 Aims of this study  
 
1. Evaluate the extent of demyelination in WM and GM  
2. Classify GM demyelination into lesion Type and according to the qualitative 
evaluation of MHC class-II 
3. Test the possible correlation between the density of microglial activation in the first 
and the deeper three cortical layers with the extent of cortical demyelination 
4. Assess the presence of inflammatory infiltrates in the MS brain cortex 
5. Assess the presence and quantify MRP14+ monocytes/macrophages in the cortex 
6. Quantify white matter perivascular inflammation in chronic active lesions measuring 
absolute and relative contribution of B and T cells subsets.  
7. Test for correlations between immune cells densities measured in WML and the 
extent of demyelination in WM parenchyma. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
84 
 
3.2 Results 
3.2.1 Myelin loss is more extensive in GM than in WM 
Lesions in the WM were randomly distributed in the cerebrum and I always observed lesions 
in the periventricular areas for each case analysed. Lesions in GM were characterized by a 
ribbon-like pattern sometimes extending over multiple gyri and showing homogeneity of 
MHC-II staining within each case (Fig 3.1 A, B, C).  Myelin loss was defined by the lack of 
MOG immunostaining and its extent expressed as a percentage of WM and GM. 
Quantification of ~19 tissue blocks for each of the 21 cases showed that the area of GML 
was more extensive than WML (median ± IQR, GML% = 28 ± 27 and WML% = 6 ± 10, ***p < 
0.0001) (Fig 3.2 A) and that there was a linear correlation between the demyelination in 
these two compartments (r = 0.5273, p = 0.014, Fig 3.2 B). 
3.2.2 Type III GM lesions are the most frequent 
Cortical lesions were identified and characterized according to lesion classification proposed 
by Peterson and Bo (Peterson et al., 2001, Bo et al., 2003b) on the basis of MOG 
immunohistochemistry. We observed Type III (Fig 3.3 A) and Type I and III lesions (Type 
I/III) extending from the pial surface into the WM (Fig 3.3 B) but did not observe Type II and 
Type IV lesions. In total three hundred and fifty two cortical lesions were detected in 395 
tissue blocks from 21 MS cases. Type III lesions were the most frequently observed in our 
cohort (mean number of lesions/case ± SEM, Type III = 11 ± 1, Type I/III = 7 ± 2, paired t-
test, p = 0.05 Fig 3.3 C). Type III lesions represented the 67% (237/352) of all GM lesions 
and Type I/III lesions accounted for 33% (115/352) of the total lesions (Fig 3.3 D). 
3.2.3 Paucity of inflammation in GM parenchyma 
Since a recent report on biopsies tissue revealed the presence of inflammatory infiltrates in 
GM lesions (Popescu et al., 2011, Lucchinetti et al., 2011) there is increasing interest in the 
assessment of inflammation in the perivascular space of cortical vessels. Although in 
secondary progressive MS presence of immune cells in GM has been seldom observed, we 
detected small numbers of CD8+, CD4+ T and CD20+ B cells around blood vessels in GML 
(Fig 3.4 A, B, C respectively). Notably this observation was made in just two cases (MS426, 
MS371) with severe microglial activation and extensive GM demyelination. Given to the very 
low frequency of this finding, they could not be quantified. 
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Figure 3.1 Ribbon-like pattern of demyelination and microglia activation in grey matter 
lesions (A) MOG immunohistochemistry allows to identify the edge of the lesion (black 
arrows). (B) MHC-II positive microglia is more activated at the edge of a lesion that seems to 
extend from the subarachnoid space (SAS) into the deeper cortex. (C) An example of GM 
lesion, detected with MOG staining, extending with a ribbon-like pattern over several gyri. It 
must be noted that this is an exceptional case (MS378). (D) MOG staining in a control case 
shows normal non lesional GM. Images A and B acquired at 10X, scale bars = 100µm. 
Images C and D acquired at 4X, scale bar C = 2 mm, D = 200µm. 
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Figure 3.2 Demyelination is more extensive in grey matter than in white matter  
(A) Demyelination in GM was more extensive than in WM (median ± IQR, GML% = 28 ± 27 
and WML% = 6 ± 10, ***p < 0.0001) and showed a positive correlation between these two 
compartments (p = 0.01, r = 0.52673) (B) Each black dot in both graphs represents the 
percentage of demylination in GM and WM for each MS case. In each of the 19 FF 
blocks/MS case the GM and WM areas, as well as GML and WML areas, were outlined and 
then summed within each case. GML and WML were then expressed as a percentage of the 
total areas of GM and WM. 
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 Figure 3.3 Subpial lesions are the most frequent in cortical pathology 
(A) An example of the detection of Type III GM lesion with MOG immunostaining (black 
arrows point at the lesion border). (B) An example of Type I/III lesion which involves the GM 
and the WM. I performed the analysis of lesion Type considering I and III lesions together to 
reprent the frequent observation in MS pathology that purely subpial (Type III) lesions also 
include areas of demyelination in WM (Type I). (C)Type III lesions were a more frequent 
finding: the mean number of Type III lesions/case was higher than the number of Type I/III 
lesions/case (*p = 0.05). (D) Type III, subpial lesions represented the 67% while Type I/III 
lesions were 33% of the total GM lesions.  
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Figure 3.4 Paucity of perivascular infiltrates in grey matter pathology 
(A) CD20+ B cells were rarely detected in GM lesions infiltrates. (B) An example of the 
presence of few CD8+T cells in the perivascular space of blood vessel in a GM lesion. (C) 
CD4+ T were also detected from sequential sections of the same GM lesion, all images 
acquired at 200X, inserts scale bars = 20µm.  
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3.2.4 Density of MRP14+ cells in the cortex: an increased density is 
associated with active lesions  
We detected a small number of MRP14+ cells in GM using immunohistochemistry on snap 
frozen tissue blocks (Fig 3.5 A). In order to verify whether they were in the GM parenchyma 
or associated with the cortical microvasculature, we used double immunofluorescence for 
MRP14 and laminin, a major protein in basal lamina of vessels (Fig 3.5 B). The laminin 
staining shows the localization and the distribution of microvessels in first cortical layers and 
in the overlying meninges (Fig 3.5 C). MRP14+ cells were always found associated with the 
cortical and meningeal microvasculature. We then quantified MRP14+ cells density per 
cortical layer (Fig 3.5 D) and showed that they are less dense in the first cortical layer when 
compared with the second (p = 0.0082) and the third (p = 0.0322). Interestingly the density in 
each layer showed a progressive, but not statistically significant, decrease going towards 
deeper layers. The median densities of MRP14 positive cells for each layer are reported in 
Table 3.1. We then divided the tissue blocks according to MHC-II density in active and silent 
GM lesions, as described in the methods, to show that MRP14+ cells are more dense in 
active lesions when compared to silent GM lesions (p = 0.0286, Fig 3.5 E). 
Table 3.1 Quantification of MRP14 positive cells in each cortical layer: quantification 
was performed on one 200X image including all cortical layers and covering the 
same cortical region of MHC-II quantification on one snap frozen tissue block   
Cortical layer Density of MRP14+ cells/mm2 
(median ± IQR) 
I 3 ± 12 
II 13 ± 15 
III 12 ± 14 
IV 10 ± 15 
V 8 ± 11 
VI 8 ± 8 
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Figure 3.5 The density of MRP14+ cells associated with cortical microvessels is 
increased in active grey matter lesions 
(A) The immunohistochemistry for MRP14+ shows the presence of macrophage-like cells in 
the cortex. Image acquired at 200X, inset scale bar = 20µm. (B) The double 
immunofluorescence for MRP14 (red) and laminin (green) shows that all macrophage-like 
cells are associated to cortical microvasculature. Image acquired at 400X, scale bar = 20µm. 
(C) The immunofluorescence for laminin (green) shows the high density of microvessels in 
the first cortical layers. (D) The quantification of MRP14+ cells showed an increased density 
of MRP14+ cells in layers II (** p = 0.0082) and III  (* p = 0.0322) when compared to layer I. 
(E) The density of MRP14+ cells is increased in the cortex of active grey matter lesions 
compared to the cortex of silent GM lesions (*p = 0.0286). 
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3.2.5 A gradient of MHC-II+ cells density correlates with the extent of 
demyelination in the cortex 
The quantification of MHC-II immunohistochemistry in each cortical layer showed no 
statistically significant difference in microglial numbers between layers, although the trend 
was a decrease on microglia density from the first to the second layer followed by a constant 
low increase from the second until the sixth layer (Fig 3.6 A). Since MHC-II is upregulated by 
active microglia, but constitutively expressed by macrophages and antigen presenting cells, 
morphology of cells was considered during the quantification: counting included round or 
ramified MHC-II positive cells in cortex. All densities per layer according to the different 
morphologies are reported in Table 3.2: MHC class-II density for all events was used for 
testing the correlation with GML%. The average density in layers I to III and layers III to VI 
showed a positive correlation with demyelination in GM (Fig 3.6 B and C respectively). 
Table 3.2 Quantification of MHC-II+ cells in each cortical layer: densities are reported 
here according to their morphology: round or ramified. In the last row of table is 
reported the density of all positive cells regardless of their morphology.  
 
MHC-II 
cells/mm2 
Layer I Layer II Layer III Layer IV Layer V Layer VI 
round 62 ± 58 38 ± 46 41 ± 36 42 ± 33 41 ± 40 39 ± 34 
ramified 47 ± 76 17 ± 49 13 ± 64 29 ± 54 35 ± 87 35 ± 74 
all 109 ± 120 66 ± 75 72 ± 83 68 ± 87 71 ± 106 93 ± 91 
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Figure 3.6 Microglial activation correlates with the extent of demyelination in the 
cortex 
(A) MHC-II density in layer I shows a trend to be higher than in layer II and then it shows an 
increasing gradient from layer II to layer VI. The average density of MHC-II positive cells in 
layers I to III (B) and in layers IV to VI (C) positively correlate with the extent of 
demyelination in the cortex. An example of MHC-II immunostaining in GM lesions (D) 
showing higher microglial activation than the same immunostaining in the GM of a control 
case (E), image acquired at 20X, scale bars = 100µm. 
3.2.6 Characterization of inflammation in white matter chronic active 
lesions  
Quantification of CD20+ B cells, CD3+, CD4+ and CD8+ T cells subsets in perivascular 
infiltrates was performed for chronic active WMLs in order to assess absolute and relative 
contribution to inflammation in WM perivascular infiltrates. Absolute and relative 
quantification of the numerical density of B and T cell subsets in WML are shown in Table 
3.3. T cells were more abundant than B cells (**p = 0.023) and CD8+ cells outnumbered 
CD4+ cells (**p = 0.023) (Fig 3.7 A). The percentage of lymphocytes expressing CD3+ was 
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higher than the percentage of CD20+ B cells (p < 0.0001), the percentage of T cells 
expressing CD8+ was higher than the percentage of T cells expressing CD4 (p < 0.0001) 
(Fig 3.7 B). An example of immunohistochemistry for each lymphocyte subset found in 
perivascular infiltrates is shown in Fig 3.7 C, D, E, F. 
Table 3.3 Absolute and relative quantification of B and T cell subsets: quantification of 
density in chronic active lesions perivascular infiltrates was performed on 200X 
images of four blood vessels in chronic active WML. The percentage of each subset 
was calculated on total lymphocytic nuclei counted. 
Immune cell subset 
marker 
Density in WML 
(cells/mm2, median ± IQR) 
% in WML 
(median % ± IQR) 
B cells, CD20 370 ± 459 33 ± 12 
T cells, CD3 787 ± 751 67 ± 11 
Th cells, CD4 295 ± 271 35 ± 15 
CTL, CD8 550 ± 584 66 ± 15 
Th, T helper cells, CTL, cytotoxic lymphocytes; IQR interquartile range; WML, white matter 
lesion 
3.2.6.1 Lack of correlation between inflammation and extent of demyelination in 
chronic active WM lesions 
The density of CD20+ B cells, CD3+, and CD8+ T cells subsets, measured as cells/mm2 in 
WML perivascular infiltrates, showed no significant linear correlation with the percentage of 
demyelination in WM (Fig 3.9 A, B, C). Only the density of CD4+ T cells showed a positive 
correlation. However, no statistically significant correlation was observed between the sum 
of CD3+T and CD20+ T and demyelination in WM (Fig 3.9 E).  The density of T cells in WML 
infiltrates showed a positive correlation (r = 0.8416, p < 0.0001) with the density of B cells. 
The same correlation was observed between CD4+ and CD8+ T cells in WML (r = 0.7558, p 
< 0.0001) (Fig 3.9 F, G respectively). 
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Figure 3.7 Characterization of perivascular infiltrates in chronic active WM lesions 
(previous page) 
(A) The quantification of immune cell subsets in perivascular spaces of WM chronic active 
lesions showed that the density of CD20+ B cells (median ± IQR, 370 ± 459 cells/mm2) is 
significantly lower than CD3+ T (787 ± 751 cells/mm2, **p = 0.023) and that CD4+ T cells 
(295 ± 271 cells/mm2) are less than CD8+ T cells (550 ± 584 cells/mm2, **p = 0.023). (B) 
The same cellular counts expressed as percentages of total lymphocytic nuclei shows that B 
cells represent (median ± IQR), 33 ± 12%, T cells (67 ± 11 %), CD4+ T helper cells (35 ± 
15%) and cytotoxic CD8+ T cells (66 ± 15%). The median percentage of CD3+ and CD8+ T 
cells is higher than that of CD20+ B and CD4+T cells respectively ( ***p < 0.0001). An 
example of the immunostaining for CD3+, CD20+, CD4+ and CD8+ is given panels (C-F). All 
images acquired at 200X, scale bars = 70µm. 
 
Figure 3.8 Positive correlations between immune cell subsets density in WM 
perivascular infiltrates but not between the extent of WM demyelination and 
inflammation (next page) 
The densities of B and T cells in the white matter infiltrates show a strong positive correlation 
(A) which was observed also between the densities of CD4+ and CD8+ T cells in WML (B). 
Although cases with more extensive WML% tend to have more florid inflammatory infiltrates 
there is no statistically significant correlation between WML% and the density of CD3+ T 
cells (C), CD20+ B cells (D), CD8+ T cells (E) and the sum of CD20+ and CD3+ (F). Instead 
the correlation between the density of CD4+ T cells and WML% is statistically significant (p = 
0.0495, r = 0.4338) (G). 
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3.3 Discussion 
3.3.1 More extensive demyelination in the cortex correlates with 
white matter lesion load 
In accordance with different studies on post-mortem MS brain we found that grey matter 
pathology is a common finding in the MS brain and its relative extent is higher in the cortex 
than in white matter parenchyma (Kutzelnigg et al., 2005, Magliozzi et al., 2007, Howell et 
al., 2011).  We also observed a strong correlation between the lesion load in the cortex and 
in the white matter parenchyma suggestive that, even if the pathological mechanisms 
underlying lesion formation and the accumulation of demyelination over time might be 
different between these two compartments, they are interdependent. In this sense neuronal 
death in the cortex and axonal loss in the white matter are interlinked by anterograde and 
retrograde degeneration. In fact axonal damage in WM can induce acute secondary cell 
death of cortical neurons (Meyer et al., 2001) and cell death and demyelination in the cortex 
can lead to axonal loss in WM (Peterson et al., 2001). There is in fact evidence in histology 
and MRI studies that during the progressive phase of MS, cortical pathology, predominantly 
of the subpial type, is accompanied by a more diffuse pathology in the white matter 
(Horakova et al., 2008, Geurts et al., 2005a, Kutzelnigg et al., 2005). The higher percentage 
of demyelination in cortex might be explained by a faster accumulation of tissue damage in 
GM than in WM during MS progression. 
3.3.2 Subpial lesions and paucity of perivascular inflammation 
characterize cortical pathology 
We found that the predominant grey matter lesion type was subpial. Furthermore, we 
observed that the pattern of cortical demyelination showed an homogeneous trend within 
each case. This was also observed for the qualitative evaluation of microglia activation. We 
also showed that in cortical lesions perivascular spaces are rarely populated by B and T cell 
subsets but are often associated with an increased microglial activation, in accordance with 
previous observations (Peterson et al., 2001). Since a study on biopsies material showed 
that 82% of cortical lesions exhibit significant CD3+ T cell infiltrates (Lucchinetti et al., 2011), 
we can speculate that cortical lesions occur on a background of lymphocytic inflammation in 
the parenchyma only earlier in the disease course, for example during the relapsing-
remitting phase. If this is the case then, the non-inflammatory character of chronic cortical 
demyelination observed most frequently in post-mortem samples may relate to the long 
interval between lesion formation and autopsy or even to a different mechanism underlying 
cortical pathology between the early relapsing-remitting and the late chronic progressive 
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phases. We could also speculate that these different observations might reflect the changes 
in the expression of adhesion molecules on cortical blood vessels over time during the 
disease course. It has been shown that in patients with RRMS CD8+ T cells, but not CD4+ T 
cells, display an increased rolling and arrest in inflamed murine brain venules, which is 
dependent on binding to P-selectin (Battistini et al., 2003). In conclusion, there is evidence 
that the extent of lymphocytes infiltration in cortical lesions may also depend on patient 
population, as lymphocyte infiltration has so far been reported to be present in purely cortical 
lesions of biopsied patients. We might speculate either that the pathogenesis of cortical 
demyelination is different in the subgroup of MS patients sampled in those studies, or that 
inflammation in the perivascular space of cortical vessels is transient and therefore seldom 
detected in samples from chronic progressive MS patients.  
3.3.3 Higher density of MRP14+ cells associated to cortical 
microvasculature of active grey matter lesions  
In chronic active cortical lesions the density of MRP14+ macrophages was significantly 
higher than in chronic silent lesions and these macrophages were found associated with 
cortical microvasculature with their density decreasing away towards the deeper cortical 
layers. In particular their density exhibited a trend to be increased in layers II and III in 
agreement with the finding of a substantial loss of neurons with pyramidal morphology in 
layer III of the SPMS brain (Magliozzi et al., 2010). These observations, taken together with 
an opposite gradient of increased density of activated microglia, suggest an association 
between the increased adhesion of macrophages to cortical microvessels and microglia 
activation. This pathology finding is suggestive that cortical MRP14+ 
macrophages/monocytes might be involved in tissue damage and secretion of pro-
inflammatory cytokines.  
There is in fact evidence that in MS WM plaques axonal injury is not tightly associated with 
the adaptive immune response but is instead associated with innate immune response 
consisting of macrophage activation (Henderson et al., 2009). In addition, the induction of 
systemic inflammation, using LPS, during the remission phase of monophasic EAE, induced 
a switch in the inflammatory mediator profile in the microglia/macrophages that in turn was 
associated with exacerbation of axonal injury (Moreno et al., 2011). Further evidence in this 
sense comes from the increases in circulating inflammatory monocytes that have been 
shown to correlate with relapses in EAE mice (King et al., 2009). We could assume, on the 
basis of our observations, that also in the MS brain cortex any inflammatory response, either 
systemic of compartmentalized within the CNS, could communicate with the parenchyma via 
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humoral routes (Dantzer et al., 2008) inducing an increase in microglia activation and 
monocytes/macrophages adhesion to blood vessels.  
A disrupted BBB might also be at the basis of penetration of pro-inflammatory soluble 
signals to cortical parenchyma in during chronic CNS inflammation. Another function of 
MRP14+ cells on cortical blood vessels could be to disrupt the integrity of the BBB. In fact it 
has been shown that MRP14/MRP8 complex, which comprises up to 40% of cytosolic 
proteins in neutrophils (Edgeworth et al., 1991, Roth et al., 1993, Zwadlo et al., 1988) has, 
once released, a disruptive effect on endothelial integrity by inducing apoptosis and necrosis 
in endothelial cells (Viemann et al., 2007, Viemann et al., 2005). Because high amounts of 
MRP14/MRP8 are released by activated phagocytes in the course of inflammation in many 
different diseases, including MS (Frosch et al., 2000, Frosch et al., 2003, Kane et al., 2003, 
Odink et al., 1987, Bogumil et al., 1998, Foell et al., 2004, Foell and Roth, 2004, Benoit et 
al., 2006), MRP14/MRP8-induced endothelial damage is likely to represent an important 
pathological mechanism involved in BBB dysfunction also in MS cortical pathology.  
3.3.4 The degree of microglial activation correlates with the extent of 
GM demyelination  
We showed that the numerical density of MHC class-II expressing cells positively correlated 
with the extent of demyelination in the cortical GM, suggesting a role of microglia in the 
process of chronic cortical demyelination in the progressive MS brain. Almost any 
manipulation or insult to the brain that disturbs homeostasis leads to microglia activation, 
which manifests as a change in morphology and the upregulation or de novo synthesis of 
receptors on the cell surface (Kreutzberg, 1996). The detection of activated microglia is such 
a common sign in different pathological conditions that evidence of brain pathology that is 
not accompanied by the activation of microglia is hard to find (Perry et al., Ransohoff and 
Perry, 2009, Hanisch and Kettenmann, 2007). Microglia express surface receptors, including 
toll-like receptors, RAGE and a number of purinergic receptors (Salminen et al., 2009, 
Haynes et al., 2006) to detect damage associated molecular pattern molecules (DAMPs) 
such as heat shock proteins, oxidized lipids, ATP and DNA. Therefore any injury that can 
lead to degeneration of neurons and neuronal processes, will generate DAMPs that in turn 
might activate microglia. This kind of response arises rapidly and consists in the synthesis of 
proinflammatory cytokines and other inflammatory mediators. These cytokines in turn could 
induce the synthesis of chemokines, leading to the recruitment of neutrophils and monocyte 
from the blood.  
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However, we could also speculate that what we detect as “activated microglia”, shown by 
morphological assessment, in the brain with progressive MS might be instead an 
“alternatively activated” phenotype typically associated with an anti-inflammatory profile 
(Aloisi et al., 1999, Boven et al., 2006). Our observation based on the density of MHC class-
II expression and morphological changes do not allow any conclusion and we could only 
speculate that in the MS cortex the progressive loss of neurons (Magliozzi et al., 2010) could 
lead to microglial “priming” during early lesion stages. As neuronal death progresses, 
microglia would then retain an innate immune memory of the ongoing, never completely 
resolved, neuropathological process, which in turn could be associated with a heightened 
responsiveness to other inflammatory soluble stimuli.  
3.3.5 T cells characterize perivascular inflammation of white matter 
lesions 
Our analysis of WM pathology showed that, in the florid inflammatory infiltrates 
characterizing chronic/active lesions, CD3+T cells were more common than CD20+ B cells 
and CD8+ T cells outnumbered CD4+ T cells. In the past, other histological investigations on 
MS brain quantified perivascular, and also parenchymal inflammation, within active and 
chronic active WM lesions (Traugott et al., 1983b, Hauser et al., 1986, Booss et al., 1983) 
showing a prevalence of CD8+ T cells over CD4+ T cells and that CD8+ T cells closely 
interact with demyelinated axons (Neumann et al., 2002). However, many studies have 
focused on CD4+ T cells, based on the evidence that MBP-specific CD4+ T cells can 
transfer EAE (Ben-Nun and Cohen, 1981, Ben-Nun et al., 1981) but recently, studies 
investigating the pathogenic role of auto-aggressive, cytotoxic CD8+ T cells in MS 
pathogenesis were intensified (Friese and Fugger, 2009, Friese and Fugger, 2005). In fact 
CD8+ T cells have been found clonally expanded in the cerebrospinal fluid, in the blood and 
in the lesions of MS patients (Babbe et al., 2000, Crawford et al., 2004, Skulina et al., 2004), 
and their role in MS pathology has been reassessed based on the evidence of CD8-
mediated lysis of HLA-matched oligodendrocytes (Jurewicz et al., 1998) and transection of 
dissociated single neurons (Medana et al., 2001). In addition, continuous confocal imaging of 
autoaggressive, cytotoxic CD8+ T cells in living organotypic cerebellar brain slices has 
shown CD8-mediated damage to myelinated axons as well as “collateral bystander 
damage”, consisting in vast demyelination, when their cognate antigen was processed and 
presented by oligodendrocytes (Sobottka et al., 2009). We commonly found CD8+ T cells 
associated with white matter pathology but the extent of demyelination in WM did not 
correlate with their density measured in the perivascular space of chronic active lesions. This 
lack of correlation was also observed for CD20+ B cells and for the total inflammation 
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calculated as the sum of CD20+ B and CD3+ T cells but not for CD4+ T cells. The analysis 
of inflammatory infiltrates in white matter instead revealed a strong correlation between the 
densities of CD4+ and CD8+ T cells and of CD3+ T and CD20+ B cells in WM lesions. This 
is in keeping with the role of CD4+ T cells as helper, together with B cells as antigen 
presenting cells, in shaping the CD8+ T response in the compartmentalized perivascular 
environment where they can interact by means of cell-to-cell contact and secretion of 
cytokines. 
3.3.6 Conclusions 
Here we have shown that GM demyelination has a greater relative extension than in WM 
and is predominantly of the subpial type. In addition, more severe cortical pathology was 
characterized by microglia activation and a higher density of MRP14+ 
monocytes/macrophages associated with microvessels but exhibited a paucity of B and T 
cells subsets that were seldom detected. These observations highlight the importance of 
cortical damage in MS pathology and confirm the differential pathology findings in white 
matter lesions, which were instead highly inflammatory and exhibited numerous CD8+ T 
cells even at the end of the disease. On this basis of these observations the concepts that 
grey matter demyelination accumulates in part independently from the one in white matter 
and that different pathological mechanisms might underlie it, have emerged. Even if the 
lesion load in WM and GM show a positive correlation, during the later stages of the disease 
the underlying immunological and neuropathological mechanisms might be different from the 
ones present at the beginning. In fact it has been proposed that while inflammatory “waves” 
characterize the early stages of the disease, it is neurodegeneration that drives slow lesion 
expansion during progression, especially in the cortex (Reynolds et al., 2011). In this sense 
my observation of lymphocyte infiltration in GM is limited, due to the low n number in post-
mortem cases, and a possible future direction could be the comparison of disease duration 
and age at death between MS cases with or without GM lymphocytic infiltration. The 
detection of inflammation in the meninges has in recent year been considered to be 
associated with cortical pathology and therefore we wanted to characterize it further to verify 
their relationship. 
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Chapter 4 
 
Relationship between meningeal inflammation and 
cortical pathology     
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4.1 Introduction 
Multiple sclerosis has been classically considered a white matter disease mainly owing to 
poor visualization of demyelination within grey matter areas with conventional histological 
staining methods. However early pathology studies (Brownell and Hughes, 1962) on MS 
post-mortem brain had already shown that grey matter regions are also heavily affected and 
more recently, with the introduction of myelin immunohistochemistry, the topic of 
demyelination in GM has gained new impetus (Bo et al., 2003b, Bo et al., 2003a, Peterson et 
al., 2001). In a similar way the presence of immune cell infiltrates in the leptomeninges 
overlying the cerebrum has been described as a common pathological feature in post-
mortem MS brain by older (Guseo and Jellinger, 1975) and more recent studies (Howell et 
al., 2011).  
The pathology of grey matter lesions differs from that of white matter lesions with regard to 
paucity of lymphocytic infiltrates, absence of complement deposition and only moderate BBB 
disruption. Therefore, there is some debate concerning whether different pathogenetic 
mechanisms might be involved in the formation and then the accrual of GM lesions during 
the different phases of the disease, in particular whether the accumulation of damage in GM 
could be partly independent from focal WM lesions during the disease progression (Bo et al., 
2007, Kutzelnigg et al., 2005, Chard and Miller, 2009). Whilst the significance of perivascular 
and parenchymal infiltrations associated with white matter lesions has been considered the 
cause behind demyelination through the direct destruction of axons by activated immune 
cells (Trapp et al., 1998), the presence of perivascular infiltration in the meninges has been 
considered the cause of direct damage to the oligodendrocytes and myelin by both antibody 
dependent and antibody independent mechanisms. In particular the antibody independent 
mechanisms is thought to be exerted by the secretion of toxic soluble mediators produced by 
the immune cells in the meninges  (Reynolds et al., 2011).  
4.1.1 The relationship between cortical pathology and meningeal 
inflammation: the detection of ectopic B cell follicles 
Therefore, a number of pathology studies have been carried out first to characterize the 
extent and the severity of grey matter lesions and then to describe in detail the phenotype of 
the immune cells present in the meninges and their possible interactions within the MS brain 
during the progressive phase of the disease. First the presence of an extensive subpial 
ribbon-like pattern of demyelination in cases with SPMS has been reported (Bo et al., 2003b, 
Kutzelnigg et al., 2005).  
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At the same time with the reassessment of cortical demyelination in MS and the debate 
about its pathogenesis, different studies revealed the presence and also characterized the 
immune cells infiltrates in the leptomeninges overlying cortical pathology both in post-
mortem MS brain (Serafini et al., 2004) and in EAE model (Magliozzi et al., 2004). Notably 
these seminal studies revealed the presence of lymphoid-like structures in the meninges 
characterized by large aggregates of proliferating CD20+ B cells and CD3+ T cells, 
interspersed with CD21+, CD35+ Follicular Dendritic Cells together with CD138+ plasma 
cells. Serafini and Magliozzi also detected the presence and showed the expression of 
relevant homing lymphoid chemokines, such as CXCL13 and CCL21, and B-cell-activating 
factor (BAFF), suggestive of germinal centres formation within the meninges. These 
observations indicated that, under chronic inflammatory conditions, the immune specialized 
meningeal compartment is where ectopic lymphoid follicles can develop and where 
pathogenic B-cell responses could be sustained in autoimmune disorders of the CNS. 
Following these evidences further investigation of a larger cohort of cases was carried out 
with the goal of assessing the possible association of these lymphoid-like structures with 
clinical and pathological features, revealing that these large proliferating B and T cell 
aggregates were present in 41% of SPMS cases that were characterized by a more severe 
cortical pathology and also by a more aggressive disease course (Magliozzi et al., 2007). A 
definitive study, that included analysis of 123 SPMS cases  with a wide range of ages at 
death and disease duration, confirmed the frequency of ectopic follicle-like structures in the 
meninges and their association with increased parenchymal grey matter pathology as well 
as showing a positive correlation between widespread, non-organized, meningeal 
inflammation with the extent of grey matter lesion area (Howell et al., 2011). 
4.1.2 Ectopic B cell follicle-like structures in the meninges and the 
compartmentalization of the immune response within the CNS  
The cases exhibiting more severe cortical pathology were also characterized by an 
increased density of immune cells in the meninges and this was associated with a gradient 
of microglial activation. In addition, a clear gradient of neuronal loss, glia limitans damage 
and astrocyte loss in the cortical layers was associated with the presence of meningeal 
inflammation (Magliozzi et al., 2010). In agreement with the presence of ectopic B-cell 
follicle-like structures in the leptomeninges, the analysis of CSF from MS patients has 
identified the recapitulation of all features of B cell development that is normally restricted to 
lymphoid organs (Corcione et al., 2005). Furthermore, clonally expanded B lymphocytes 
have been detected in white matter lesions, meninges and CSF, suggesting that local 
106 
 
expansion of B cell clones occurs and persists over time in the meninges (Lovato et al., 
2011).  
The compartmentalization of an (auto)immune response within the CNS is believed to create 
a permissive microenvironment for the induction of antigen-specific humoral responses in 
MS as has also been observed within the target organs in other autoimmune diseases such 
as rheumatoid arthritis (Pablos et al., 2005, Paavonen et al., 2002) (Gause et al., 1995, 
Schroder et al., 1996), Sjörgen’s syndrome (Stott et al., 1998, Amft et al., 2001) (Dorner et 
al., 2002), myasthenia gravis (Sims et al., 2001), Grave’s disease (Armengol et al., 2001) 
and Crohn’s disease (Kaiserling, 2001).  
4.1.3 CD161 association with IL-17 secreting immune cell subsets and 
with multiple sclerosis pathology 
However, the identity, specificity and relative proportions of immune cells infiltrating the CNS 
in the MS brain, particularly the meningeal compartment, remains poorly characterized.  
Although CD8+ T cells are the most frequent T-cell subset identified in white matter chronic-
active lesions (Booss et al., 1983, Hauser et al., 1986), where they have been shown to be 
clonally expanded (Babbe et al., 2000), little is known about their contribution to meningeal 
inflammation, their detailed phenotype, and relevance to grey matter pathology.  
A recent study reported that a CD8+ T-cell subset, expressing high levels of NKRP-
1A/CD161 and able to produce IL-17 and IFN-γ, is increased in the peripheral blood of 
patients and present in chronic active WML (Annibali et al., 2010). In addition CD161 was 
presented by the International Multiple Sclerosis Genetic Consortium as one of the non-MHC 
candidate loci (Hafler et al., 2007) though it did not reach the suggestive evidence level in a 
subsequent meta-analysis (De Jager et al., 2009). Furthermore CD161 expression has been 
recently associated with lymphocytes of T-helper 17 (Th17) or T-cytotoxic 17 (Tc17) 
phenotype (Cosmi et al., 2008, Maggi et al., 2010). IL-17 has been implicated in MS 
pathogenesis (McFarland and Martin, 2007) and reported to be expressed at relatively high 
levels in circulating lymphocytes of MS patients (Durelli et al., 2009) and in the majority of 
CD8+ cells infiltrating MS brain lesions (Tzartos et al., 2008). In this regard also mucosal 
associated invariant T (MAIT) cells have been described as tissue-targeted (CCR6+ 
expressing) cells that secrete IL-17, sharing many similarities with the CD8+CD161high 
previously described (Dusseaux et al., 2011).  
MAIT cells in humans are innate T cells restricted by MR1, a major histocompatibility 
complex class Ib molecule, and expressing a semi-invariant Vα7.2-Jα33 TCR α chain in 
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preferential combination with Vβ2 and Vβ13 (Treiner et al., 2003). They can be identified in 
blood and tissue by the co-expression of CD161 and TCR Vα7.2 and they include most, if 
not all, the IL-17 secreting CD8 T cells (Dusseaux et al.). The mechanisms linking innate 
immunity and autoimmune response are still poorly understood therefore, we wanted to 
investigate the presence of MAIT cells in the MS brain, focusing in particular on the 
subarachnoid space that might be the location where interactions between immune cells 
seem to be crucial for the initiation and the maintenance of CNS inflammation.  
4.1.4 CNS as an “immunologically specialized” organ and the 
lymphatic drainage of the brain 
The CNS has been classically considered to be an immune privileged organ since antigenic 
material, including tumors and tissue graft failed to elicit a systemic T cell-mediated 
immunological response when transplanted in its parenchyma (Galea et al., 2007a, Carson 
et al., 2006). These observations are in keeping with the fact that CNS has limited 
regenerative capacity when compared to other organs, where tissue injury from an 
inflammatory response is potentially less damaging. Furthermore, the brain parenchyma is 
encased within an inexpandable skull and, therefore, has no ability to accommodate 
changes in volume caused by inflammation-induced swelling. Experimental evidence has 
since long revealed that the CNS immune privilege is not absolute and that foreign material 
implanted into the CNS can elicit an immune response, albeit one that is delayed and more 
carefully regulated than in the periphery (Ransohoff et al., 2003). Therefore a better 
description of the relationship between the peripheral immune system and the brain is that 
the CNS is an immunologically specialized site rather than immunologically privileged. In fact 
the location where foreign material is introduced into the CNS has a great influence on the 
severity of the elicited immune response. Severity increases with proximity to the brain 
(Matyszak and Perry, 1996, Perry, 1998) and materials implanted within the meninges are 
capable of eliciting a robust immune response. Therefore, the propensity of these sites to 
allow the initiation of a typical peripheral immune response suggests that the ventricular and 
the subarachnoid CSF may function as a site of immune surveillance both in physiological 
and pathological conditions. The surface of blood vessels and fibrous trabeculae is where 
infiltrating lymphocytes establish contacts with other lymphocytes and antigen presenting 
cells (Bartholomaus, 2009 and Kivisakk, 2009): a function that both B cells (Harp et al., 
2008, Harp et al., 2010) and macrophages possess (van Zwam et al., 2011). 
Cerebrospinal fluid (CSF) is produced from the arterial blood by the choroid plexuses of the 
lateral and fourth ventricles by a combined process of diffusion, pinocytosis and active 
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transfer. A small amount is also produced by the ependymal cells in the choroid plexus itself. 
The CSF then flows through the ventricular system and returns over the surface of the brain 
and spinal cord via the subarachnoid spaces (Harling-Berg et al., 1999) and is ultimately 
reabsorbed by the arachnoid villi back into the superior sagittal sinus (Weller et al., 2009). 
Another route of antigen drainage from the CNS parenchyma to the cervical lymph nodes, is 
via the interstitial fluid (ISF) that flows along the perivascular spaces of capillary and arteries, 
that is between the basement membrane and smooth muscle cells of the tunica media. ISF 
travels out of the brain along blood vessels that reach first the CSF in the leptomeninges 
(Weller, 1998, Preston et al., 2003) and finally the cervical lymph nodes. Also the CSF can 
follow this route by passing from the ventricles into the white matter (Bechmann et al., 2001) 
where it may also be absorbed directly into the blood. It was also thought that the CSF in the 
subarachnoid space connected directly with the subpial space and the cortex, although 
ultrastructural studies have shown that the pia mater separates the subarachnoid space from 
the brain and the CSF from the ISF (Krahn, 1982, Alcolado et al., 1988, Hutchings and 
Weller, 1986, Weller, 2005, Zhang et al., 1990). These findings suggest that macrophages 
can access and take up molecules from CSF and ISF due to their ability to traffic across the 
pial membrane. It is instead the astrocyte processes of the glia limitans on the surface of the 
cerebral cortex and the subpial collagen on the surface of the human spinal cord that 
constitute the main barrier to the passage of inflammatory cells from the subarachnoid space 
into the CNS. Taken together these observations could describe how a small soluble antigen 
from the CNS parenchyma could reach the afferent arm of the immune system through the 
meninges to the cervical lymph nodes. Nevertheless, since there are no lymphatics in the 
brain it is still unclear how myelin debris, resulting from demyelinating cortical lesions, can 
leave the brain parenchyma and gain access to the peripheral immune system.  
4.1.6 Role of microglia in cortical pathology 
The parenchyma of cortical lesions underlying the inflamed meninges shows an increase in 
the activation of microglia and the expression of myeloperoxidase suggesting that microglia 
production of reactive oxygen species is likely to be involved in cortical demylination (Gray et 
al., 2008). In accordance with this observation, MS cases harbouring ectopic follicle-like 
structures in the meninges show that the barrier between cortical parenchyma and the 
overlying CSF, the glia limitans, is damaged and that a gradient of neuronal loss from the 
first cortical layer into the deeper ones is accompanied with astrocytes loss and an opposite 
gradient of increased density of activated microglia (Magliozzi et al., 2010). Microglia are 
very sensitive to disturbances in the microenvironment and since it resides behind the BBB, 
bathed by only by the interstitial fluid, the contact with serum products in itself represents a 
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danger signal that indicates BBB breach (Ransohoff and Perry, 2009). Microglia activation 
can be modulated by and responds to many different soluble pro-inflammatory signals like 
nitric oxide (Moreno et al., 2011), IFN-γ (Hashioka et al., 2009), IL-17 (Tzartos et al., 2011). 
In vitro experiments using mixed glia and MOG-specific T cells from EAE have shown that 
both IFNγ (Th1) and IFNγ/IL-17 (Th1/Th17) secreting T cells enhanced MHC class-II 
expression of microglia (Murphy et al., 2010). In accordance with these findings IFN-γ had 
been shown to be a potent inducer of MHC class-II on a variety of antigen-presenting cells 
(Steimle et al., 1994). Other functional studies revealed that IFN-γ, a potent inflammatory 
signal that can control more than 200 genes and whose major sources are CD4+, CD8+ T 
and NK cells, can bind on neurons and microglia through IFN receptors (Hashioka et al.) and 
is able to induce the production of different cytokines and chemokines by microglia (Rock et 
al., 2005). On the basis of these observations we wanted to investigate activation of 
microglia in grey matter lesions by assessing the density of MHC class-II in all cortical layers 
and correlate it with the phenotype and the amount of immune cells present in the overlying 
meninges. 
 
 
 
 
 
 
 
 
 
 
 
 
110 
 
4.1.7 Aims of this study 
1. Quantitative description of meningeal inflammation: quantification of the densities of  
B and T cell subsets in the meninges 
2. Test the possible correlations between meningeal inflammation and grey matter 
pathology measured by demyelination extent and microglial activation 
3. Compare the severity of GM and WM pathology between cases with high meningeal 
inflammation and cases with low meningeal inflammation   
4. Characterize meningeal inflammation in order to identify CD161-expressing 
lymphocytes and verify their correlation with GM pathology 
5. Assessment of immunopathological processes in the meninges: leakage of CNS 
antigens (MOG) and cell-to-cell contact between T lymphocytes and meningeal 
macrophages 
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4.2 Results 
4.2.1 Definition of meningeal inflammation 
Inflammatory infiltrates in the meninges of progressive MS were a common pathological 
finding in this study. Immune cells identified by immunohistochemistry showed common 
patterns of distribution but different absolute densities from case to case. These infiltrates 
were found between the cortical pial surface and immediately adjacent blood vessel walls, 
more often with a widespread scattered distribution (Fig 4.1 A-E and G) and sometimes 
exhibiting an organized distribution into more defined cellular clusters (Fig 4.1 F and H). 
Immune cells were found all along the cortical ribbon within the delicate system of fibers that 
constitutes the subarachnoid cavity, although they were more frequently in the depth of sulci 
where they are often organized in small (10-30 cells) clusters around or in the close vicinity 
of blood vessels. Firstly I quantified CD20+ B cells and CD3+ on the same fixed frozen 
blocks reported in the previous chapter for GML and WML quantification, secondly I 
quantified CD4+ and CD8+ T cells in 4 snap frozen tissue blocks from the same MS cases to 
show the absolute and relative contribution of these immune cells subsets to inflammation in 
the meninges (Fig 4.1 I and L). I then compared the results to the same immune cell subsets 
quantified in WML perivascular infiltrates, as shown in the previous chapter, to assess that 
the relative contribution of of B and T cell subsets in the two compartments is not different. 
Each case was then classified according to the density of inflammatory cells in the 
meninges, calculated as the sum of B and T cell numbers in the subarachnoid space (SAS) 
and defined here as meniningeal inflammation. Since the density of meningeal inflammation 
was not normally distributed (Shapiro-Wilk test, ***p < 0.0001) we chose the median value to 
divide the cases into high (above the median) and low (below the median) density of 
inflammation in the SAS.  
Figure 4.1 Quantification of meningeal inflammation in the MS progressive brain: high 
and low density  
Immunohistochemical characterization of meningeal inflammatory infiltrates showing 
examples of low (column on the left) and high (column on the right) density meningeal 
inflammation.CD3+ T cells (A, B), CD20+ B cells (C, D), CD4+ T helper (E, F) and CD8+ 
Cytotoxic T cells (G, H). The presence of immune cells is most frequently widespread in the 
meninges over the gyri and more clustered the depth of the brain sulci. The quantification of 
each subset, measured as number of cells/mm of cortex and expressed as median ± IQR, 
showed that (I) CD20+ cells were 16 ± 54, CD3+ 41 ± 86, CD4+ 14 ± 28 and CD8+ 24 ± 60. 
(L) The contribution of each subset was then indicated as percentage of the total 
lymphocytic nuclei showing that CD3+T cells (64 ± 12 %) outnumbered CD20+ B (36 ± 12 
%) and that, among the former, CD8+ T cells (62 ± 15 %) were found more frequently than 
CD4+ T(38 ± 15) (*** p < 0.0001) (L). All images were acquired at 20X magnification. Scale 
bars: (A-H) = 200µm, inset in (A-H) = 20µm. 
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4.2.1.1 Meningeal inflammation correlates with the extension of demyelination in 
grey matter 
A visual example of the screening strategy, consisting in the selection of tissue blocks 
containing the cortex from frontal, temporal, parietal and occipital brain regions, is given in 
Fig 4.2 A, B where a match between a coronal section stained for MOG, a corresponding 
tissue block from the frontal cortex and its MOG staining is shown. I tested the correlation 
between the density of meningeal inflammation and the percentage of cortical demyelination 
as measured in the previous chapter, which showed that there is a linear positive relation 
between the two variables measured (Fig 4.2 C), i.e. that increasing meningeal inflammation 
is associated with more extensive GM demyelination. This linear correlation was also shown 
for each subset quantified individually and was progressively stronger for CD4+< CD3+ < 
CD8+ T cells < CD20+ B cells (Fig 4.2. D-G respectively). This cohort included 4 primary 
progressive cases, which when analyzed separately but did not reach statistical significance 
(not shown) due to the small number of cases. Nevertheless it must be noted that 3 out 4 of 
the PPMS cases exhibited a high density of meningeal inflammation and extensive cortical 
pathology. In order to rule out the possibility that post-mortem delay might have an effect on 
the presence of meningeal inflammation we compared the post-mortem delay of high versus 
low meningeal inflammation cases to show there is no statistically significant difference (Fig 
4.2 H).  
4.2.1.2 Percentage of B and T cell subsets in meningeal inflammation is the same 
in white matter inflammation 
In order to verify whether there is a relationship between meningeal and white matter 
inflammation I compared the relative contribution of B and T cell to show that they were the 
same for each subset quantified in both the WM and SAS compartments (Fig 4.3). In 
particular T cells were more abundant than B cells (***p<0.0001) and CD8+ cells 
outnumbered CD4+ cells in both WML and SAS (***p<0.0001) (Fig 4.3 A, B). In order to 
verify the possible relationships between immune cell subsets contributing to meningeal 
inflammation we tested for possible correlations between their densities. As previously 
observed by our quantification of inflammatory infiltrates in WML, also the analysis of the 
inflammation in the meningeal compartment showed that the density of CD20+ B cells was 
strongly correlated with the density of CD3+T cells. Furthermore the same positive 
correlation was shown and CD4+ T with CD8+ T cells density (Fig 4.3 C and D). 
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4.2.2 Increased GM, but not WM, demyelination and more Type I GM 
lesions in cases with high meningeal inflammation 
Based on the quantification of B and T cells in the meninges I divided the MS cases into 
“high” and “low” meningeal inflammation in order to assess possible differences in the 
extent, measured as percentage of demyelinated cortex, and the type of cortical 
demyelination, Type III (Fig 4.4 A) and Type I/III (Fig 4.4 B), between these two groups of 
secondary progressive MS brains. We found that MS cases with high meningeal 
inflammation had higher proportion of demyelinated cortex when compared to cases with low 
meningeal inflammation (median ± IQR, high GML% = 41 ± 23 , low GML% = 16  ± 14, p = 
0.0007, Fig 4.4 C) while this difference was not statistically significantwhen the same 
analysis was performed between these two groups for the extent of demyelination in WM 
(median ± IQR, high  WML% = 11 ± 18 and F- WML% = 5 ± 6, p = 0.0817 , Fig 4.4 D). 
Furthermore Type I/III lesions were more frequent in cases exhibiting high meningeal 
inflammation (median number of lesions/case ± IQR, 8 ± 8) when compared to cases with 
low density (1 ± 4, * p = 0.0012, 4.4 E). 
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Figure 4.2 Meningeal inflammation correlates with grey matter demyelination extent 
(A) An example of the sampling and screening strategy of tissue blocks: at least one tissue 
block with preserved meninges (inset) was studied from each of the following brain regions 
(temporal cortex, pre-central gyrus, superior frontal gyrus, parietal lobe, cingulate cortex and 
insular). (B) MOG staining allows the measurement of the extent of demyelination in WM 
and GM (black arrows point to the edge of a GM lesion) while haematoxylin shows the 
presence of possible lymphocytic nuclei in the overlying meninges. The image was acquired 
at 20X magnification. (C) Meningeal inflammation, that is the sum of CD20+ B and CD3+ T 
cells density in the meninges, positively correlates with demyelination in the cortex. The 
vertical line indicates the median density of meningeal inflammation (52cells/mm) in the 
subarachnoid space (SAS) and the horizontal line indicates the median GM lesion area 
percentage (28%). All the cases with a meningeal inflammation density higher than the 
median are indicated by red dots in all figures. The cases with low meningeal inflammation 
are indicated by black dots in all figures. Scale bars: (A) = 20mm, (B) = 100µm. (D-G) Linear 
correlation with grey matter demyelination was also found for each B and T cell subset 
quantified individually and was progressively stronger for CD4+< CD3+ < CD8+ T cells < 
CD20+ B cells. (H) The post mortem delay (PMD), indicated in hours, was not significantly 
different between cases exhibiting high meningeal inflammation and cases with low 
meningeal inflammation. 
Figure 4.3 Similar percentages of B and T cell subsets in meningeal and WM 
perivascular inflammation and positive correlation between the densities of immune 
cell subsets in the meninges 
The comparison between the percentages of CD3+T, CD20 B cells (A) and CD4+ and CD8+ 
T cells (B) showed a similar contribution (p = 0.0843) of each subset to inflammatory 
infiltrates in both the meninges and white matter chronic active lesions infiltrates. The 
densities of B and T cells in the meninges showed a strong positive correlation (r = 0.9312, p 
< 0.0001) (C) which was observed also between CD4+ and CD8+ T cells (r = 0.8831, p < 
0.0001) (D). 
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Figure 4.4 More extensive demyelination of Type I/III in MS cases exhibiting high 
meningeal inflammation 
MOG immunohistochemistry represents a sensitive method to detect, measure and identify 
cortical demyelination: an example of Type III (A) and Type I/III (B) lesions. Both images 
acquired at 4X. (C) The demyelination is more extensive in the cortical GM of cases with 
high meningeal inflammation (red dots) (median ± IQR, GML% = 41 ± 23 %) than in cases 
with low meningeal inflammation (black dots) (GML% = 16 ± 14, ***p = 0.0007) while there is 
no statistical significant difference between these two groups of cases in terms of WM 
demyelination (high WML% = 11 ± 18, low WML% = 5 ± 6, p = 0.0817) (D). There were 
more Type I/III lesions in MS brains with high meningeal inflammation when compared MS 
brains with low meningeal inflammation (median number of lesions/case ± IQR, high = 8 ± 8, 
low = 1 ± 4, **p = 0.0012) (E). All the cases with high meningeal inflammation density are 
indicated by red dots. The cases with low meningeal inflammation are indicated by black 
dots. 
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4.2.3 Microglial activation was increased in the cortex of cases with 
high meningeal inflammation and correlated with the density of B and 
T cell subsets in the meninges 
We then assessed whether there was any relationship between the level of meningeal 
inflammation and microglial activation in the underlying cortical GM measured by quantifying 
the density of MHC class-II+ cells in each cortical layer. I observed an increased average 
density of microglia expressing MHC class-II in all cortical layers of cases with high 
meningeal inflammation when compared to cases with low meningeal inflammation and 
controls, and also an increased density in layer III of cases with low meningeal inflammation 
when compared with the 4 non neurological controls (2 tissue blocks each)(Fig 4.5 A). In 
particular cortical microglia of cases with high meningeal inflammation exhibited a 
characteristic round morphology indicative of the activation state which was instead not 
observed in cases with low meningeal inflammation (Fig 4.5 B and C respectively). We also 
showed that the average density of MHC class-II staining in the first three cortical layers 
positively correlated with the density of CD3+ B, CD20+, CD4+, CD8 T cells in the meninges 
(Figure 4.5 D-G respectively). 
Figure 4.5 Meningeal inflammation correlates with grey matter microglial activation 
In cases with high meningeal inflammation (red line), the average density (mean ± SEM) of 
MHC class-II expressing microglia for each cortical layer was higher when compared to 
cases with low meningeal inflammation (black line, ***p<0.001) and controls (green line, 
***p<0.001). 4 SF blocks were quantified for each MS case (n=21) and 4 controls (n=4).In 
layer III the density of MHC class-II in low inflammation cases was higher than in controls, 
*p<0.018 (A). MHC class-II staining in the cortex of a case with high meningeal inflammation 
(B) shows the prevalence of microglial ramified morphology and more positive cells than in 
the cortex of a case with low meningeal inflammation (C). Both images were taken at 20X 
magnification. Scale bars: (D and E) = 200µm. The average density of MHC class-II positive 
microglia in the first three cortical layers correlated with the density of CD3+T cells (D), 
CD20+ B cells (E), CD4+ T cells (F) and CD8+ T cells (G) in the meninges. (H) MHC-II 
immunostaining in the cortex of a control case shows very low level of activated microglia 
density. All the cases with high meningeal inflammation density are indicated by red dots. 
The cases with low meningeal inflammation are indicated by black dots. 
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4.2.4 Relationship between CD161+ expressing lymphocytes in the 
meninges and the severity of pathology in cortical GM 
Given the prevalence of CD8+T cells over the other immune cell subsets measured in the 
meninges and their strong association with grey matter pathology I wanted to further 
characterize their phenotype focusing on CD161+, a surface marker associated with IL-17 
secretion. I found that CD161+ expressing lymphocytes were present in the subarachnoid 
space (Fig 4.6 A). Therefore, using double immunofluorescence we quantified CD8+CD161+ 
(17 ± 19 cells/mm, median ± IQR), CD8-CD161+ (40 ± 39 cells/mm) and CD8+CD161- (39 ± 
61 cells/mm) in the SAS.  CD8+CD161+ cells represented 11 ± 5 % of the total lymphocytes, 
the 31 ± 20 % of total CD8+ cells and the 31 ± 11 of the total CD161+ cells in the meninges 
(see Table 4.1 for absolute and relative counts). I then assessed their relationship to the 
severity of pathology in the underlying grey matter. Both CD8+CD161+ and CD8-CD161+ 
cells positively correlated with the extent of GM demyelination and with the average density 
of MHC class-II in the first three cortical layers (Fig 4.6 C-E). 
Table 4.1 Absolute and relative quantification of CD8+CD161+, CD8+CD161- and CD8-
CD161+ in the meninges   
Immune cell subset 
marker 
Density in SAS 
(cells/mm, median ± IQR) 
% in SAS 
(median % ± IQR) 
CD8+CD161+ on 
total lymphocytes 
17 ± 19 11 ± 5 
CD8+CD161- on 
total lymphocytes 
39 ± 61 26 ± 12 
CD8-CD161+ on 
total lymphocytes 
40 ± 39 24 ± 12 
All nuclei, DAPI 63 ± 77 39 ± 14 
CD8+CD161+ on 
total CD8+ cells 
 31 ± 20 
CD8+CD161+ on 
total CD161+ cells 
 31 ± 11 
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4.2.4.1 CD161+ subsets contribute equally to inflammatory infiltrates in the 
meninges and in white matter lesions 
CD161+ expressing lymphocytes were also present in the WM lesion perivascular infiltrates 
(Fig 4.6 B) where they represented 13 ± 10 % of the total lymphocytes (see Table 4.2 for 
absolute and relative counts). Interestingly as observed for the others B and T cell subsets 
previously quantified in the meninges and in white matter infiltrates, I found a similar 
percentage of CD161+ subsets contributing to inflammation in both compartments. In Fig 
4.6, panels F to H, the percentages of CD161+ subsets on total lymphocytes and the 
percentages of CD8+CD161+ on total CD8+ T cells and total CD161+ cells are indicated by 
a dot for each case analyzed.  
Table 4.2 Absolute and relative quantification of CD8+CD161+, CD8+CD161- and CD8-
CD161+ in WML perivascular infiltrates  
Immune cell subset 
marker 
Density in WML 
(cells/mm2, median ± IQR) 
% in WML 
(median % ± IQR) 
CD8+CD161+ on 
total lymphocytes 
139 ± 122 13 ± 10 
CD8+CD161- on 
total lymphocytes 
286 ± 297 31 ± 10 
CD8-CD161+ on 
total lymphocytes 
209 ± 251 23 ± 11 
All nuclei, DAPI 316 ± 235 35 ± 10 
CD8+CD161+ on 
total CD8+ cells 
 29 ± 14 
CD8+CD161+ on 
total CD161+ cells 
 36 ± 22 
 
4.2.5 Identification of MAIT cells in the MS brain 
Based on our finding of CD161-expressing cells in the meninges and WML, and given the 
interest surrounding the role of MAIT cells in autoimmunity, I wanted to assess their 
presence in the MS brain. I identified MAIT cells, defined by the co-expression of CD161+ 
and TCRVα7.2, in the meninges (Figure 4.8 A to C) and WML (Figure 4.8 D) where they 
represented 17 ± 17 % and 8 ± 10 % of total CD161+ cells in WML (median ± IQR, 122 ± 
127 cells/mm2) and the meninges (7 ± 5 cells/mm) respectively (Figure 4.8 F). Notably all 
TCRVα7.2+ cells also expressed CD161. I found MAIT cells at a low frequency with a range 
of 20 to of 50 cells/tissue block considering the quantification in the meninges and in white 
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matter infiltrates. Interestingly MAIT cells were always found associated, in close vicinity or 
in contact with, other lymphocytic nuclei and CD161+ expressing cells. I characterized on 
one tissue block sequential sections sampling the same meningeal infiltrate to find that MAIT 
cells (Fig 4.8 C) were interspersed in a cluster of CD161+ expressing lymphocytes which 
were also positive for CD8+CCR6+ cells (Figure 4.8 E). The detection of CCR6 is in keeping 
with the tissue-homing characteristic of these pro-inflammatory cells. 
4.2.6 Close apposition between CD8+ T cells clusters and MRP14+ 
cells on blood vessels in the SAS 
Given my previous observation of MRP14+ cells associated with GM microvasculature, I 
wanted to investigate whether they were present in the meninges. I found MRP14+ cells in 
the subarachnoid space where they were preferentially scattered along the pial surface of 
the cortex or associated with the outer wall of blood vessels (Fig 4.10 A and B). I often 
observed MRP14+ cells in the immediate vicinity of infiltrates in the meninges and frequently 
found them interspersed within clusters of lymphocytic cells. Therefore I wanted to 
characterize their possible association with CD8+ T cells as it has been shown that the 
binding of MRP14 to Toll-like receptor 4 on CD8 T cells is essential for the induction of 
autoreactivity and the secretion of IL-17 (Loser et al., 2010). Interestingly I screened all the 
cases with high meningeal inflammation and found the presence of a close apposition of 
MRP14+ cells with clusters of CD8+T cells in the SAS (Fig 4.10 C). 
4.2.7 Leakage of myelin oligodendrocyte glycoprotein in the SAS 
In three cases (MS426, MS237 and MS371) showing high meninegal inflammation and 
exceptional microglial activation in the cortex we found abundant immunostaining for MOG in 
the meninges (Fig 4.11 A, B). At higher magnifications it was clear that the staining for MOG 
showed a globular pattern located within the interstitium of the meninges and that it was 
sometimes extracellular and sometimes associated with round cellular nuclei positive for 
haematoxylin (Fig 4.11 C). 
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Figure 4.6 Density of CD161+CD8+ and CD161+CD8- lymphocytes in the meninges 
correlates with the severity of grey matter pathology 
Double immunofluorescence shows CD161+ cells (red), CD8+ cells (green), CD161+CD8+   
(yellow) and lymphocytic nuclei (blue) in the meninges (A) and in a perivascular infiltrate of a 
chronic active WM lesion (B) where CD8+CD161+ cells can also be found in the 
parenchyma (white arrow). All images were acquired at 20X magnification. Scale bars: (A 
and B) = 20µm. 4 SF blocks were quantified for each MS case (n=21). Each dot indicates 
the median value of each measure for each MS case. (C, D) CD161+CD8+ and 
CD161+CD8- cell densities in the meninges correlated with the extent of demyelination in 
GM. (E) CD161+CD8+ cells in the meninges also correlated with MHC class-II average 
density in the first three cortical layers. Quantification of the subsets identified by double 
immunofluorescence for CD8 and CD161 showed that the relative percentage of double 
positive cells in relation to total lymphocytes in the WML (median ± IQR, 13 ± 10 %) and 
SAS (11 ± 5 %) was not different, p = 0.1. (F) The proportions of CD8+CD161+cells 
amongst total CD8+ lymphocytes in WML (29 ± 14 %) and in the SAS (31 ± 20 %) and 
amongst total CD161+ lymphocytes in WML (36 ± 22 %) and in SAS (31 ± 11 %) were not 
different, p = 0.7 and p = 0.2 respectively (G,H). 
 
 
Fig 4.7 Negative and isotype controls for CD161 CD8 sequential double 
immunofluorescence 
(A) The detection of CD161 amplified with Tyramine and visualized in red followed by the 2^ 
 Ab for the detection of CD8 (negative control) shows only CD161 specific signal and no 
CD8 signal. (B) The incubation with CD161 isotype control followed by CD8 Ab detected in 
green show absence of CD161 detection. All images acquired at 20X, scale bars=20µm 
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Figure 4.8 MAIT cells form part of inflammatory cell infiltrates in the meninges and in 
WM lesions of the MS brain 
A proportion of CD161+ cells (green) (A) also expressed TCRVα7.2+ (red) (B) and thus had 
the characteristics of MAIT cells (yellow when overlapping red and green channels) in the 
meninges (C) and in white matter infiltrates (D). (E) Example of CD8+ (green) CCR6+ (red) 
and double-positive (yellow) cells in the SAS. Microphotographs (A, B, C) show different 
double immunofluorescence combinations on sequential sections of the same tissue block. 
Blue (DAPI) stains all nuclei. All images were acquired at 20X magnification. 4 SF blocks 
were quantified for each MS case exhibiting high meningeal inflammation as described 
earlier in this chapter (n=9). Each dot indicates the median value of each measure for each 
MS case. Scale bars: = 20µm. (F) Quantitative analysis of cell numbers showed that MAIT 
cells are a readily measurable proportion of total CD161+ cells in WML (median ± IQR, 17 ± 
17 %) and in SAS (8 ± 10 %). 
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Fig 4.9 Negative controls for TCRVα7.2 CD161 and for CCR6 CD8 sequential double 
immunofluoresence 
(A) The detection of TCRVα7.2 amplified with Tyramine and visualized in red followed by the 
2^ Ab for the detection of CD161 (negative control) shows only TCRVα7.2 specific signal 
and no CD161 signal. (B) The detection of CCR6 amplified with Tyramine and visualized in 
red followed by 2^ Ab for the detection of CD8 (negative control) shows only CRR6 specific 
signal and no CD8 signal. (DAPI staining was performed but blue channel is missing from 
images due to a temporary failure of imaging software).  All images acquired at 20X, scale 
bars=20µm 
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Figure 4.8 MRP14+ cells in the meninges: cell-to-cell contact with CD8+T cells 
An example of the pial and perivascular localization of MRP14+ macrophages (red) in 
respect to laminin (green), which highlights the pial basal lamina and cortical 
microvasculature (A) and also meningeal blood vessels (B). An example of MRP14+ 
macrophages (red) within the meninges in close contact with CD8+ T cells (white arrow and 
inset) (C). All images acquired at 20X, scale bars: A-C and inset = 20µm. 
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Figure 4.11 Presence of myelin debris in the meninges 
An example of the presence of myelin debris (MOG immunostaining) in the meninges 
localized around blood vessels (A and inlet B) and exhibiting a globular shape close to 
nuclei positive for haematoxylin (C) suggestive of myelin laden macrophages. (D) Another 
example of myelin debris in the SAS, detected within a meningeal infiltrate. (E) On the 
sequential section, the image shows MHC-II positive cells within the same meiningeal 
infiltrate, suggesting the presence of myelin debris, macrophages and lymphocytic cells 
within the same inflammatory infiltrate in the meninges. Images A, D and E acquired at 10X 
(scale bar = 100µm), image B at 20X (scale bar = 50µm) and C at 400X (scale bar = 20µm). 
 
 
 
129 
 
4.3 Discussion 
4.3.1 Correlation between cortical pathology and ongoing 
inflammatory processes in the meninges of primary and secondary 
progressive MS brain 
Here I have demonstrated that the extent of cortical demyelination was associated with 
meningeal inflammation showing that increasing density of B and T cells in the subarachnoid 
space was accompanied by a progressive increase in the percentage of demyelination in the 
cortex. I observed a gradient of widespread meningeal inflammation which is a common 
feature of the progressive MS brain in agreement with previous pathology studies on 
forebrain (Howell et al., 2011). Interestingly 3 out 4 primary progressive cases in this cohort 
showed high meningeal and white matter inflammation suggesting an important role for 
inflammation also in this MS sub-type (Choi et al., 2012) for which the neurodegenerative 
component is often thought to be the prevailing mechanism underlying the development of 
lesions (Miller and Leary, 2007, Lucchinetti et al., 1999, Lucchinetti et al., 2000, Thompson 
et al., 1997). Because MRI cannot be used at present to study meningeal inflammation and 
subpial cortical pathology, I cannot evaluate when cortical pathology begins during the 
disease course. However a study on biopsies taken during the early stages revealed that 
cortical demyelination was associated with meningeal and perivascular inflammatory 
infiltrates (Lucchinetti et al., 2011). It might be that the cortical demyelination that occurs 
close to the onset of the disease differs substantially from the cortical demyelination 
observed during the progressive phase. We might further speculate that the 
immunopathological mechanisms underlying cortical pathology might change over time 
during the long lasting MS disease course. My findings of correlations between inflammation 
in the meninges and the degree of parenchymal grey matter demyelination are suggestive of 
a role for meningeal inflammation in cortical pathology, although my observations cannot be 
taken as definitive evidence of causality. In fact there is still the possibility that meningeal 
inflammation could occur as a consequence of cortical damage, although this is not 
supported by available evidence. Furthermore the observed prevalence of Type I lesion in 
cases with high meningeal inflammation is suggestive that they could first develop as subpial 
and then extend to subcortical white matter. However, there is still the possibilty that two 
lesions, one in subcortical white matter and one in subpial cortex, form independently and 
extend until they actually merge and seemingly become one lesion. 
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4.3.2 Possible B and T cells interactions in the meninges and effects on 
cortical immunopathology 
I found B and T cells often clustered together within the same meningeal infiltrates 
suggestive of ongoing interactions between these immune cell subsets within the 
subarachnoid space. Furthermore B and T cell subsets density in the meninges is strongly 
correlated indicating that their immunolopathological functions within the meninges might be 
interlinked. Although the evident limitations of analyzing post-mortem samples in order to 
detect dynamic processes there is supportive evidence of the role of B cells as drivers of the 
T cell response by means of antigen presentation and cytokines secretion in the MS brain. In 
this regard memory B cells from treatment naϊve RRMS patients, but not the ones from 
healthy donors, have the ability to present neuroantigens - MBP and MOG peptides- to 
autologous T cells and to induce a proliferative T cell response and IFN-γ production (Harp 
et al., 2010). Furthermore activated B cells are also able to release pro-inflammatory 
cytokines such as IFN-γ, IL-2, -4, -12, -13 and TNF (Meinl et al., 2006, Ray et al., 2011). In 
particular the pro-inflammatory effects of TNF, which may contribute to MS, include an 
increase in endothelial permeability affecting the BBB (Claudio et al., 1994, Duchini et al., 
1996), demyelination (Hartung et al., 1992, Ledeen and Chakraborty, 1998), and 
oligodendrocytes damage (Takahashi et al., 2003). In keeping with the evidence of a B cell 
pro-inflammatory profile in the CNS, it has been shown that the B-cell phenotype is skewed 
in MS with B cells exhibiting a relative deficiency in their capacity to produce the down-
regulatory cytokine IL-10 (Duddy et al., 2007) and an exaggerated production of 
lymphotoxin-α and TNF (Bar-Or et al., 2010). My finding of no difference between the 
representation of all the lymphocyte subsets measured in the meninges and in WML 
infiltrates, suggests that the (re)activation of the immune response in the two compartments 
is not independent. In regard to a relationship between immune cells in the meninges and in 
WM parenchyma, there is evidence that the same B cell clones are shared between the two 
(Lovato et al., 2011) and that common T cell clones can be found in multiple sites of the 
brain (Junker et al., 2007), suggesting that CSF flow through the meninges might play a role 
in their infiltration to different anatomical locations.  
In the past few years the role of B cells and humoral immunity in the pathogenesis of MS has 
been reassessed, mainly because Rituximab, an anti-CD20 monoclonal antibody that 
specifically depletes B cells, is a potent immunomodulatory therapy for the treatment of 
RRMS and a subgroup of PPMS with active disease (McFarland, 2008, Hauser et al., 2008, 
Hawker et al., 2009). Notably, the efficacy of Rituximab in the treatment of MS patients is 
independent of secreted antibody since it does not affect plasma cell frequency or serum 
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and CSF antibody levels (Petereit et al., 2008). Thus, the attention has recently focused also 
on the functions of B cells that are independent from their antibody secretion and in 
particular on the possible impact that memory B cells have on T cell regulation and activation 
by acting as antigen presenting cells (Good et al., 2009, Bar-Or et al., 2001). The observed 
high inflammation is indicative of exacerbation of the compartmentalized chronic immune 
response within the meninges of the progressive MS brain and it could also be a sign of 
epitope spreading (Goebels et al., 2000). This type of immune autoreactivity can propagate 
“intramolecularly” to new epitopes contained in the original immunizing antigen, or 
“intermolecularly”, when responses to separate unrelated antigens are seen. The physical 
location where antigen presentation occurs to generate epitope spreading is of critical 
importance to the possible development of treatments for autoimmune disease perpetuated 
by this mechanism. In the MS brain, it is believed that after the tissue damage induced in the 
beginning by autoreactive T cells, there is an increase of neuroautoantigens released from 
the tissue into the interstitial fluid and CSF of the subarachnoid space (Madeddu et al., 2012, 
Mitosek-Szewczyk et al., 2011). Therefore, I can speculate that the meningeal compartment 
is where this process of exacerbation of the (auto)immune response, consisting in the 
broadening of the spectrum of autoreactive B and T cells, might take place. 
4.3.3 Detrimental role of activated microglia in cortical pathology   
The primary inflammatory component of cortical lesions is the activated microglia (Kidd et 
al., 1999, Peterson et al., 2001, Gray et al., 2008) which I found correlated spatially and 
quantitatively to the density of immune cells in the overlying meninges in accordance with 
previous studies (Bo et al., 2003b, Dal Bianco et al., 2008). Cases with low meningeal 
inflammation did not show any significant difference from controls except for an increase in 
microglial density in layer III in keeping with observed reduction of pyramidal neurons in this 
layer (Magliozzi et al., 2010) and supportive of the association between microglial 
inflammation and degeneration (Frischer et al., 2009) in MS brain. Previous studies from this 
laboratory have demonstrated significant damage to the glia limitans (Magliozzi et al., 2010), 
in presence of meningeal inflammation, suggesting that microglial activation could be caused 
by the diffusion of inflammatory signals produced by the activated immune cells in the 
meninges. Activated microglia could then contribute to cortical pathology through the release 
of cytotoxic molecules. Evidence supporting this possibility is that soluble proteins injected 
into the subarachnoid space are readily detected on the pial surface and within subpial 
cortical gray matter in adult rat brain (Broadwell and Sofroniew, 1993).  
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4.3.4 The role of CD161 expressing lymphocytes in cortical pathology   
4.3.4.1 CD8+CD161+ cells 
Following the recent association of CD8+CD161+ lymphoctyes  with MS pathology (Annibali 
et al., 2010), I have shown here that this subset, present in the meninges and in white matter 
infiltrates, contributes with a similar proportion to the immune cell population infiltrating both 
compartments. I also found that the extent of demyelination, as well as microglial activation 
in the GM of the progressive MS brain correlated with the density of CD161+ expressing T-
lymphocytes in the SAS, both CD8+ and CD8-. CD8+CD161+ lymphocytes have the 
potential to act as pro-inflammatory cells, since they have been shown to express perforin 
and secrete IL-17 and IFN-γ (Annibali et al., 2010, Maggi et al., 2010, Billerbeck et al.) or 
TNF (Takahashi et al., 2006) upon stimulation in vitro. Therefore, I propose that these 
cytokines, which can activate cortical microglia (Tzartos et al., 2011) and be directly 
cytotoxic on neurons (Harry et al., 2008), might be the humoral factors released by activated 
immune cells in the meninges that leak into the cortical parenchyma through the damaged 
glia limitans. This hypothesis is supported by the evidence that these cytokines can give rise 
to meningeal inflammation and extensive subpial demyelination when injected into the 
subarachnoid space of DA rats with MOG-induced subclinical EAE (Gardner, 2009). 
Although the CNS-infiltrating CD161+ lymphocytes that do not co-express CD8+ or 
TCRVα7.2 need to be further characterized, a recent analysis of a cohort of RRMS patients 
identified in peripheral blood and in the CSF a novel NK1/NK17 subset characterized by the 
expression of CD56+, CCR4+, CD161+ and by the secretion of IL-17 and IFN-γ (Pandya et 
al., 2012). Therefore, I hypothesize that the CD161+ CD8-/ TCRVα7.2- found in CNS tissue 
may comprise these pro-inflammatory NK1/NK17 cells. 
4.3.4.2 MAIT cells 
MAIT cells had previously been identified in peripheral blood and gut lamina propria in 
mouse and humans (Martin et al., 2009) and their phenotype includes expression of IL-17 
and high levels of CCR6, indicating preferential homing to tissue (Dusseaux et al.). Our 
observations of the presence of different populations of CD161+ lymphocytes characterized 
by the secretion of IL-17, together with the previously reported presence of ectopic B cell 
follicles in the meninges (Serafini et al., 2004, Magliozzi et al., 2007, Howell et al., 2011) is in 
accordance with findings from EAE models showing that a Th17 response is essential to 
induce B-cell maturation within the CNS (Mitsdoerffer et al., 2010, Peters et al., 2011).  We 
could speculate that the entry of MAIT cells to the CNS could trigger and sustain IL-17 
mediated inflammation, thus driving B cell expansion and maturation. In the case of the MS 
brain it seems likely that these interactions could take place within the subarachnoid space 
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and form part of the chronic compartmentalized inflammatory process documented in 
progressive MS. It is also possible that a compartmentalized chronic inflammatory response 
to a virus or bacteria within the CNS, provoking constitutive cytokines and/or chemokines 
expression in the meninges, might induce the entry of lymphoid tissue-inducer cells (Cupedo 
et al., 2009, Hughes et al., 2010) in this compartment. In this regard it is interesting to notice 
that lymphoid tissue-inducer cells have been shown to share a pro-inflammatory profile with 
Th17 cells, as well as their requirement of the transcription factor RORγT. These 
phenotypical characteristics are also possessed by γδ T cells (Lochner et al., 2008) and, 
notably, invariant NKT cells (Michel et al., 2008, Moreira-Teixeira et al., 2011). A similar 
initiation of the immune response is found in mucosal associated lymphoid tissues (MALT), 
which provide critical protection at mucosal surfaces, by directly detecting antigens and 
danger signals from their local environment and secreting pro-inflammatory cytokines and 
chemokines to attract antigen presenting cells (Brandtzaeg, 2010, Tezuka and Ohteki, 
2010).  
4.3.5 The leakage of MOG debris and MRP14+ macrophages in the 
meninges: a link with (autoreactive) T cells 
My findings of close contact between MRP14+ macrophages and CD8+T cells around blood 
vessels and also of the presence of myelin debris in the subarachnoid space supports the 
idea that reactivation of immune cells in MS occurs in the subarachnoid space. If I then 
assume the presence of autoreactive (myelin-specific) T cell clones in the CSF, I could 
speculate that the place where they encounter their cognate antigen within the CNS, is the 
subarachnoid space. Notably, the expression of MRP14 is also upregulated in cutaneous 
lupus erythematosus and stimulation of CD8+T cells from individuals with lupus with MRP14 
results in the upregulation of IL-17 mediated via Toll-like receptor 4 signalling (Loser et al., 
2010). My findings are suggestive that antigen-presenting cells present in the 
immunologically specialized subarachnoid space could uptake CNS-derived antigens and to 
present them. During a chronic compartmentalized immune response this process of 
constant leakage of tissue antigens and their encounter with immune cells in a pro-
inflammatory environment might lead to a vicious circle of constant reactivation of 
lymphocytes ultimately provoking direct and indirect inflammatory-mediated damage to the 
underlying cortex.  
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4.3.6 Conclusions 
Taken together, my data show a significant association between the density of meningeal 
inflammation and the severity of cortical pathology. Based on the evidence of CD161+ and 
MAIT cell presence in the MS brain, I suggest a possible immuno-pathological mechanism 
for the formation of GM lesion. The homing of IL-17 secreting lymphocytes to the CNS could 
contribute directly to microglial chronic activation and indirectly to the exacerbation of B cell 
response, leading to the formation of ectopic lymphoid follicles within the meninges. This 
likely detrimental immune activation within the CNS is a potential target for therapeutic 
strategies aiming to prevent or arrest chronic inflammation during progressive MS. 
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Chapter 5 
 
Chemokines expression in grey matter lesions and 
lymphocyte repertoire of chemokines and T cell 
receptors 
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5.1 Introduction 
T cells are instructed to differentiate into different developmental and effector subsets by 
many signals, such as the stimulation through the TCR complex, co-stimulatory molecules, 
chemokines, cytokines, small molecules and metabolites (Smith-Garvin et al., 2009, Fraser 
and Germain, 2009). Chemokines (chemotactic cytokines) are small heparin-binding 
proteins that are able to direct the movement of circulating leukocytes to sites of 
inflammation (Charo and Ransohoff, 2006) or to the lymph nodes (Yoshie et al., 1997, 
Zlotnik et al., 1999, Cyster et al., 1999, Cyster, 1999)  where they are (re)activated after their 
TCR, in presence of other co-stimulatory signals, recognizes the cognate antigen. Naive and 
effector/memory T cells have distinct repertoires of trafficking ligands and receptors that 
restrict their ability to interact with specialized microvessels in different anatomical 
compartments and consequently, have different patterns of migration. In particular the fate of 
antigen-experienced lymphocytes can be further subdivided into different subsets based on 
the presence on their membranes of characteristic sets of trafficking receptors that favour 
their accumulation in certain target organs (Mora and von Andrian, 2006). Recognition by 
and signalling through the TCR is the defining event for T cell and plays an essential role in 
setting the border between a specific immune response and autoimmunity. It has been 
shown that in MS the TCR repertoire is skewed and that oligoclonal expansions of T cells 
populations characterize the peripheral blood (Muraro et al., 2003) and the lymphocytes 
infiltrating the WM lesions (Babbe et al., 2000) suggesting a relationship between the 
frequency of T cell clones and the development of autoimmune pathology. 
5.1.1 Role of chemokines in cortical pathology 
There is growing evidence for the role of chemokines in the regulation of CNS disease 
based on the observation that increased levels of chemokines have been associated to 
several brain diseases, therefore suggesting that these molecules function is to regulate 
inflammation in the brain (Charo and Ransohoff, 2006). In particular there is evidence that 
microglia is at the same time target and source of cytokines as part of auto- and paracrine 
communications with astrocytes, neurons, the endothelium and leukocytes infiltrates 
(Hanisch, 2002). Therefore, using RT-PCR, we wanted to compare the levels of expression 
of chemokines in the parenchyma of grey matter lesions in cases with high and low 
meningeal inflammation to verify a possible relationship between the levels of chemokines 
produced and the density of immune cells in the meninges. We focused on CCL4 
(macrophages inflammatory protein, MIP-1β) and CCL5 (Regulated upon Activation, Normal 
T-cell Expressed, and Secreted, RANTES) since their secretion is induced in murine 
macrophages by IL-17 signalling (Barin et al.); on CXCL2 (macrophage inflammatory protein 
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2-alpha, MIP2-alpha) and CXCL11 (Interferon-inducible T-cell alpha chemoattractant, I-TAC) 
since they have been found expressed in lesions of a mouse model in which EAE was 
induced by the transfer of PLP specific T cells conditioned by IL-23 (Th17) or IL-12 (Th1) 
respectively (Kroenke et al., 2008). We also wanted to assess the expression of CX3CL1 
(fractalkine). Interestingly, fractalkine has been shown to play a role both in adhesion and 
chemoattraction of immune cells in the CNS: when it is soluble it potently chemoattracts 
CD8+T cells, NK cells and monocytes (Imai et al., 1997), while its cell-bound form promotes 
strong adhesion of leukocytes (Broux et al.) to activated endothelial cells, where it is 
primarily expressed (Bazan et al., 1997). CXCR4 is expressed on CD4+T, CD8+T, B cells 
and monocytes. Interestingly monocytes adhere to BBB endothelium in response to 
CXCL12, its ligand (Man et al., 2012) and this interaction is essential for leukocyte migration 
from perivascular space into the CNS parenchyma (McCandless et al., 2006, McCandless et 
al., 2009). 
5.1.2 Chemokine receptors and transcription factors identify different     
lymphocyte subsets      
The process of T cell activation in secondary lymphoid organs is accompanied by the 
upregulation of several different adhesion proteins and chemokine receptors associated with 
recruitment to sites of inflammation in the peripheral tissues (Mora and von Andrian, 2006). 
Studies on EAE have shown that autoreactive myelin-specific effector T cells are primed in 
peripheral lymph nodes and must migrate into uninflamed CNS to initiate tissue 
inflammation, and have indicated that chemokine receptors are the molecular requirements 
for lymphocyte rolling and adhesion to activated vessels of the inflamed blood-brain barrier 
(Engelhardt and Ransohoff, 2005). The cytokine system orchestrates T cell migratory 
patterns to generate, deliver and regulate specific types of immune responses in specific 
anatomic microenvironments. Detailed analysis of functional T cell subsets has also shown 
that the specificity in the pattern of chemokine receptor expression can identify, together with 
lineage-specific transcription factors, different lymphocytic subsets (Bromley et al., 2008) 
(Table 5.1 and Fig 5.1).  
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Table 5.1 Chemokines receptors repertoire expressed on lymphocytic cells characterizing 
different subsets with different migration patterns and their ligands. Adapted from Bromley et 
al (2009) 
Receptor Ligand(s) Expression pattern Migration to 
CCR4 CCL17,CCL22 Skin-tropic CD4+ T, Th-2 
cells, Th-17 cells, Tregs 
Skin, Asthmatic 
airways, inflammation 
CCR5 CCL3,CCL4,CCL5,CCL8 
CCL11,CCL14,CCL16 
Naïve CD8+ T, Th-1 cells, 
CTLs, some Tregs 
DCs in lymph nodes, 
inflamed tissues 
CCR6 CCL20 Th-17 Inflamed tissue 
CXCR3 CXCL9, CXCL10, 
CXCL11 
Th-1, CTLs, Th-17, NKT, 
some Tregs 
Inflamed tissue and 
lymph nodes 
CXCR4 CXCL12, CXCR7 CM T, Naïve T Resting lymph nodes, 
blood vessels 
CXCR5 CXCL13 CD4+ FTh, Some Tregs 
 
B-T cell border in 
lymph node GCs 
CXCR6 CXCL16 NKT tissue 
CTLs, cytotoxic CD8+ T lymphocytes; CM, central memory; GC, germinal center; FTh, 
follicular helper T cells 
CXC chemokine receptor 3 (CXCR3) is expressed primarily on activated T cells and NK cells 
(Qin et al., 1998, Rabin et al., 1999, Romagnani et al., 2001) and its known human ligands 
are CXCL9 and CXCL10 (Cole et al., 1998, Loetscher et al., 1996). The evidence of the 
involvement of this chemotactic axis in MS has been first obtained from studies in EAE 
showing that the levels of CXCL10 were related to relapses (Fife et al., 2001, Glabinski et 
al., 1997, Godiska et al., 1995). Then flow cytometric analysis on circulating and CSF T cells 
of MS patients has shown a significant enrichment of CXCR3 bearing CD4+ and CD8+ T 
cells in the CSF (Misu et al., 2001, Sorensen et al., 1999). In addition, CXCR3+ cells have 
been detected in perivascular cuffs in MS lesions together with elevated levels of expression 
of CXCL10 in the CSF of the MS brain (Balashov et al., 1999, Simpson et al., 2000, 
Sorensen et al., 2002b). 
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Figure 5.1 Chemokine receptors and transcription factors characterizing T cell subsets 
On the left, a schematic representation of chemokine-mediated amplification of effector 
CD4+ Th1, Th2, Th17 and follicular helper T cells responses in inflamed tissues. On the 
right, the same schematization shows chemokine-mediated amplification of Tregs that 
express identical chemokines receptors. After being activated, naive T cells differentiate into 
distinct CD4+ T helper cells subsets depending on the interleukins milieu, which drives a 
program of differentiation that includes the induction of lineage-specific transcription factors, 
such as T-bet for Th1, RORγT for Th17 and Foxp3 for Tregs, as well as specific chemokines 
receptors, such as CXCR3 for Th1, CCR6 for Th17 and CXCR5 for follicular helper T cells. 
Red boxes highlight the T cell subsets we tried to identify in the MS brain. Arrows indicate 
the secretion of interleukins of chemokines, round light blue cells represent T cells, flat pink 
cells indicate tissue-resident cells. Adapted from Bromley et al (2009). 
 
It has been shown that B cells in CSF from patients with MS and neurologic control subjects 
express chemokine receptor CXCR5 (Sorensen et al., 2002a) and that its ligand, CXCL13, is 
a potent chemotactic signal involved in the control of the organization of B cells within 
follicles in lymphoid tissues (Ansel et al., 2000). These evidences, together with the reported 
presence of ectopic B cell follicles in the meninges of MS brain (Magliozzi et al., 2007) 
indicate the importance of this chemotactic axis in the immunopathogenesis of organized 
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meningeal inflammation. In addition it has been reported that CXCL13 is present in MS WM 
lesions and at increased concentrations in CSF from patients (Krumbholz et al., 2006, Kuenz 
et al., 2008, Sellebjerg et al., 2009).  
B and T cells do also express CXCR4 and its ligand, CXCL12, is also present in MS lesions 
and in CSF from MS patients (Krumbholz et al., 2006, Moll et al., 2009). In particular it has 
been reported that CXCL12 is redistributed towards vessel lumena within MS WM lesions, 
suggesting that the presence of this chemokine is essential for the extravasation of 
inflammatory cells bearing CXCR4 (McCandless et al., 2008a). In addition it has been 
reported that antagonism of CXCR4 inhibits EAE and the accumulation of Th1 cells in the 
CNS (Kohler et al., 2008).  
Together with CXCR3, CCR5 is associated with trafficking of activated memory T cells, 
predominantly of Th1 phenotype (Syrbe et al., 1999), to sites of inflammation in vivo (Moser 
and Loetscher, 2001) or during bacterial infections (Yurchenko et al., 2006). In MS CCR5 
expressing T cells are increased in MS patients both in the peripheral blood, when compared 
to controls (Balashov et al., 1999), and in the CSF (Teleshova et al., 2002). 
Th1 cells also express the chemokine receptor CXCR6 whose expression on MBP-specific T 
cells has been shown to correlate with IFN-γ production (Calabresi et al., 2002). CCR4 has 
been reported to expressed by lymphocytes exhibiting a Th2 phenotype (Kim et al., 2001) 
and to be a marker, together with CCR6, of CD4+ T cells secreting IL-17 (Acosta-Rodriguez 
et al., 2007). Transcription factors also characterize different lymphocytes lineages. In 
particular Th1 has been associated with T-bet (Szabo et al., 2000), Th17 with RORγT 
(Ivanov et al., 2006) and regulatory T cells (Tregs) with Foxp3 (Hori et al., 2003a).  
Our aim was to further characterize the inflammatory infiltrates and evaluate the contribution 
of each subset to meningeal inflammation. We therefore tried to optimize the protocols for 
different antibodies in order to assess the presence of these chemokines, their receptors and 
transcription factors on lymphocytes in the MS brain tissue.  
5.1.3 TCR repertoire in MS 
Since the activation of T cells effector functions is dependent on the specificity of their TCR, 
analysis of TCR DNA and amino acid sequences has been aimed at revealing their role in 
pathological mechanisms (Babbe et al., 2000) and helping to resolve their antigen specificity 
(Hohlfeld et al., 2008). TCRs are membrane-bound heterodimers, two types of which, αβ 
and γδ, have been identified so far. Within each chain the Complementarity Determining 
Region 3 (CDR3) plays a major role in specificity of antigen recognition. Like antibodies, the 
T-cell receptor β-chain CDR3 region is encoded in the genome as variable gene segments 
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(V), diversity segments (D), joining segments (J), and constant region genes (C). The many 
different combinations of V, D, and J gene segments, arising from recombination in the 
thymus as well as random insertion of nucleotides, represent the so-called combinatorial 
repertoire (Arden et al., 1995) (Fig 5.2) whose analysis of lengths distribution is called 
spectratyping (Kepler et al., 2005).  
 
Figure 5.2 Schematic diagram of sequential rearrangement steps, transcription and 
translation of the TCRVB gene in T cells 
In this example, first a Dβ2 to Jβ2.3 rearrangement occurs (A), followed by a Vβ4 to Dβ2-
Jβ2.3 rearrangement (B), resulting in the formation of a Vβ4-Dβ2-Jβ2.3 coding joint 
(genomic DNA) (C). The rearranged TCRVB gene is then transcribed into precursor mRNA 
(D), spliced into mature RNA (E), and finally translated into a TCRβ protein chain forming 
part of the T cell receptor (F). The two extrachromosomal TRECs that are formed during this 
recombination process are indicated as well; they contain the D-J signal joint and the V-D 
signal joint, respectively (G). My TCRVB amplification strategy consisted in a multiplex PCR 
approach on the genomic DNA of single cells laser captured from brain tissue: primers were 
designed for Vβ and Jβ genes. Adapted from Van Dongen et al. 2003. 
 
 
The comparison of the TCRVB sequences between MS patients has revealed that, although 
Vβ5.2 cells are often clonally expanded in blood and CSF, the predominant TCR clone is 
unique to each MS case and that similar clonal expansions can be found in the same patient 
at different time points (Matsumoto et al., 2003). Further studies on the TCRVB repertoire of 
peripheral blood mononuclear cells and CSF-derived T cells in MS patients have identified a 
skewed repertoire suggestive that a limited number of T cell clones could be driving the 
chronic immune response in MS (Laplaud et al., 2004). In addition, it has been shown that 
auto-reactive clones can persist in the peripheral blood for years and expand during clinical 
relapses (Skulina et al., 2004). The TCRVB analysis of the CSF of a RRMS patient also 
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found a reduced complexity of the repertoire at the time of the exacerbation indicative of 
antigen specific clonal expansion within the CNS (Muraro et al., 2006).  Interestingly, the 
comparison of the TCR repertoire in distinct WM lesions in different MS patients has 
revealed that some pervasive T-cell clones exists in distinct lesions and confirmed that these 
clones “private” (unique) to individual patients (Junker et al., 2007). In fact, no constantly 
repeated clonal expansions between patients (common public repertoire) has ever been 
shown and only few Vβ families expansions appear to be more frequent than others. Our 
aim was to compare TCR Vbeta chains of CD8+T cells in the meninges and in white matter 
to investigate the relationship between CD8+T cells clonal expansions in these two 
compartments. The finding of overlapping TCRVB chain sequences in WM lesions and 
meningeal infiltrates would be indicative that CD8+ T cells clonal expansions taking place 
within the meninges infiltrate the WM parenchyma, indicating the essential role of the 
meningeal compartment in the immunopathologenesis of MS. 
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5.1.4 Aims of this study 
1. Characterize the expression levels of chemokines in the parenchyma of grey matter 
lesions comparing cases with high versus low meningeal inflammation and non 
neurological controls 
2. Characterize lymphocyte subsets infiltrating the CNS according to the chemokine 
receptors on their membrane, testing the possibility to detect them with a panel of 
antibodies. In particular, to investigate the presence of the CXCR3-CXCL9, CXCR3-
CXCL11, CXCR5-CXCL13 and CXCR4-CXCL12 chemokine axis in the meninges 
and in WM lesions of the MS brain.  
3. Optimization of immunofluorescence to identify Th1, Th17 and Tregs subsets based 
on the detection of their respective lineage-specific transcription factors: T-bet, 
RORγT, Foxp3  
4. Dissection of single CD8+ T cells from the meningeal and WM lesion inflammatory 
infiltrates in order to analyze their TCRVB specificity using a multiplex PCR approach 
on genomic DNA. The aim was to compare TCRVB specificity in the meninges and in 
WM CD8+ T cells infiltrates in order to clarify whether CD8+ T cells clonal 
expansions in the meninges were also present in WM lesions or not. 
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5.2 Results 
5.2.1 Expression of chemokines in the GM parenchyma 
Given my observation of increased microglial activation in the cortex of MS cases in 
presence of high meningeal inflammation, I wanted to assess the levels of expression of 
cytokines whose secretion is controlled by IFN-γ and IL-17 in the cortical parenchyma. I 
sampled from the second to the fifth cortical layer of one lesion from each MS case and 
three controls, performed quantitative real time PCR analysis for CCL4, CCL5, CX3CL1, 
CXCL2, CXCL11, CXCR4 normalised against GADPH expression, then compared the 
samples from cases with high meningeal inflammation to the ones from cases with low 
meningeal inflammation. Although all these genes were expressed at a level above 
background in all MS cases, regardless of the classification based on meningeal 
inflammation, I found no statistically significant difference between these two groups (Fig 
5.3). Nevertheless I showed high level of expression of CXCL2 and CXCL11 in particular in 
cases with high meningeal inflammation (Fig 5.3 A, B). On the contrary Fractalkine, CCL5 
(RANTES) and CXCR4 were expressed at high level in cases with low meningeal 
inflammation (Fig 5.3 C-E). CCL4 was the most upregulated gene among the ones I 
measured in cortical grey matter parenchyma in both groups at the same level (Fig 5.3 F). I 
then compared all MS cases to controls to show that even if the expression of all gene 
analysed was higher in the former, this difference did not reach the threshold of statistical 
significance (Table 5.2 Fig 5.3 G-N). A limitation in my observation is the low n number of 
the MS cases for which the expression levels of the genes could be detected. The missing 
samples should be run again to increase the n number and reach an appropriate statistical 
power. 
On the same tissue samples, and under the same conditions, I also tested RT-PCR primers 
provided by QIAGEN  for the amplification of human IL23A, IL17A, IL8, CXCL1, CCL21, 
CCL19, CXCL9, CXCL10, CXCR3, CCR3 and CCR2 (see Chapter 2, table 2.5 for details). 
Although I could detect amplification of the house keeping gene GADPH in the same 
experiment run in parallel, I had no amplification detectable using these primers. This could 
mean that the above genes are not expressed by the GM parenchyma in these samples or 
that the primers could not efficiently amplify the template. 
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Figure 5.3 Chemokine expression by the cortical parenchyma of GM lesions in the MS 
brain (previous page) 
The comparison of normalized expression levels of chemokines in the cortical parenchyma 
of cases with high meningeal inflammation versus low meningeal inflammation (A-F) and of 
all MS cases versus control cases (G-N) showed no statistical significance between these 
groups although all genes were expressed above background in MS cases when compared 
to controls. CXCL2 (A, G) and CXCL11 (B, H) were expressed above background and 
showed a trend to be increased in cases with high meningeal inflammation. CX3CL1 (C, I), 
CCL5 (D, L) and CXCR4 (E, M) were expressed above background and showed a trend 
toward the increase in cases with low meningeal inflammation. CCL4 was the most up-
regulated chemokine at the same levels in both high and low meningeal inflammation cases 
(F, N). All normalized expression levels are expressed as mean ± SEM. 
5.2.2 Detection of CXCR5 and CXCR3 on lymphocytes in the MS brain 
First I performed the optimization of the immunofluorescence protocol for the detection 
CXCR5 and CXCR3 on human tonsils (Fig 5.4 A, B). I used the same protocol conditions on 
MS brain tissue and found CXCR5+ (Fig 5.4 C) and CXCR3+ lymphocytes (Fig 5.4 D) in WM 
lesion infiltrates, in agreement with previous pathology studies (Sorensen et al., 2002b). I 
then tried to characterize CXCR5+ cells in WM and identified CD4+CXCR5+ cells (Fig 5.4 E-
G). Although these observations were only qualitative and performed only in the MS cases 
with more florid inflammatory infiltrates I could observe CXCR3+ cells more frequently than 
CXCR5+: both markers were always found on lymphocytic-like cells distributed in the 
perivascular space of blood vessels in chronic active WM lesions.  
5.2.3 CXCL12 redistribution in the meninges of MS patients  
CXCL12 was seen to be expressed on vessels throughout the control (Fig 5.5 A) and MS 
tissue (Fig 5.5 B). However, I observed a different localization of CXCL12 in blood vessels in 
the MS brain when compared to controls. In fact CXCL12, which was normally located in the 
perivascular space as indicated by CD31 in controls (Fig 5.5 A), exhibited an altered pattern 
in MS cases, redistributing in meningeal vessels towards the luminal surface (Fig 5.5 B). 
This observation is accordance with a previous pathology study by McCandless who has 
reported the same loss of polarity in vessels of WM parenchyma (McCandless et al., 2008a). 
Our study extended this finding to the meninges and showed that loss of CXCL12 polarity in 
meningeal vessels is accompanied by the infiltration of lymphocytes into the CSF (Fig 5.5 D, 
E). Consistent with this, all of the vessels showing redistribution of CXCL12 were found to be 
situated adjacent to type III subpial lesions (Fig 5.5 D, E). The quantification of CXCL12 
redistribution showed that it was present in 4.43 ± 1.8% of meningeal blood vessels of the 
MS cases whereas this was never observed in controls (Fig 5.5 F). The optimization of the 
staining, the experiments and the quantification were performed by Peter Reynolds for his 
Bsc project under the supervision of Paolo Muraro and mine.  
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Figure 5.4 Detection of CXCR5+CD4+ and CXCR3+ cells in WM lesion infiltrates 
We first optimized the antibodies for (A) CXCR5 (clone RF8B2, BD) and (B) CXCR3 (clone 
1C6/CXR3, BD) with immunohistochemistry on human tonsils. I then detected (C) CXCR5+ 
and (D) CXCR3+ in WM chronic active lesion infiltrates using immunofluorescence (green) 
and DAPI (blue) to stain cells nuclei. Sequential double IF for CXCR5 (green) (E) and CD4 
(red) (F) identified CXCR5+CD4+ cells (yellow) (G) (DAPI staining was performed but blue 
channel is missing from images C, E, F, G due to a temporary failure of imaging software). 
All images acquired at 20X, except D at 10X (all scale bars = 20µm) 
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Figure 5.5 CXCL12 redistribution in meningeal vessels in the MS brain 
(A-C) CD31 showed the localization of the vessel endothelia (brown) where CXCL12 (blue) 
was detected. In normal vessels CXCL12 was located on the basolateral surface (arrows) of 
the vessel (A). A proportion of blood vessels in the meninges of MS brain showed the 
redistribution of CXCL12 (arrowheads) from the abluminal side towards the vessel lumena 
(B, C). MOG immunostaining shows a type III subpial lesion extending along the surface of a 
gyrus (arrows), with associated meningeal aggregation (D, E). The meningeal vessels 
marked as BV are examples of the locations of vessels found to show CXCL12 redistribution 
(D, E). The mean percentage of vessels showing redistribution of CXCL12 in MS (4.43 ± 
1.8%) was significantly higher than in control tissue sections (0%), * p=0.015 (F). P value 
was calculated using a non-parametric unpaired t-test. 
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5.2.4 Optimization of immunofluorescence for Foxp3, T-bet and 
RORγT and in brain tissue 
I tried to optimize the protocols to detect T cells lineage-specific transcription factors, such 
as T-bet (Th1), RORγT (Th17) and Foxp3 (Tregs) in brain snap frozen tissue. Although I 
could detect Foxp3+ CD4+ T cells in snap frozen human tonsils (Fig 5.6 A) I could not detect 
Foxp3 in brain tissue (Fig 5.6 B). Antibodies for T-bet and RORγT did not detect any clear 
signal in the brain tissue (Fig 5.6 C). The antibodies I used for the detection of T-bet and 
ROR-T were the only ones available on the market at the time of my experiments. Technical 
information provided by the companies producing T-bet (Santa Cruz) and RORγT antibodies 
was reporting their optimal use for flow cytometric analysis and western blotting only.  
 
Figure 5.6 Optimization of immunofluorescence for Foxp3, RORγT and T-bet 
(A) Detection of Fop3 (red) in CD4 (green) T cells in snap frozen human tonsils. (B) The 
same Foxp3 antibody did not detect any Foxp3 (green) in CD3+ (red) T cells in the MS 
brain. (C) RORγT (red) and (D) T-bet (red) were not consistently detected in MS brain. 
Images A, B, C acquired at 20X, image D acquired at 40X, scale bars = 20µm   
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5.2.5 PCR on genomic DNA extracted from cells after laser capture   
I tried to amplify TCRVB rearrangements from CD8+ T cells laser captured from brain tissue 
using a multiplex PCR approach on genomic DNA. First I tested the PCR conditions for the 
master mix and the thermal cycling for the two sets of 24 primers on serial dilutions  of 
plasmid Q334 (1:10, 100000 to 1 copy) as positive control for Tube 1 (6 primers for 
TCRJB1genes and 23 primers for TCRVB genes) (Fig 5.7 A), and on the same serial 
dilutions of plasmid F6 as positive control for Tube 2 (containing 7 primers for TCRJB2 and 
the same 23 TCRVB primers of Tube 1) (Fig 5.7 B). For both reactions I observed a specific 
amplification band of intensity decreasing according to the dilution of the sample, indicating 
the sensitivity of the multiplex PCR conditions. 
I then tested whether our protocol for the extraction of single cells from tissue, followed by a 
short digestion with pK, could affect the integrity of the gDNA in these samples and whether 
any reagent in the digestion solution, could inhibit the following PCR amplification. Therefore 
I tried to amplify a single gene (CACNA1) from 150 CD8+ T cells laser-captured from brain 
and spleen. I could detect a single specific amplification product both from brain and spleen 
laser-captured CD8+T cells and also from human gDNA digested according to the same 
protocol. This showed that the integrity of the genomic DNA was preserved during the laser 
capture procedure (Fig 5.7 C). I then repeated the experiment on a progressively decreasing 
number of CD8+ cells laser captured only from brain: I could detect an amplification band 
from 100, 40, 20 and 10 cells (Fig 5.7 D). I then performed the same LCM and digestion 
procedure on 100 CD8+ cells laser captured from brain and spleen and performed the 
multiplex PCR running at the same time with Tube 1 and Tube 2 primers sets on each 
sample.  I could not detect any amplification from our samples, both in tube 1 and tube 2 
reactions, although the plasmids used as internal positive controls always showed an 
amplification band (Fig 5.7 E, F). 
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Figure 5.7 PCR on genomic DNA extracted from cells after laser capture 
(A) The BIOMED-2 set of primers in tube 1 was tested on serial dilutions of plasmid Q334 as 
positive control. (B) The BIOMED-2 set of primer in tube 2 was tested on serial dilutions of 
plasmid F6 as positive control. Amplification (200-300bp) was present also at high dilutions 
(white arrows indicate 1:10 dilutions of plasmids). (C) A standard PCR with two primers 
designed for the amplification of a gene (CACNA1E) from human genomic DNA was 
performed on 150 digested LCM CD8+ T cells from brain (letter B on each lane) or spleen 
(letter S on each lane) and on genomic DNA both digested (digested gDNA on two lanes) 
and non digested (gDNA on one lane) and showed presence of specific amplification 
(600bp). (D) The same PCR and digestion conditions of laser-captured cells were then 
applied to a gradually decreasing number (on top of each lane) of LCM cells from brain only. 
Amplification product could be detected from 100, 40, 20 and 10 CD8+ cells laser-captured 
from brain showing the integrity of the gDNA in CD8 T cells after laser-capture from brain 
tissue. The sampling of 100 CD8+ T cells from brain and spleen was then performed with 
the same protocol and their gDNA used for multiplex PCR with BIOMED-2 primers: tube 1 
(E), Tube 2 (F) but no amplification products could be detected. All DNA ladders are 100bp, 
W = water. 
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5.3 Discussion 
5.3.1 Production of chemokines by the cortex in inflammatory 
conditions: role in cortical pathology 
Here I showed that under inflammatory conditions the cortical parenchyma can produce 
chemokines whose transcription is triggered by cytokines, such as IFN-γ, TNF and IL-17, 
which I assume have been secreted by the immune cells we detected in the overlying 
meninges to then leak into the cortex to activate the microglia. A piece of evidence 
supporting this hypothesis of a pro-inflammatory (auto)immune response ongoing within the 
meninges of the MS brain is coming from observations of the effects of Natalizumab, a 
humanized mouse monoclonal antibody against the intergrin very late activation antigen 
(VLA)-4 on leukocytes. In fact it has been shown that Natalizumab can block the attachment 
of activated T cells to brain endothelial cells and thereby prevent their entry into the CNS 
(Rice et al., 2005, Niino et al., 2006) ultimately decreasing the number of cells in the CSF in 
patients (Stuve et al., 2006). Interestingly, a study comparing the peripheral blood serum and 
CSF of MS patients treated with Natalizumab, showed also a global decline in chemokines 
(CXCL9, CXCL10, CXCL11, CCL22) and cytokines in the treated patients that was most 
pronounced in CSF and less in the peripheral blood serum (Mellergard et al., 2010).  
In agreement with these observations I found that the levels of expression of CXCL11, which 
has been shown to be present in the CSF of RRMS patients (Szczucinski and Losy, 2011), 
and the levels of  CXCL2, which has been recently shown to be induced in mouse endothelia 
in vitro after stimulation with TNF and IL-17 (Griffin et al., 2012), were above background in 
the cortex of the MS brain. Both CXCL2 and CXCL11 are strong chemotactic signals, the 
first for neutrophils and the second for activated T cells. Notably, it has been shown in EAE 
that transfer of encephalitogenic CD4(+) Th17 cells is sufficient to induce CXCL1 and 
CXCL2 transcription in the spinal cords of naive, syngeneic recipients (Carlson et al., 2008) 
while the stimulation of mouse endothelial cells in vitro with TNF and IFN-γ has been shown 
to induce CXCL9 and CXCL10 (Griffin et al., 2012), which belong to the same family of 
CXCL11 and interact with CXCR3 on T cells. I also found CCL5 expressed in the cortical 
parenchyma, possibly secreted by the activated microglia, as it has been shown in vitro after 
IFN-γ stimulation (Rock et al., 2005).  
The highest level of gene expression I observed in the MS cortex was for CCL4, which is a 
chemoattractant for natural killer cells, monocytes and immature dendritic cells (Ransohoff, 
2009) which has also been detected to be strongly expressed by human microglia in vitro in 
response to IFN-γ (Rock et al., 2005). Taken together my observations are suggestive that 
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the activated microglia and also the endothelium of microvessels in the cortex are 
responding to the soluble pro-inflammatory signals produced in the meninges by secreting 
chemoattractant signals that in turn could elicit the increased recruitment of inflammatory 
cells. I could therefore speculate that the microglial activation observed in the parenchyma of 
demyelinated grey matter could contribute to the perpetuation of the pro-inflammatory 
process in the meninges of the progressive MS brain. 
5.3.2 Lymphocyte subsets migration to the CNS depends on their 
chemokine receptors  
I have shown the presence in the MS brain of lymphocytes positive for CXCR3 and CXCR5. 
Although this qualitative observation does not allow to define the phenotype of CXCR3+ 
cells in MS brain, lymphocytes that upregulate CXCR3 after activation can include Th1 cells 
(Syrbe et al., 1999), CTLs (Guarda et al., 2007), Th17 (Acosta-Rodriguez et al., 2007) and 
NK T cells (Thomas et al., 2003). A previous pathology report has found that the majority of 
T cells in the CSF express CXCR3+ in MS patients and also that the numbers of CXCR3+ 
cells and CD3+ cells in WM lesions, regardless of their lesional stage, showed strong 
positive correlation with each other (Sorensen et al., 2002b). In addition it has been shown 
that in juvenile idiopathic arthritis memory CD4+ T cells expressing CXCR3+, both in 
peripheral blood and in synovial tissues, can secrete IFN-γ (Acosta-Rodriguez et al., 2007) 
suggesting that CXCR3 expression on T lymphocytes is associated with a Th1 phenotype. 
Although we could not detect the expression of its ligands CXCL9 and CXCL10 by the 
cortical parenchyma of GM lesions, CXCL10 in CSF of MS patients has been shown to be 
significantly higher compared to control subjects (Franciotta et al., 2001), to positively 
correlate with CSF leukocytes counts (Sorensen et al., 1999) and to other markers of 
intrathecal inflammation such as neopterin, MMP-9 and IgG-synthesis (Sorensen et al., 
2001). I could speculate that the chemokine axis CXCR3-CXCL9 and CXCR3-CXCL10 is 
involved in the entry of Th1 cells, secreting IFN-γ, in the inflamed MS brain both in WM and 
in the meninges.  
My detection of CXCR5 cells in the MS brain, together with the report of increased levels of 
CXCL13, which is CXCR5 ligand, in the CSF of active MS (Sellebjerg et al., 2009) and WM 
lesions (Krumbholz et al., 2006) indicates that CXCL13 may play a major role in the 
recruitment of T cells to the CNS. The evidences that also B cells can express CXCR5 
(Sorensen et al., 2002a) and that ectopic B cell follicles have been described in the 
meninges of progressive MS brain (Magliozzi et al., 2007) are suggestive that this 
chemokines axis might be essential for the formation of these structures within the MS brain. 
I also report the presence of CXCR5+CD4+ T cells which have been described as follicular 
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helper T cells (Tfh) (Fazilleau et al., 2009) and whose frequency has been found increased 
in patients with systemic lupus erythematosus (Simpson et al., 2010), rheumatoid arthritis 
(Ma et al., 2012) and autoimmune thyroid disease (Zhu et al., 2011). I might therefore 
speculate that the CXCR5-CXCL13 chemokine axis is playing a role in the selective 
migration to the MS brain of B and Tfh cells. Interestingly Tfh cell, identified by the co-
expression of CD4+ and CXCR5 have been shown to play an essential role essential for 
lymphoid follicles formation and B cell maturation by cytokines production (Leon et al., 2012, 
Diehl et al., 2012).   
5.3.3 Redistribution of CXCL12 in the meninges of MS patients 
I showed that CXCL12 redistribution is present in blood vessels in the meninges where it is 
spatially associated with the presence of inflammatory infiltrates and subpial cortical lesions. 
The polarised expression of CXCL12 found in normal vessels supports the proposal that 
CXCL12 is usually located in the perivascular space to prevent immune cell infiltration into 
the parenchyma whereas in the MS brain its redistribution towards the luminal surface is 
essential for the infiltration of CXCR4-expressing lymphocytes (McCandless et al., 2008a). 
My study extends this finding to the meninges therefore suggesting that loss of CXCL12 
polarity is one of the routes for the infiltration of lymphocytes into the CSF. Consistent with 
this, all of the vessels showing redistribution of CXCL12 were found to be situated adjacent 
to inflammatory infiltrates suggesting a role of the CXCL12-CXCR4 chemokine axis in the 
formation of inflammation in the meninges. 
The modulation of CXCL12 and CXCR4 has been previously studied, in animal models of 
MS, as potential therapeutical target. It has been shown that, when a CXCL12-
immunoglobulin fusion protein is administered, it causes suppression of EAE (Meiron et al., 
2008). However, the disruption of CXCR4-CXCL12 interaction has created conflicting results 
in EAE, with both the suppression of a relapsing model (Kohler et al., 2008) and the 
worsening of a chronic model with increased immune cell infiltration into the CNS 
(McCandless et al., 2006). More recently, an experiment simulating an in vitro BBB with a 
flow chamber showed that CXCL12-mediated adhesion of PBMCs to the endothelium is 
more efficient in monocytes than in other lymphocytes. Notably, the lymphocytes without 
monocytes failed to transmigrate in response to CXCL12, whereas the addition of 
monocytes restored lymphocytes transmigration (Man et al., 2012). Therefore, based on 
these pathology and experimental findings it seems possible to consider CXCR4-CXCL12 as 
a therapeutical target to block lymphocytes entry into MS brain, although more experiments 
should clarify in animal model the mechanisms of lymphocytes extravasation proposed by 
Man and colleagues. 
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5.3.4 No amplification of TCRVB genes using a multiplex PCR approach 
on genomic DNA 
The BIOMED-2 set of primers were designed for the detection of clonally rearranged TCRVB 
genes with high sensitivity. In particular these primers have been designed to be used in 
sets for multiplex PCR approach on a genomic DNA template. However, the optimization of 
the multiplex PCR conditions has shown that the standard amount of template DNA for this 
application should be 100ng (van Dongen et al., 2003).  
My approach, based on the laser capture of as few as possible CD8+T cells was aiming at 
determining the TCRVB specificity down to the single CD8+T cell. Unfortunately this method 
did not provide enough DNA for optimal amplification. Probably in my multiplex PCR 
strategy, which had 30 primers in a single reaction, amplification was inhibited by the 
competition for the template during the very first cycles of amplification. In fact, my 
experiment with a standard PCR approach, with just two primers designed for gene 
amplification on gDNA template, showed that the number of cells for an effective 
amplification was around 40. However, the presence of the PET membrane, which is laser-
captured together with the cells, might represent a further element of disruption of the PCR 
conditions. Further optimization for this approach would require the design of another PCR 
strategy (nested) for a first round of amplification of a limited number of TCRVB genes. 
Alternatively, the number of laser-captured cells from tissue might be increased until the 
optimal amount of template gDNA is reached but then the possibility to have many different 
TRCVB specificities in one sample, without an evident clonal expansion, would impair the 
significance of the results. 
In literature a similar approach has been reported using cDNA generated after mRNA 
extraction from 15000 laser-captured T cells (Junker et al., 2007), which then poses the 
limitation of the amount of inflammatory infiltrates to sample. In the same study also single 
cell PCR analysis of TCRVB has been reported, but again two cycles of double-nested RT-
PCR had to be performed. 
5.3.5 Conclusions 
I observed an increased expression level of the mRNA of chemokines (CCL4, CCL5, 
CXCL2, CXCL11 and CX3CL1) in MS brain cortical lesions when compared to control GM 
suggesting that they might play a role in the recruitment of inflammatory cells to the overlying 
meninges and to GM parenchyma. In particular I have shown that CXCL12, normally found 
around blood vessels, redistributes towards the lumena of meningeal blood vessels, and is 
spatially associated with lymphocytic infiltrates. These observations indicate a possible 
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mechanism of lymphocyte entry to the inflamed meninges. The characterization of 
chemokine receptors on lymphocytes infiltrating the CNS has shown the presence of 
CXCR3+ cells, probably indicative of Th1 cells infiltration, and of CXCR5+CD4+ follicular 
helper T cells, which are reported to be increased in autoimmune conditions and might be 
associated with the formation of ectopic B cell follicles in the meninges. Further 
characterization of the chemokine receptors on immune cells subsets infiltrating the MS 
brain might provide new insights into the mechanisms of inflammatory cells trafficking to the 
CNS and possibly new therapeutical targets to achieve the modulation of pathologic immune 
responses in the MS brain. 
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Chapter 6 
 
Meningeal inflammation and disease progression    
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6.1 Introduction 
6.1.1 The clinical course of multiple sclerosis: primary and secondary 
progressive 
After a variable period of relapsing-remitting phase a progressive accrual of residual 
neurological dysfunction develops. This phase of the disease, defined as secondary 
progressive (SPMS), is at heart of the medical, social and economic impact of multiple 
sclerosis. Progressive form, for a subset of patients with MS (10 to 20%), is different and 
consists in progression of disability from onset without episodes of relapse and remission. 
This subtype of MS clinical course is termed primary progressive (PPMS) (Miller and Leary, 
2007). The analysis of the natural history of MS has shown that, even if the duration and the 
clinical features of the initial relapsing-remitting course can be highly variable, the accrual of 
disability characterizing the progressive phase occurs at a similar rate in the majority of the 
patients and is independent of the inital course (Confavreux and Vukusic, 2006). In addition 
it has been shown that the age at which progression is reached is not substantially 
influenced by the initial course of the disease, including the frequency of relapses (Scalfari et 
al., 2010, Confavreux et al., 2000). Notably clinical progression in both SP and PP forms of 
MS is widely reported to start at 40 years of age (Kremenchutzky et al., 2006). However, 
early relapse frequency does associate with what is going to be a more rapid and severe 
clinical course overall but the predictive effect of early relapse rate on disease progression 
disappears once the progressive course begins (Confavreux et al., 2003). 
6.1.2 The role of compartmentalized meningeal inflammation in 
disease progression 
The clinical characteristics that separate secondary progressive MS from the relapsing-
remitting disease are better defined than the immunological differences between these two 
phases. However, a number of studies that have compared the immune response of RRMS 
and PPMS patients in peripheral blood and within the CSF have provided evidence 
supporting the concept that compartmentalization of the immune response within the CNS 
characterizes disease progression (Meinl et al., 2008). The analysis of peripheral blood have 
shown that both primary and secondary progressive MS patients have higher percentages of 
circulating CD4+ and CD8+ T cells expressing T-bet, a transcription factor present in 
leukocytes during Th1 responses, than RRMS and controls. In addition the percentages of 
circulating CD4+ and CD8+ T cells expressing T-bet have also been shown to correlate with 
disease activity (Frisullo et al., 2012). This supports the idea that while the RRMS course is 
characterized by pro-inflammatory immune cells which can acquire the ability to migrate into 
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the brain parenchyma from the periphery and to give rise to MRI-visible lesions in PPMS and 
SPMS the immune response becomes chronically activated behind an intact BBB where it 
becomes compartmentalized (Lassmann et al., 2007). This would explain why the changes 
in relative proportions, as well as phenotype, of B and T cells, between the periphery and the 
CNS during the late progressive phase of the disease. 
Although the frequency of CD8+T cells in the peripheral blood is approximately half that of 
CD4+ T cells, they are instead much more frequent than CD4+ in MS plaques of chronic MS 
(Hauser et al., 1986). Some authors have therefore investigated the phenotype of T cells in 
the blood and the CSF of MS patients showing that 90% of the CD4+ and 76% of the CD8+ 
T cells in the CSF within 3 years of disease onset were either central or effector memory T 
cells, as shown by the expression of CD45RO+, (Okuda et al., 2005) and that 90% of the 
memory CD4+ T were of the central memory type, as defined by the combination of CCR7+ 
and CD45RO+, with no difference between the blood and the CSF (Kivisakk et al., 2004, 
Kivisakk et al., 2003). In addition it has been shown that the production of INF-γ in the CSF 
was mainly restricted to CCR7-negative T cells (Giunti et al., 2003) and that in RRMS highly 
differentiated CD8+ T cells enrich the CSF, when compared to blood, more than CD4+ T 
cells (Jilek et al., 2007). The fact that CD8+ T cells in the CSF are highly differentiated is 
suggestive that they might have proliferated within the target organ in response to antigenic 
stimulation and that they are activated T cells. In addition the plasma and CSF levels of 
granzyme, a direct indicator of T cell-mediated cytotoxicity, have been compared reporting 
an increase in CSF during a relapse indicating that CD8+ T cell toxicity is specifically 
increased in CNS (Malmestrom et al., 2008).  
Furthermore it has been reported that within the CSF of MS patients the percentages of 
CD4+ TNF+ T cells were significantly higher than in controls (Shi et al., 2009) in agreement 
with the increased levels of TNF in the same compartment when compared to plasma of 
controls and MS patients in remission (Obradovic et al., 2012). Another piece of evidence 
supporting the importance of an immune response localized within the CNS is that some 
brain-infiltrating CD8+T cells persisted in the CSF or blood for longer than 5 years 
suggesting that they may play a role in disease progression (Skulina et al., 2004). At the 
same time pathology reports have observed an increased immune response within the 
meninges, again suggesting a compartmentalization of the (auto)immune response within 
the meninges and  showing that it is associated with a faster disease progression (Howell et 
al., 2011). It has also been proposed that B cells might contribute to the exacerbation of an 
(auto)immune response within the CNS by molecular mimicry, producing antibodies which 
are cross-reactive between different auto- and allo-antigens, ultimately leading to 
progressive accumulation of autoantibodies within the target organ (Owens et al., 2003). In 
160 
 
this sense there is the evidence that MS cases with ectopic follicle-like structures in the 
meninges are indeed associated with a younger age at onset and death (Magliozzi et al., 
2007). Further evidence of the detrimental role of an inflammatory environment determined 
by the local increase of cytokines concentration over disease progression in MS comes from 
the association of Th1 cytokines, such as IL-12 and TNF, with a more severe clinical 
progressive phase (Sharief and Hentges, 1991, Balashov et al., 1997).  
6.1.3 The neuropathological basis of clinical progression 
The pathological mechanisms underlying disease progression are a matter of debate and 
there are different hypotheses about what contributes to it. The causes of the diversity 
between these two phases of the disease have been attributed to:  
I) neurodegeneration  
II) differences in the nature of the immunological response 
III) balance between injury and repair of the CNS.  
I) The limited presence of new gadolinium-enhanced lesions detected by MRI during 
progression (Filippi et al., 1995b, Losseff et al., 1996) cannot explain the accumulation of a 
wide range of neurological symptoms. In addition the lack of effect of immunomodulatory 
therapies (Bramanti et al., 1998, Leary et al., 2003, Pender and Wolfe, 2002) suggests a 
non-inflammatory nature of progression. These evidences have stimulated the concept that 
neurodegeneration, by definition a relentless process of death and decay of neural 
structures, may be the reason underlying progressive phase (Frohman et al., 2006, Nave 
and Trapp, 2008). In regard to MS and neurodegeneration as mechanisms underlying 
progression it must be noted that in contrast with classic neurodegenerative diseases, all MS 
lesions, regardless of the stage and type of the disease, are associated with some degree of 
inflammatory infiltrates. Further, regardless of the course, phase or site of the disease, 
neurodegeneration in MS appears to occur on a background of tissue inflammation. The 
analysis of the spatiotemporal distribution of WML  in RRMS and PPMS patients, using T1 
and T2 weighted MRI images, has shown that PPMS patients have a higher regional 
probability of lesions in the callosal body, the corticospinal tract, and other tracts adjacent to 
the lateral ventricles, suggesting  a particular vulnerability to neurodegeneration during 
disease progression (Filli et al., 2012). 
II) Neuropathology studies show the persistence of peripheral immune cells focal infiltrates in 
the white matter and actively demyelinating lesions (Frischer et al., 2009). In addition to 
neurodegeneration, to explain the seemingly non-responsiveness of CNS inflammatory 
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process to therapies during progression, the idea of a compartmentalized inflammation has 
been developed (Bradl and Lassmann, 2009), according to which inflammation becomes 
increasingly compartmentalized within the meninges and, behind a relatively intact BBB, in 
the perivascular spaces (Meinl et al., 2008) and also with a reduced duration of the 
progressive phase (Howell et al., 2011). The observation that the cases with meningeal 
follicles also show an increased cortical pathology has led to hypothesize that meningeal 
inflammation, cortical pathology and disease progression are interlinked. 
III) The notion that CNS repair capacities may be exhausted at the onset of progression 
(Hagemeier et al., 2012) is well in line with large natural history studies indicating that clinical 
variables only influence the first early disease phase until moderate disability has 
accumulated, whereas the progressive phase is characterized by accumulation of disability 
as an apparently self-perpetuating process (Confavreux and Vukusic, 2006). These 
observations are supportive that, although substantial damage can be sustained in an early 
phase, permanent clinical deficits appear to coincide in time when functional regeneration 
capacity is exhausted, reflecting a possible mechanism for the onset of progression (Fancy 
et al., 2011). Recently it has been shown, in an experimental animal model of induced 
demyelination, that remyelination is increased in old mice exposed to the systemic milieu of 
youthful mice through heterochronic parabiosis. In particular restored remyelination in old 
animals involves the recruitment of blood-derived monocytes from the young parabiotic 
partner since the blockade of their migration can partially inhibit remyelination (Ruckh et al., 
2012). Taken together these observations are supportive that effective remyelination is 
generally associated with a younger age during which early episodes of demyelination are 
marked by relapses; it is therefore likely that only later with age, the progressive phase could 
arise as a consequence of deficiencies in the regenerative response (Hampton et al., 2012). 
6.1.4 The association between grey matter pathology and clinical 
symptoms characterizing progression 
The role of grey matter pathology in disease progression has been suggested by the 
association with some clinical symptoms accumulating with slow progressive severity and 
characteristic of grey matter involvement, like seizures, cognitive impairment and fatigue. In 
fact the prevalence of MS patients with epilepsy is 3 to 6-folds higher than the general 
population (Poser and Brinar, 2003) and there is correlation between seizures and cortical 
juxtacortical lesions (Wishart and Sharpe, 1997). Cognitive impairment is also a common 
and disabling manifestation of MS and shows clinical features suggestive of grey matter 
involvement (Sanfilipo et al., 2006, Benedict et al., 2004). Also fatigue has been linked with 
cortical pathology, in particular to the subcortical lesional pattern, in a range of imaging 
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studies (Calabrese et al., 2010c, Filippi et al., 2002, Niepel et al., 2006). Since the use of 
computerized MR methods has allowed measurement of total and regional brain volumes 
(Miller et al., 2002), progressive decreases in total brain volumes have been consistently 
reported in patients with MS (Losseff et al., 1996, Rudick et al., 1999, Fox et al., 2000). In 
particular the measurement of neocortical volume has revealed that atrophy characterizes 
only cognitively impaired patients and is significantly correlated with a poorer performance 
on tests of verbal memory, attention/concentration and verbal fluency (Amato et al., 2004). In 
addition PET studies have linked changes in grey matter hypometabolism with cognitive 
impairment in patients with MS (Blinkenberg et al., 2000).   
Taken together with these findings the extensive cortical lesions observed predominantly in 
the progressive MS brain may be an important pathologic correlate of irreversible disability 
(Roosendaal et al., 2009, Roosendaal et al., 2011). Progressive accumulation of damage in 
the cortex might explain the observed dissociation between markers of inflammatory 
demyelination, gadolinium-enhanced WM lesion burden and disease progression. However, 
also WM involvement clearly impacts these clinical manifestations of MS, as the correlations 
between GM damage and clinical status remain only moderate (Sanfilipo et al., 2006). In 
particular a recent study has reported that, although in MS GM is more atrophic than WM, it 
is the total WM volume which shows an inverse correlation with physical disability measure 
by EDSS (Shiee et al., 2012). Therefore a still open question is the extent to which WM and 
GM damage interact with one another and contribute to disability in MS (Grassiot et al., 
2009). 
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6.1.5 Aims of this study 
I first wanted to assess whether the clinical milestones of disease progression in this cohort 
of MS cases reflected the ones of the general MS population. I compared the clinical 
milestones of cases with high versus cases with low meningeal inflammation and then tested 
possible correlations between the clinical milestones and: 
1. the lesion load in WM and GM  
2. the number of grey matter lesion types  
3. the density of MRP14+ cells in cortical lesions 
4. the density of cortical activated microglia 
5. the density of inflammation in the meninges of the MS brain 
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6.2 Results 
6.2.1 Clinical features of the MS population in this study 
This study was performed on 21 MS cases (17 SP-MS and 4 PP-MS), of which 13 females 
and 8 males with median age at death = 60 and age range 40-83 which reflected the entire 
cohort in the UK Multiple Sclerosis Tissue Bank (median age at death = 60, range 30-96 
years, n = 450). All cases were accompanied by extensive general practitioner’s notes 
including detailed neurologist reports (Reynolds et al., 2011). The comprehensive summary 
of the time to wheelchair and time to death for each case is represented in Fig 6.1 A. The 
median values are reported in Table 6.1. The lifetime clinical histories were prepared for 
each patient by clinical neurologists with a specialist interest in MS and their summarized 
data are reported in Table 6.2. The comparison between cases with high versus low 
meningeal inflammation for the time points or the durations in years of each clinical 
milestone, such as age at onset, time to wheelchair and age at death, are reported for each 
case in Fig 6.1 B-D and the median values are reported in Table 6.3.  
Table 6.1 Summary of clinical milestones for all cases (median ± IQR, years) 
Clinical milestones All cases (years) 
Age at onset 37 ± 14  
Onset to progression 10 ± 11 
Age at progression  40 ± 17  
Time to wheelchair  14 ± 15  
Age at wheelchair 48 ± 26  
Time from wheelchair to death 12 ± 15  
Age at death 60 ± 23  
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Case MS 
subtype 
Sex 2 yrs 
relapse 
rate 
Age at 
onset 
Age at 
progression 
Age at 
wheelchair 
Age at 
death 
Disease 
duration 
PMD Cause of death 
MS426 SP F 2 18 28 34 48 30 21 Multiple sclerosis 
MS387 SP F 6 32 35 36 43 11 13 Multiple sclerosis 
MS379 
SP 
F 
ND 32 ND ND 49 17 21 Multiple sclerosis, 
Pulmonary embolism 
MS377 SP F 1 27 ND ND 50 23 22 Aspiration pneumonia 
MS376 SP F 3 37 40 44 58 21 19 Multiple sclerosis 
MS371 SP M 1 24 33 36 40 16 27 Bronchopneumonia 
MS364 
SP 
F 
1 22 32 34 56 34 14 Bronchopneumonia, 
multiple sclerosis 
MS363 
SP 
M 
ND 15 ND 30 42 27 20 End stage of multiple 
sclerosis, respiratory failure 
MS335 
SP 
M 
2 24 36 39 62 38 13 Recurrent aspiration 
pneumonia, multiple 
sclerosis, renal failure 
MS306 
SP 
M 
1 35 50 57 78 43 17 Clostridium difficile 
diarrhoea, multiple sclerosis 
MS241 
SP 
F 
ND 43 58 62 83 40 15 Septicaemia, 
bronchopneumonia, MS, 
diabetes mellitus 
Table 6.2 Clinical demographics describing the MS subtype and the main clinical milestones defining disease progression, including cause of 
death and the post mortem delay before the brain was dissected. 
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PMD, post-mortem delay; ND, no data; YRS, years; SP, secondary progressive; PP, primary progressive 
Case MS 
subtype 
Sex 2 yrs 
relapse 
rate 
Age at 
onset 
Age at 
progression 
Age at 
wheelchair 
Age at 
death 
Disease 
duration 
PMD Cause of death 
MS237 SP M 1 37 64 72 77 40 19 Pneumonia, heart attack 
MS181 SP F 4 39 ND 69 71 32 20 Pneumonia, MS 
MS179 
SP 
F 
1 44 ND 48 70 26 20 Aspiration pneumonia, 
sepsis, multiple sclerosis 
MS147 
SP 
F 
3 38 49 52 60 22 27 Pneumonia, multiple 
sclerosis 
MS143 
SP 
F 
ND 59 ND 65 77 18 13 Pulmonary embolism, 
multiple sclerosis 
MS120 
SP 
F 
2 37 41 60 72 35 21 Metastatic liver disease, 
multiple sclerosis 
MS383 
PP 
M 
0 34 34 36 42 8 17 Aspiration pneumonia, 
multiple sclerosis 
MS378 PP M 0 41 41 46 53 12 15 Pneumonia 
MS313 
PP 
M 
0 37 37 58 66 29 16 Gastrointestinal bleeding 
caused by peptic ulcer 
disease,MS 
MS247 
PP 
F 
0 60 60 66 67 7 12 Multiple sclerosis, 
respiratory failure 
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Figure 6.1 Overview of clinical demographics 
(A) The time from onset to wheelchair (dark orange) and time to death (red) are indicated in 
years for each MS case. MS cases are listed sequentially from the lowest number and 
classified according to the density of meningeal inflammation. Primary progressive cases are 
highlighted as PP. The comparison of the median ± IQR age at onset (B),  time to 
wheelchair (C) and age at death (D) of cases with high meningeal inflammation (red dots) 
versus cases with low meningeal inflammation (black dots) showed no statistically significant 
difference. 
6.2.2 A trend to more severe, shorter disease course in cases with high 
meningeal inflammation 
Cases were grouped according to the density of meningeal inflammation, as I did for all 
previous analysis. Then median values of clinical milestones such as age at onset, age at 
wheelchair, time from wheelchair to death, age at death and disease duration, were 
compared to reveal that in our cohort there was no difference between these two groups that 
reached the level of statistical significance (Table 6.3) although there was a trend for cases 
with high meningeal inflammation to die at younger age (Fig 6.1 D). The comparison of the 
survival curves of the group with high meningeal inflammation versus the one with low 
meningeal inflammation clearly showed a tendency of the former to reach severe degree of 
disability earlier than cases with low meningeal inflammation (Fig 6.2 A-D). In particular the 
cases with high meningeal inflammation showed a trend to a younger age at death (high 
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meningeal inflammation age at death = 50 ± 26, low meningeal inflammation age at death = 
65 ± 19, p=0.0541) (Fig 6.2 D). 
Table 6.3 Summary all clinical milestones for the MS cases grouped according to high or low 
meningeal inflammation (median ± IQR) 
Clinical milestones High density meningeal 
inflammation 
Low density meningeal 
inflammation 
Age at onset 34 ± 18 37 ± 20  
Onset to progression 10 ± 17  11 ± 11  
Age at progression 33 ± 36 40 ± 15  
Time to wheelchair 14 ± 16  14 ± 16  
Age at wheelchair 41 ± 21  57 ± 26  
Time from wheelchair 
to death 
8 ± 9  12 ± 14  
Age at death 50 ± 26  65 ± 19  
 
 
Figure 6.2 MS cases with high meningeal inflammation show a trend to a more severe 
disease course 
Survival curves comparing MS cases with high meningeal inflammation (red line) to cases 
with low meningeal inflammation (black line) for disease duration (A), age at wheelchair (B), 
time from wheelchair to death (C), age at death (D) show no statistically significant 
difference, although there is a trend for the cases with high meningeal inflammation to die 
younger, p = 0.0541(D). 
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6.2.3 WM lesion load, but not GM lesions, correlate with clinical 
milestones of disease progression 
In order to assess the possible relationship between demyelination and clinical milestones, 
the lesion load in GM was tested for correlations with age at onset (Fig 6.3 A, p = 0.77, r = -
0.0694), time to wheelchair (Fig 6.3 B, p = 0.4067, r = -0.02021), age at wheelchair (Fig 6.3 
C, p = 0.1262, r = -0.3634), time from wheelchair to death (Fig 6.3 D, p = 0.9259, r = 
0.0229), age at death (Fig 6.3 E, p = 0.1831, r = -0.3021) and disease duration (Fig 6.3 F, p 
= 0.7454, r = -0.077) showing no statistically significant correlation with any of them. On the 
contrary time to wheelchair (p = 0.044, r = -0.4666), the age at wheelchair (p = 0.0034, r = 
0.6365), the age at death (p < 0.0001, r = -0.7693) and disease duration (p = 0.013, r = -
0.5446) showed a statistically significant negative correlation with the extent of WM 
pathology (Fig 6.3 G-N).  
6.2.4 Type I/III grey matter lesions, but not Type III, are a pathological 
sign of faster progression 
In order to assess the kind of relationship between the type of demyelination patterns in grey 
matter and disease clinical milestones, I correlated the number of lesions of Type I/III and 
Type III in each MS case, data shown previously in Chapter 3, with age at onset, disease 
duration, time to wheelchair, age at wheelchair, time from wheelchair to death and age at 
death. I found that in general the more Type I/III lesions were present, the faster disease 
milestones were reached (Fig 6.4 A-F): in particular this negative correlation was statistically 
significant for age at wheelchair (Fig 6.4 D, p = 0.0201, r = -0.5281) and age at death (Fig 
6.4 F, p = 0.0194, r = 0.0556). On the contrary, the more Type III lesions were present, the 
slower disease milestones were generally reached (Fig 6.4 H-N): this positive correlation 
was statistically significant for disease duration (Fig 6.4 H, p = 0.0166, r = 0.5161), time to 
wheelchair (Fig 6.4 I, p = 0.0253, r = 0.5112), age at wheelchair (Fig 6.4 L, p = 0.1661, r = 
0.3311) and age at death (Fig 6.4 N, p = 0.4345, r = 0.049). 
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Figure 6.3 Lesion load in WM shows negative correlations with the main milestones of 
clinical progression 
Each dot represents an MS case.Red dots are cases with high density meningeal 
inflammation, black dots cases with low meningeal inflammation.The extent of demyelination 
in the cortex did not show any statistically significant correlation with age at onset (A), time 
to wheelchair (B), age at wheelchair (C), wheelchair to death (D), age at death (E) and 
disease duration (F). White matter demyelination extent showed a negative correlation with 
time to wheelchair (H), age at wheelchair (C), age at death (M) and disease duration (N) but 
not with age at onset (G) and time from wheelchair to death (L).P and r values of significant 
correlations are highlighted in red. NS = non significant. 
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Figure 6.4  Influence of GM lesion types I/III and type III on disease progression 
Each dot represents an MS case. Red dots are cases with high density meningeal inflammation, black 
dots cases with low meningeal inflammation.The number of GM lesions of Type I/III (X axis of all 
graphs in the column on the left) are associated with faster disease progression as shown by 
signifcant negative correlations with age at wheelchair, p = 0.0201, r = -0.5281(D), age at death, p = 
0.0194, r = -0.556 (F) and a trend to negative correlations with age at onset, p = 0.2721, r = -0.2512 
(A), disease duration p = 0.2871, r = -0.2437(B), time to wheelchair p = 0.3395, r = -0.2319 (C) and 
time from wheelchair to death p = 0.9569, r = -0.0133 (E). The number of GM lesions of Type III (Y 
axis of all graphs in the column on the right) are associated with slower disease progression as shown 
by signifcant positive correlations with disease duration, p = 0.0166, r = 0.5161(H), time to wheelchair, 
p = 0.253, r = 0.5112 (I) and age at death p = 0.049, r = 0.4345 (N). P and r values of significant 
correlations are highlighted in red.  
I/III 
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6.2.5 Role of cortical MRP14+ in disease progression 
The increased presence of MRP14+ cells associated to cortical microvessels could 
represent a sign of active grey matter lesion or a sign of a more aggressive ongoing 
pathology. In order to verify this possibility I assessed the correlation between the average 
density of MRP14+ cells in the first three cortical layers with the main clinical milestones to 
find that there was no significant correlation. Although it must be noted that a trend to a 
negative correlation between MRP14+ cells in the cortex and all clinical measures was 
observed: in particular for age at wheelchair and age at death (Fig 6.5 A, B). This trend is 
indicative that the more macrophages/monocytes are present in the cortex, the faster 
disability milestones are reached. 
 
Figure 6.5 Trend to a negative correlation between MRP14+ cells density in the first 
cortical layers and age at wheelchair and at death 
There was a trend showing that the more MRP14+ cells are found in the cortex the earlier 
these MS cases reach clinical milestones, such as age at wheelchair (A) and age at death 
(B) 
6.2.6 Role of microglia in disease progression  
Although an increased density of MHC-II positive microglia is a common feature of severe 
cortical pathology, the assessment of its relationship with clinical milestones of progression 
revealed no statistically significant association or any particular trend. All the correlations r 
and p values are reported in Table 6.4. 
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Table 6.4 No correlation between cortical microglia activation and clinical milestones 
Clinical measure of progression Correlation with MHC-II density in 
cortical layers I-III 
Age at wheelchair r = -0.2892, p = 0.2297 
Time from wheelchair to death r = -0.06165, p = 0.802 
Age at death r = -0.2781, p = 0.2222 
Disease duration r = -0.0006496, p = 0.9978 
 
6.2.7 Relationship between immune cell subsets in the meninges and 
disease progression   
The density of meningeal inflammation, calculated as the sum of B and T cells in the 
meninges, showed a negative correlation with the age at death (p = 0.0137, r = -0.5289) (Fig 
6.6 A). Even if the level of meningeal inflammation, when correlated with all the other clinical 
milestones previously listed, was showing a similar trend, none reached statistical 
significance: interestingly the closest statistical significance was reached with the time from 
wheelchair to death (p = 0.1099, r = -0.3787) (Fig 6.6 B). I then assessed the correlation 
between all the immune cell subsets quantified in the meninges and all clinical milestones 
(Table 6.5). CD20+B cells, CD3+, CD4+ and CD8+ T cells density in the meningeas all 
showed significant negative correlations with age at death, with the strongest correlation 
being the one with CD8+T density (p = 0.009, r = -0.5549) (Fig 6.6 C-F).  Correlation of 
CD8+CD161+ cells in the meninges never reached statistical significance when tested 
against all clinical milestones: interestingly the strongest trend was the time from wheelchair 
to death (p = 0.0795, r = -0.4122) (Fig 6.6 G). 
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Figure 6.6 Meningeal inflammation correlates with age at death 
The density of B and T cells in the meninges shows a negative correlation with age at death 
(A) but just a trend not statistically significant with time from wheelchair to death (B). The 
densities of CD20+ B cells (C), CD3+ T cells (D), CD8+ (E) and CD4+ T cell also show a 
statistically significant negative correlation with age at death. CD8+CD161+ cells in the 
meninges showed a trend to a negative correlation with the time from wheelchair to death 
(G). 
 
(yrs) 
(yrs) 
(yrs) 
(yrs) (yrs) 
(yrs) 
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Table 6.5 Summary of all the correlations between immune cell subsets density measured in 
the meninges and clinical milestones. Significant correlations are highlighted in red, trends 
are underlined (Spearman test, r and p values). 
Immune 
cell 
subset in 
SAS 
(cells/mm) 
Age at 
onset 
Time to 
wheelchair 
Age at 
wheelchair 
Wheelchair 
to death 
Age at 
death 
Disease 
duration 
CD3+ T r = -0.3322 
p = 0.1524 
r = -0.09279 
p = 0.7056 
r = -0.3326 
p = 0.1641  
r = -0.3786 
p = 0.11  
r = -0.05533 
p = 0.0093 
r = -0.224 
p = 0.3459 
CD20+ B r = -0.1835 
p = 0.4386 
r = -0.0993 
p = 0.6859 
r = -0.2233 
p = 0.3581 
r = -0.3373 
p = 0.1579 
r = -0.4483 
p = 0.0415 
r = -
0.1873 
p = 0.4291 
CD3+ 
plus 
CD20+  
r = -0.2727 
p = 0.2448 
r = -0.1248 
p = 0.6108 
r = -0.291 
p = 0.2268 
r = -0.3787 
p = 0.1099 
r = -0.5289 
p = 0.0137 
r = -
0.2324 
p = 0.3241 
CD4+ Th r = -0.3406 
p = 0.1417 
r = -0.1916 
p = 0.4321 
r = -0.3719 
p = 0.1169 
r = -0.3347 
p = 0.1614 
r = -0.5491 
p = 0.0099 
r = -
0.2768 
p = 0.2374 
CD8+ 
CTT 
r = -0.3807 
p = 0.0978 
r = -0.02373 
p = 0.9232 
r = -0.3499 
p = 0.1420 
r = -0.3452 
p = 0.1477 
r = -0.5549 
p = 0.009 
r = -
0.1527 
p = 0.5204 
CD8+ 
CD161+ 
r = -0.02341 
p = 0.9219 
r = -0.07381 
p = 0.7639 
r = -0.00087 
p = 0.9972 
r = -0.4122 
p = 0.0795 
r = -0.178 
p = 0.44 
r = -
0.04814 
p = 0.8403 
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6.3 Discussion 
6.3.1 High meningeal inflammation characterizes more severe clinical 
courses 
Analysis of the clinical data has shown that this cohort of cases is representative of the 
global MS population, and that progressive phase begins at the same age (40 years) both in 
secondary and primary disease course cases, in agreement with other natural history 
studies (Scalfari et al., 2010, Kremenchutzky et al., 2006). This evidence, taken together 
with the observation that also in PPMS an increased rate of clinical progression is 
associated with a higher density of meningeal inflammation (Choi et al., 2012), is suggestive 
of the same or similar mechanisms underlying progression in both these different MS clinical 
sub-types therefore reassessing the contribution of meningeal inflammation to the clinical 
progression versus the mechanisms of degeneration in PPMS. I showed here that the 
clinical course of cases with high meningeal inflammation exhibits the tendency to reach all 
main clinical milestones faster than cases with low meningeal inflammation and that they are 
characterized by an earlier death in keeping with previous reports linking meningeal 
inflammation with a more severe MS course (Howell et al., 2011, Magliozzi et al., 2007). In 
the previous chapter I showed the correlation between the extent of cortical GM 
demyelination and meningeal lymphocytic density. That observation is now interlinked with a 
shorter, more severe disease course. These observations indicate that in MS cases with 
high meningeal inflammation the extent of grey matter demyelination is greater and the 
disease progression faster. This supports the hypothesis that an increased concentration of 
myelo- and neuro-toxic substances in the subarachnoid space may, directly or indirectly via 
the activation of microglia, play a major role in the induction of subpial pathology (Magliozzi 
et al., 2010, Peterson et al., 2001, Bo et al., 2003b, Serafini et al., 2004, Dal Bianco et al., 
2008, Frischer et al., 2009, Howell et al., 2011). When this (auto)immune response becomes 
compartmentalized within the CNS, the chronic presence of high density meningeal 
inflammation might lead to a faster accrual of cortical damage, neurological symptoms and 
death at younger age. 
6.3.2 The role of white and grey matter pathology in MS progression 
When I correlated all the measures of progression with the lesion load in white matter and 
cortical grey matter we found, on the contrary to what I would have expected, that all clinical 
milestones, with the only exclusion of age at onset and time from wheelchair to death, were 
linked with WM pathology rather than with GM pathology. This observation is suggestive that 
an increasing burden of demyelination, and ultimately of axonal loss, in the white matter 
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tracts of the brain is, in this cohort of cases, the major pathological substrate of progressive 
clinical disability. However my previous findings, shown in Chapter 3, that extent of WML 
was correlated with the extent of GML is suggestive that they are both interdependent: the 
axonal transaction in WML is linked with the observed neuronal loss in the cortex by the 
retrograde degeneration and neuronal death in the cortex is reflected by loss of tracts in WM 
and spinal cord. Taken together with the fact the demyelination is greater in the cortex, I 
might speculate that damage to cortical neurons and white matter axons occurs and mounts 
up in different ways during different phases of the disease. In this respect diffuse changes 
such as tissue damage to normal appearing white and grey matter and an increasing 
accumulation of cortical GM pathology, seemingly unrelated to axonal loss within focal WM 
lesions, are likely to play an important role in the accumulation of motor, sensory and 
cognitive disability that characterize MS progressive phase (Reynolds et al., 2011). From my 
observations it remains very likely that damage to the grey matter is associated with damage 
in the white matter and seemingly that the underlying pathological mechanisms might 
change over the disease course.  
In addition to this, cortical involvement in the early phase of MS observed on imaging studies 
raises the intriguing possibility that the cortical grey matter may represent the primary and 
initial target of the disease progress (Geurts et al., 2005b, Calabrese et al., 2010d). A debate 
whether this process would develop first with neuronal and axonal degeneration in the cortex 
by direct or indirect damage to oligodendrocytes and microglial activation leading to 
subsequent demyelination, the so-called “inside-out” model, or whether it is the loss of the 
insulating myelin sheath that indirectly contributes to axonal energy deficit and ultimately to 
axonal degeneration, the so-called “outside-in” model (Geurts et al., 2009) is still ongoing. 
The obvious limitation of this study on post-mortem progressive MS brain does not allow our 
data to draw any conclusion in regard to when cortical pathology occurs and precisely how it 
occurs during the different phases of the disease course. However, studies on EAE model, 
showing that peripheral subclinical immunization with MOG, followed by the injection of IFN-
γ and TNF in the subarachnoid space, can generate demyelinated lesions in the neocortex 
and spinal cord exhibiting a typical subpial pattern with remarkable similarities to cortical 
lesions in the MS brain (Kerschensteiner et al., 2004, Merkler et al., 2006), are evidences in 
support of the concept that GM pathology occurs in part independently from WM lesions and 
may precede WM pathology. 
I observed that the more Type III-subpial lesions are found in the cortex, the slower clinical 
milestones are reached. On the contrary, the more Type I lesions are present in grey matter, 
the more severe is the disease course. This observation shows the importance of the pattern 
of demyelination and the number of lesions in grey matter as indicative measures of the 
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disease course and that they have the potential to become a marker of disease activity, 
complementary the currently used magnetic resonance markers which are global brain 
atrophy and T2 hypertense lesions (Horakova et al., 2012). Even if the extent of GM 
demyelination did not correlate with disease progression, as we previously showed, it seems 
that the number of Type I lesions, that ultimately cover all layers seemingly expanding to 
subcortical white matter, can make the disease progression worse, in particular the later 
stages of the disease. This is also suggestive that subpial lesions might develop early in the 
disease expanding to Type I lesions only later on, and in presence of high meningeal 
inflammation, as we previously showed. This interpretation is supported by evidence 
produced by MRI studies that cortical lesions increase in number and size with disease 
progression (Calabrese et al., 2007b, Calabrese et al., 2009, Calabrese et al., 2010d). 
6.3.3 The role of activated microglia and of cortical MRP14+ cells on 
disease progression 
Although the cases with high menigeal inflammation were associated with higher microglial 
activation in the cortex and active GM lesions exhibited an increased density of MRP14+ 
macrophages/monocytes, these two pathology measures did not show any significant impact 
on disease progression. Since the states of microglia activation might evolve quickly 
throughout the MS pathologic process (Hanisch and Kettenmann, 2007) it likely that at the 
end of progression, when we sampled the cortex, its status was just reflecting the nature of 
past inflammatory stimuli having acquired the phenotype of “postactivated” memory 
microglia therefore loosing the ability to regress to a completely naive status. In fact the 
density of MHC-II microglia was very homogeneous within each MS case without areas of 
activation next to areas with a silent phenotype. The lack of any correlation between 
measures of progression and density of MRP14+ in the cortex might suggest an earlier 
involvement of these cells in tissue damage even if they can be found increased in the most 
active lesions at the end of progression.  
6.3.4 Detrimental role of meningeal inflammation on the late phase of 
disease progression 
I also found quite consistent negative correlations between age at death and density of 
CD20+ B and CD3+, CD4+T cells, with the strongest correlation being the one with CD8+T 
cells. In this respect autoreactive HLA antigen class I-restricted CD8+T cells responses, 
consisting in IFN-γ and TNF secretion, are widely prevalent in MS and it has been shown 
that a large proportion of these are specific for neuroautoantigens and not a mere bystander 
phenomenon (Crawford et al., 2004). In line with this observation another interesting study 
179 
 
has shown enhanced TNF production by enriched populations of bulk CD8+ T cells from 
patients with SPMS (Buckle et al., 2003). In addition the proportion of CD4+ and CD8+ T 
cells from peripheral blood expressing INF-γ increases significantly in patients with 
progressive MS compared to control group (Becher et al., 1999). Taken together with our 
finding of CD8+T as the prevalent immune cell subset in the meninges and their positive 
correlation with cortical demyelination and microglial activation, these evidences are 
supporting a detrimental role for meningeal CD8+ T cells in the last phase of disease 
progression. I also found a negative correlation between the density of B cells in the 
meninges and age at death. This finding is suggestive of a pathological role of B cells in 
accelerating the progressive phase of MS directly contributing to tissue damage or indirectly 
providing inflammatory signals to sustain T cells response within the CNS.  
6.3.5 Conclusions 
Both the primary and secondary progressive MS brain are characterized by meningeal 
inflammation whose density is a pathological hallmark indicative of the severity of clinical 
progression. Although it is the extent of WM demyelination, and not of GM, that showed a 
negative correlation with disability milestones, the prevalence of GM Type I lesions within a 
case is a sign of a faster progression, in particular during the last phase of the disease. 
These observations are supportive that the pathological mechanism underlying clinically 
progressive phase in MS might consist in the accrual of cortical pathology driven by the 
compartmentalization of the immune response within the meninges. The same age at onset 
of primary and secondary progressive MS forms could imply that the exhaustion of the 
regenerative response of the CNS might underlie the slow but steady neurodegeneration in 
the cortex in both MS forms. Under the immunological point of view, the 
compartmentalization of the immune response could represent the interruption of peripheral 
immune regulatory mechanisms within the target organ leading to an increased density of 
pro-inflammatory immune cells in the meninges which we showed were correlated with age 
at death. The suppression of inflammation within the meninges might become a promising 
therapeutical target for progressive MS. 
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Chapter 7 
 
General summary and discussion 
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7.1 The relevance of cortical pathology in MS 
The work presented in this thesis described that GM demyelination correlates with a pro-
inflammatory meningeal inflammation and cortical microglial activation and that WM 
demyelination is four times less extensive. Furthermore, I described that the 
compartmentalized immune response within the meninges is linked with a younger age at 
death, suggesting that it is an important determinant of disability during progression. These 
observations, in agreement with other pathology reports on MS brain (Choi et al., 2012, 
Magliozzi et al., 2007), suggest that the detection and the measurement of global tissue 
damage, using MRI, could become a sensitive predictor of long-term clinical outcomes in MS 
patients and that the analysis of the inflammation in the CSF could become a marker to 
closely monitor disease activity. In addition, my data indicate the possibility that targeting 
meningeal inflammation could be an effective therapeutical strategy for progressive MS 
patients since this form of the disease is not responsive to systemic immunomodulatory 
treatments. 
Although the presence of cortical lesions had been observed in early studies on MS 
pathology (Sander, 1898, Dinkler, 1904), its relevance remained underestimated and, due to 
technical limitations, its detection and quantification have been delayed to more recent 
pathological studies (Brownell and Hughes, 1962, Guseo and Jellinger, 1975). For long time 
in fact the concept that MS is a white matter disease has directed the research efforts to 
focus mainly on the events leading to demyelination in WM parenchyma. However, more 
recent studies have reported the detailed quantification and characterization of GM lesions 
and have reassessed the relevance of cortical pathology in MS (Kutzelnigg et al., 2005, 
Peterson et al., 2001). At the same time, new MRI protocols have helped in detecting cortical 
damage also in the earliest stages of the disease. In particular cortical atrophy visualized by 
MRI has been associated with the cognitive impairments affecting MS patients (Chard and 
Miller, 2009, Amato et al., 2004) and a strong correlation with the progression of disability 
has emerged in longitudinal MRI studies (Fisniku et al., 2008, Fisher et al., 2008).  In 
addition, the detection of organized and diffuse meningeal inflammation has been 
associated with more severe cortical pathology (Magliozzi et al., 2007, Howell et al., 2011) 
supporting the concept of the detrimental role of the compartmentalization of the 
(auto)immune response within the progressive MS brain (Ransohoff et al., 2003, Galea et 
al., 2007a).  
Taken together these observations have suggested that the immunopathological 
mechanisms underlying cortical pathology can be in part independent from white matter 
pathology. The presence of cortical and meningeal inflammation also in MS biopsies 
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(Lucchinetti et al., 2011) has provided a piece of evidence suggesting that different 
immunopathological mechanisms underlie white matter and grey matter tissue damage 
depending on the disease stage. My observation of an increased infiltration of pro-
inflammatory lymphocytes subsets in the meninges in presence of extensive cortical 
demyelination at the end of the disease has suggested that the intensity of the immune 
response in the meninges is involved in the accrual of demyelination of grey matter during 
progression.  
7.1.1 The extent and the type of grey matter demyelination 
The observations reported in this thesis have confirmed that gray matter demyelination is a 
common pathological finding and that its extension is such that it affects a much higher 
percentage of the cortex than it does in the white matter. My findings also showed that 
cortical damage is characterized by the prevalence of Type III (subpial) lesions which appear 
to emanate from the pial surface into the cortex and can persist over multiple gyri in 
agreement with previous pathology reports (Kutzelnigg et al., 2005). Interestingly Type I/III 
lesions, which affect both grey and white matter, are also a frequent finding, more often in 
the cases with a generally more severe pathology. The limitation of my analysis on post-
mortem samples does not allow us to clarify whether these lesions start in the cortex and 
diffuse to the WM or vice versa.  
7.1.2 The paucity of inflammatory infiltrates in grey matter lesions 
I reported few active cortical lesions exhibiting the presence of perivascular infiltrates which 
are anyway very poor in the content of immune cells and showing far less than what is 
usually observed in the white matter parenchyma. However, there are reports of biopsies, 
sampled during the diagnostic process on patients who later developed MS, showing that 
cortical demyelination is inflammatory in early MS (Lucchinetti et al., 2011). Little is known 
about cortical demyelination in early MS because both conventional MRI and DIR protocols, 
the latter not routinely performed, can detect some but not all cortical lesions. Other neuro-
imaging studies in early MS have revealed, non-lesional abnormalities (De Stefano et al., 
2003, Dalton et al., 2004, Vrenken et al., 2006) suggesting that the cortex might be damaged 
near the time of onset: a new emerging concept although supported by very few case 
reports of cortical-onset multiple sclerosis (Calabrese and Gallo, 2009, Popescu et al., 
2011).  
I cannot draw any conclusion about earlier pathological events from our study and I can only 
speculate that grey matter lesions are present from the onset and are characterized by 
parenchymal and meningeal inflammation. Once the progressive phase of the disease 
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starts, the differential patterns of adhesion molecules expressed by luminal endothelial cells 
of blood vessels in white and grey matter (Battistini et al., 2003, Piccio et al., 2002) might 
underlie the difference in regard to inflammatory infiltrates between GM and WM. My 
observations indicate that during progression it is the presence and the intensity of 
inflammation within the subarachnoid space that could drive cortical pathology.  
7.1.3 The role of CD4+ T cells in GM infiltrates 
I showed that among the few lymphocytic nuclei found in the perivascular space of active 
grey matter lesions, there are CD4+ T cells. In order to cross the BBB they must have been 
activated in the periphery before infiltrating the CNS or in the meninges where macrophages 
are reported to be the predominant MHC class-II expressing cell type (Kivisakk et al., 2009). 
In this sense there is evidence that myeloid dendritic cells within the CNS can activate naive 
myelin-specific T cells and facilitate their differentiation to Th17 cells (Bailey et al., 2007) or 
into both Th1 and Th17 cells (Deshpande et al., 2007). Therefore I could argue that the 
CD4+ T cells, that I detected in grey matter lesions associated with demyelination and 
increased microglial activation, might have a pro inflammatory phenotype characterized by 
the secretion of Th1 or Th17 cytokines.  
Pathology studies on MS brain have reported that astrocytes can express MHC class-II, 
although they do it at negligible levels (Zeinstra et al., 2000, De Keyser et al., 1999). 
Therefore the astrocytes forming the glia limitans are unlikely to be the APCs mediating 
initial T cells reactivation. By contrast microglia, following the exposure to inflammatory 
stimuli, for example the exposure to INF-γ, can express high levels of MHC class-II and co-
stimulatory molecules (Aloisi, 2001), produce both IL-12 (Becher et al., 2000) and IL-23 
(McGeachy et al., 2009) and trigger cytokine production by T cells (Ford et al., 1996, Juedes 
and Ruddle, 2001). On the basis of these observations I suggest that in the chronically 
inflamed MS brain, in particular during the progressive phase of the disease, a vicious circle 
is established between microglial chronic activation and the infiltration of pro inflammatory 
cytokine-producing CD4+ T cells. However, GM perivascular inflammation is not a frequent 
finding in the MS brain at the end of the disease but might instead characterize cortical 
pathology in its earlier stages (Lucchinetti et al., 2011). Based on the detection of ongoing 
inflammation in the meninges at the end of the disease we might also hypothesize that the 
initial trigger for the activation of the microglia and in turn of the BBB, allowing the first 
infiltration of T cells in GM parenchyma, could come from the reactivation of immune cells in 
the CSF.  
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7.1.4 The role of CD8+ T cells in GM infiltrates 
Similar to CD4+ T cells, naive CD8+ T cells are inefficient at crossing the BBB in the 
absence of inflammation implying that they must also be activated in the periphery or in the 
meninges before infiltrating the CNS. Under non inflammatory conditions in the CNS, 
endothelial cells, macrophages and some microglial cells express MHC class-I molecules. 
As oligodendrocytes are the only cells that synthesize myelin proteins but lack expression of 
MHC molecules, it is likely that myelin antigens are cross-presented by macrophages or 
microglial cells. As cross-presentation becomes more likely under inflammatory conditions I 
could argue that it could become more and more frequent during the observed 
compartmentalization of the immune response within the CNS. Potentially also endothelial 
cells could present MHC class-I-associated peptides acquired from degraded myelin 
proteins as peptides injected directly to the CNS parenchyma seems to bind MHC class-I 
expressed by endothelial cells and trigger antigen-specific CD8+ T cells entry into the CNS 
(Galea et al., 2007b). In the presence of chronic inflammation, as observed in the 
progressive MS brain, multiple cell types could then function as APCs. Which of these 
different cell types reactivate CD8+ T cells allowing them to initiate CNS inflammation 
remains an important question to be answered.  
Interestingly, in a TCR transgenic mice in which oligodendrocytes expressed neo-antigens, 
neo-antigen-specific CD8+ T cells has been shown to be efficient at lysing the 
oligodendrocytes (Na et al., 2008, Saxena et al., 2008). Although I did not detect CD8+T 
cells in close contact with oligodendrocytes in the progressive MS brain, based on these 
evidences, I hypothesize that cell-mediated damage to oligodendrocytes in the cortex might 
be one of the mechanisms underlying the formation of cortical lesions. 
Whereas CD4+T cells can only recognize APCs expressing MHC class-II molecules and 
exert their effects mainly through the secretion of soluble mediators, CD8+T cells can 
recognize a wider range of targets that express MHC class-I molecules and can cause injury 
in the CNS both by both cell contact-mediated lysis and production of soluble inflammatory 
cytokines. The pathogenic pathways that lead to disease in individual patients with MS could 
depend primarily on either T cell subset, which could result in different mechanisms of tissue 
damage. 
7.1.5 The role of MRP14+ cells in cortical pathology 
I showed that in active cortical lesions there is an increased density of MRP14+ 
macrophages/monocytes and that they are always found associated with the basement 
membrane of the cortical microvasculature. MRP14, in association with its dimerization 
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partner MRP8, makes up to 40% of the all cytosolic proteins in neutrophils (Hessian et al., 
1993) but is much less abundant in monocytes and is expressed by recently extravasated 
macrophages found at the sites of acute MS white matter lesions (Bruck et al., 1995).  
MRP8/14 plays an important role in leukocytes interactions with the endothelium of blood 
vessels (Croce et al., 2009). In fact MRP8/14 can be released by immune cells and bind to 
the endothelium at sites where monocytes, neutrophils and lymphocytes pass through (Hogg 
et al., 1989, Robinson et al., 2002), inducing an inflammatory activation and impairing the 
integrity of tight junctions (Viemann et al., 2007, Viemann et al., 2005).  
I also reported the presence of close apposition between CD8+ T cells and MRP14+ 
macrophages in the meninges. Since another function of MRP8/14 is to regulate myeloid cell 
function by binding to Toll-like receptor-4 (TLR-4) (Vogl et al., 2007), and serum levels of 
MRP14 have been found increased in MS and RA exacerbations (Bogumil et al., 1998, 
Frosch et al., 2003), my findings suggest that contact between CD8+ T cells in the meninges 
and meningeal MRP14+ macrophages could  be essential for the stimulation of autoreactive 
CD8+ T cells within the target organ. Notably it has been shown that IL-17 was up-regulated 
upon stimulation with MRP14 of CD8+ T cells isolated from individuals with lupus 
erythematosus, supporting a major role of MRP14 in the development of autoimmunity via 
TLR-4 signalling (Loser et al., 2010). 
My findings indicate that MRP14 contribution to cortical pathology could consist of the 
impairment of BBB functions and in the production of a chronic inflammatory stimulus able to 
activate immune cells expressing TLR4.  
7.2 Lymphocytic infiltration in the meninges is characterized 
by pro-inflammatory immune cell subsets 
My immunohistochemical analysis of the inflammation within the meningeal compartment of 
the progressive MS brain has confirmed that presence of lymphocytes is a common 
pathological finding in keeping with previous observations (Guseo and Jellinger, 1975, 
Howell et al., 2011). The characterization of meningeal inflammatory infiltrates  showed that 
CD8+ T cells are the most common immune cell subset populating the meninges which was 
also reported  in previous pathology studies but only in white matter pathology (Hauser et al., 
1986). I then focused our analysis on a CD8+ T cell subset co-expressing CD161. The 
potential pathological role of CD8+CD161+ cells in MS has been proposed on the basis of 
their pro-inflammatory profile, characterized by the secretion of IL-17 and IFN-γ, and their 
increase in the peripheral blood in MS patients compared to controls (Annibali et al., 2010). 
Moreover, a strong piece of evidence supporting their pathogenic role in MS is that this T cell 
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subset has been recently shown to be virtually depleted in patients after Autologous 
Haematopoietic Stem Cell Transplantation (AHSCT) (Abrahamsson, under review). I also 
report, for the first time to our knowledge, the presence in the progressive MS brain of MAIT 
cells (Carassiti, to be submitted) which are also characterized by the expression of CD161 
and have been shown to be able to produce IL-17 (Dusseaux et al., 2011). 
7.2.1 Pro-inflammatory immune cell subsets forming meningeal 
inflammation  
I showed that CD8 T cells co-expressing CD161 form about 11% of total lymphocytes 
infiltrating the meninges and represent a median of 31% of all CD8+ T cells and also of all 
cells expressing CD161. I can speculate about their functional role in the 
immmunopathogenesis of meningeal inflammation on the basis of their phenotypical 
characterization in MS patients. Notably, a CD8 T cell population, co-expressing high levels 
of CD161, CCR6 and secreting IL-17 and IFN-γ, has been shown to be increased in the 
peripheral blood of MS patients (Annibali et al., 2010). Classically IFN-γ has been 
considered a signature cytokine of a Th1 response (Cope et al., 2011) and IL-17 of a Th17 
response (Korn et al., 2009). While the former T cell subset has been shown to be involved 
in responses to intracellular pathogens (Chen and Liu, 2009), the latter has been shown to 
participate in host defence against fungi and bacteria (Romani, 2011). Furthermore, IL-17 
secreting CD8+ cells (Tc17) have been recently described as a diverse immune cell subset 
generated when CD8+ T cells are polarized towards IL-17 production. Their phenotype is 
characterized by the lack of lytic activity but shows a functional plasticity with the 
characteristic to revert to INF-γ secretion (Yen et al., 2009). Although our data represent a 
snapshot of the terminal stage of the disease I might speculate that these functional changes 
of the lymphocytes subsets might take place in the meninges of MS brain. In fact the partial 
seclusion of this compartment from the periphery might contribute to increase locally the 
concentration of the inflammatory soluble signals that can determine the differentiation of 
immune cells into different pro-inflammatory subsets.  
Furthermore, our observations could suggest that one of these complex immunological 
interactions, which I can only propose on the basis of evidence in animal models, is the 
relationship between a Th17 response and ectopic lymphoid-like B cell follicles in the 
meninges. In fact it has been shown that transfer of Th17 cells into WT animals induces a 
pronounced antibody response with preferential isotype class switching to IgG-1, -2a, -2b, -3 
while the blockade of IL-17 signalling results in a significant reduction in both number and 
size of germinal centres (Mitsdoerffer et al., 2010). More recently the translation of similar 
experimental conditions to a transfer EAE model has shown important differences between 
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Th1 and Th17 cell recipients: only in the latter case did the inflammation provoked in the 
meninges show the characteristics of ectopic lymphoid B cell follicles (Peters et al., 2011). 
This is suggestive that Th17 may provide a triggering signal in regulating tissue inflammation 
where ectopic lymphoid follicles may play a role in the propagation of the disease (epitope 
spreading).  
An EAE experiment, using CCR6 knockout mice, has provided evidence supporting that the 
first wave of migratory T cells to the uninflamed CNS consists of Th17 cells and that their 
entry is mediated by the chemokine receptor CCR6 (Reboldi et al., 2009). Furthermore, the 
same study has also indicated that the entry of CCR6+ T cells into the CNS probably occurs 
through the choroid plexus, since the epithelial cells forming the blood-CSF barrier on the 
choroid plexus constitutively express CCL20, which is CCR6 ligand (Axtell and Steinman, 
2009). I could then hypothesize a similar immunopathological mechanism in the MS brain 
and propose that a first wave of migratory and pro-inflammatory T cells is required for the 
recruitment of a second wave of T cells that enter the CNS parenchyma in a CCR6-
independent way through activated blood vessels in WM.   
7.2.1.1 The expression of CD161 identifies lymphocytes subsets with pro-
inflammatory functions  
I showed that lymphocytes expressing only CD161 represented about 24% of total 
lymphocytes infiltrating the meninges. According to the flow cytometric analysis of the 
peripheral blood of 21 healthy individuals, which defined CD4+ subset by the expression of 
CD161, 23% of CD4+ cells also express CD161+ and are almost all memory cells (97%). In 
the same study the functional activity of this subset after stimulation in vitro has been 
analyzed demonstrating their ability to secrete considerable amounts of TNF-α, IFN-γ, IL-2 
and also of IL-4, IL-5 and IL-10 but to a far lesser extent (Takahashi et al., 2006).  By 
showing a positive correlation between the density of CD161-expressing lymphocytes in the 
meninges and the severity of the underlying cortical pathology I support that this immune cell 
subset is pro inflammatory and that a proportion of the single CD161+ cells I found in the 
CNS could include CD4+ cells. The presence and the quantification of CD4+CD161+ 
lymphocytes in the MS brain would require further characterization.   
Another recent study identified, both in peripheral blood and CSF of RRMS patients, a novel 
NK1/NK17 subset characterized by the expression of CD56+, CCR4+, CD161+, and by the 
secretion of IL-17 and IFN-γ (Pandya et al., 2012). Therefore I could discuss that the single 
CD161+ cells we found in CNS tissue may also comprise NK1/NK17 cells. Of course this 
would require further sampling and immunohistochemical analysis but the evidence present 
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in the literature is suggestive that the CD161+ expressing lymphocytes we identified might 
have a prevailing pro-inflammatory phenotype.  
A further observation by Takahashi and colleagues, comes from the analysis of human 
peripheral blood CD8+ T cells based on CD161 level of expression. In fact they have 
revealed the presence of two different CD8+T subsets: CD161int and CD161high (Takahashi 
et al., 2006) reporting that, after stimulation, CD8+CD161int can secrete INF-γ, TNF-α and IL-
2 whereas CD8+CD161high cells cannot secrete any of these cytokines. Two recent reports 
have independently raised new findings on this latter subset: the first showing that 
CD8+CD161high represent self-renewing memory cells which can survive chemotherapy 
(Turtle et al., 2009), the second showing that they express high levels of markers associated 
with Th17 functions, such as RORγT, and secrete high amounts of IL-17 after in vitro 
stimulation (Billerbeck et al., 2010). Since in this histological analysis with 
immunofluorescence, I could not distinguish between CD8+CD161int and CD8+CD161high in 
tissue, I looked for a further surface marker to identify this subset in the MS brain. 
7.2.1.2 The function of MAIT cells in the MS brain 
I indentified MAIT cells in MS brain tissue according to the co-expression of CD161 and 
TCRVα7.2 as defined by Dusseaux and colleagues (Dusseaux et al., 2011). I reported their 
presence both in the meninges and in white matter perivascular inflammatory extravasates 
where they represented about 8% and 17% of total CD161+ cells respectively. In this sense 
a previous study on MS tissue has reported the accumulation of TCRVα7.2 invariant T cells 
in MS lesions on the basis of RT-PCR evidence (Illes et al., 2004) but this is the first time to 
my knowledge that they have been identified in MS white matter lesions and in the meninges 
with double immunofluorescence. One more piece of evidence supporting a potential 
pathological role of MAIT cells comes from the flow cytometric analysis of MS patients 
before undergoing AHSCT which shows that >90% of the CD8+CD161high population 
expressed TCRVα7.2 (Abrahamsson, under review). Notably, this subset, also characterized 
by the expression of CCR6, was radically depleted after AHSCT, and remained nearly 
undetectable for the whole follow-up period of 2 years (Abrahamsson, under review).  
The group of Yamamura has analyzed the frequency of MAIT cells in the peripheral blood of 
MS patients showing that their frequency was significantly reduced during remission and 
even more profoundly in relapse when compared to healthy controls.  In addition, the 
frequency of MAIT cells in the peripheral blood reflected the disease activity as it was 
significantly reduced in patients with active disease when compared with stable patients. 
Although the mechanism for this reduction was not clarified, they proposed the trafficking of 
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MAIT cells from blood to MS lesions as a possible explanation, given that MAIT cells also 
express high levels of CCR6 and CCR5. 
However, based on the facts that positive correlations between the frequency of MAIT cells 
and CD4 iNKT and CD56brightNK are lost in MS patients but not in controls and that the 
production of IL-17 and IFN-γ by MAIT cells are not significantly different in MS patients and 
controls, the group of Yamamura has proposed that the activation of MAIT cells is controlled 
differently from that of conventional T cells.  Interestingly, by showing that MAIT cells are 
able to suppress IFN-γ production from T cells in vitro, but only in a cell-contact dependent 
manner, Yamamura proposed that their migration into MS lesions during relapses might 
indicate an immune-regulatory role of MAIT cells (Miyazaki et al., 2011). Nevertheless their 
findings in vitro do not rule out the possibility of a pro-inflammatory role of MAIT cells in MS 
brain, considering that the signals required for MAIT cells activation are not completely 
known. Further investigations on the control and activation signals of MAIT cells will clarify 
their physiological and pathological functions.  
The identification of MAIT cells in the pro-inflammatory environment of the MS meninges and 
WM lesions infiltrates in presence of extensive tissue damage suggests that their profile 
within the CNS is pro inflammatory.   
7.3 Pro-inflammatory cytokines: the link between meningeal 
inflammation and cortical pathology 
By showing that the density of lymphocyte subsets, such as CD8+CD161+ and CD8-
CD161+, in the meninges positively correlated with the extent of demyelination and 
microglial activation in the cortex I suggest that they have a pro-inflammatory functions 
which play a role in driving the accumulation of cortical pathology during the progressive 
phase of MS. This indicates a role for soluble pro-inflammatory signals that can directly and 
indirectly, through the activation of microglia, be cytotoxic to neurons. Strong evidence for 
this has been provided by Murphy and colleagues who set up co-culture experiments, using 
mixed glia and MOG-specific T cells, to reveal that T cells that secreted IFN-γ and IL-17 
were potent activators of pro-inflammatory cytokines, such as IL-1β, TNF-α and IL-6, but T 
cells that secrete only IFN-γ were less effective. In contrast both Th1 and Th1/Th17 cells 
enhanced MHC class-II and co-stimulatory molecule expression, such as CD40, CD80 and 
CD54, on microglia (Murphy et al., 2010). These findings support that T cell subsets 
infiltrating the CNS and characterized by the production of IL-17 or IL-17 and IFN-γ, are able 
to trigger inflammation, in part, through microglia activation. In addition, both these soluble 
pro inflammatory signals have indeed been detected in the CSF of MS patients (Mellergard 
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et al., 2010, Wen et al., 2012). Notably, it has been shown in MS patients that after treatment 
with Natalizumab there is a marked decline in CSF levels of pro-inflammatory cytokines, 
such as IL-1β, IL-6 and IL-8, and of chemokines associated with both Th1 (CXCL9, CXCL10, 
CXCL11) and Th2 (CCL22) responses. Therefore, I suggest that my finding of a correlation 
between the density of immune cells in the meninges and the severity of cortical pathology is 
associated with an increased presence of pro-inflammatory lymphocyte subsets, which are 
contributing to the exacerbation of cortical pathology through the secretion of potent 
inflammatory soluble signals. 
7.3.1 The activation of microglia and cortical pathology 
My quantification of leukocytes subsets, indicating a chronic pro-inflammatory response in 
the meninges, showed a positive correlation with the activation of microglia in the cortex, 
both in the superficial and in the deeper layers. I also observed a positive correlation 
between the activation of microglia and the extent of cortical demyelination. Taken together 
with the observed disruption of CSF-brain barrier, consisting in the impairment of glia 
limitans functions, and a gradient of neuronal loss away from the pial surface in the cortex, 
also reported by our group (Magliozzi et al., 2010), I hypothesize that the reason underlying 
microglial activation in the cortex is the diffusion from the meninges of IFN-γ, TNF-α and IL-
17 produced by activated immune cells.  
In addition to this, microglia activation could also be triggered by: the degenerating cortical 
myelin and neurons that microglia is trying to remove, the lack of contact between microglia 
and healthy neurons secreting neurotrophins and, superimposed to these mechanisms, the 
ageing driving disease progression. In regard to the ability of microglia to remove myelin, it 
has been shown that if myelin debris are not cleared off, they could in turn inhibit the 
remyelination by oligodendrocytes (Kotter et al., 2006). In addition, microglia could efficiently 
remove such debris, since they are equipped with a battery of receptors to perform this 
function, but I could also argue that at the basis of lesion accumulation during progressive 
MS there could be the saturation of these mechanisms of removal. Many studies in vitro and 
in vivo also suggest that microglial neurotoxicity might not only result from the presence of 
noxious stimuli but that it may also arise in conditions of altered balance of key molecules 
regulating microglial responses such as neurotransmitters and neurotrophic factors. 
Microglia cells in fact carry the appropriate receptors for gamma-aminobutyric acid 
receptors, A3 adenosine receptors, cannabinoid receptors, adrenergic receptors and 
dopamine receptors (Pocock and Kettenmann, 2007) so that a variation in their 
concentration as well their absence can heavily affect microglial phenotype. 
191 
 
Another molecule involved in the communication between microglia and neurons is 
fractalkine (CX3CL1). This molecule is produced and released by neurons (Hundhausen et 
al., 2003, Cardona et al., 2006) and its interaction with the fractalkine receptor (CX3CR1) on 
microglia suppresses microglia neurotoxicity both in vitro (Mizuno et al., 2003) and in vivo 
(Cardona et al., 2006). Finally, electrically active neurons secrete neurotrophins which 
efficiently prevent the transformation of microglia cells to MHC class-II antigen presenting 
cells (Neumann et al., 1998) and reduce their production of iNOS, NO and other pro-
inflammatory molecules in response to activation (Tzeng and Huang, 2003).  
Based on these observations, I could propose that in the MS cortex, the slow but 
progressive neuronal loss could remove all the homeostatic signals able to maintain 
microglia in a resting phenotype. Probably this loss is still below critical threshold in patients 
with RRMS but with the age, superimposing to the compartmentalization of the immune 
response within the CNS, microglia activation becomes chronic, maybe marking the change 
of the disease to the secondary progressive course. Furthermore, microglial cells that have 
been “instructed” ex vivo can carry their functional orientation into tissue in vivo supporting 
that they are able to maintain a memory of previous stimuli over time and different contest 
(Butovsky et al., 2006a, Butovsky et al., 2006b). In this regard states of microglial activation 
may change throughout the different inflammatory processes underlying MS course.  
Gene expression analysis in GM parenchyma was aimed at comparing cortical lesions from 
cases with high meningeal inflammation and exhibiting higher density of activated microglia, 
with cortical lesions from cases with low meningeal inflammation, characterized by much 
lower microglia activation and with controls. Although no statistical significance was reached 
comparing these groups, there was a clear trend showing an increase expression of 
chemoattractant chemokines, such as CCL4, CCL5, CXCL2 and CXCL11, in the MS cortex 
rather than in controls. The levels of expression of fractalkine were relatively higher in cases 
with low meningeal inflammation, when compared with high density meningeal inflammation, 
in agreement with its role in suppressing microglia toxicity (Mizuno et al., 2003, Cardona et 
al., 2006).  
Here I have reported that in cortical lesions of chronic progressive MS brain the activated 
state of microglia is associated with extensive tissue damage, suggestive of a detrimental 
role of microglial activation in cortical pathology. In addition, the increased microglial 
activation in all MS cases compared to controls suggests that during progressive MS cortical 
microglia becomes permanently activated in presence of chronic pro inflammatory stimuli 
leaking from the meninges and loses its ability to revert to a neuroprotective state. In 
particular I suggest, on the basis of experiments in vitro, that microglia contributes to 
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oligodendrocytes and neuronal death by secretion of toxic soluble signals like TNF-α and 
NO.   
It is still unknown whether microglial activation has only a detrimental role in cortical 
pathology, in particular during early stage cortical lesion formation where low amount of pro-
inflammatory signals might instead shape microglia phenotype towards a neuroprotective 
response (Magnus et al., 2001, Liu et al., 2006). This possibility would correspond more with 
the relapsing-remitting course clinical symptoms and with the reported ability of CNS tissue 
to self-repair immune-mediated tissue damage in MS.  
7.3.2 Chemokines and chemokine receptors 
I reported the presence of CXCR3 and CXCR5 positive inflammatory cells in the MS brain in 
agreement with previous studies (Sorensen et al., 2002b, Sorensen et al., 2002a). CXCR3 is 
the common receptor for CXCL9, CXCL10 and CXCL11, which I found expressed above 
background in GM lesions, and is present at high levels on activated T cells, memory T cells 
and NK cells (Yamamoto et al., 2000). Like its ligands, expression of CXCR3 in these 
immune cell subsets is controlled by IFN (Nakajima et al., 2002) and its main function is to 
promote chemotaxis (Farber, 1997). Although my findings were only qualitative, and further 
work could be done to assess the contribution of CXCR3+ lymphocytes to meningeal and 
WM inflammation, it seems likely that this chemokine axis is contributing to the MS 
pathology by attracting immune cells to the inflamed tissue. In particular, I speculate that this 
mechanism is involved in the progressive accumulation of meningeal inflammation and 
cortical pathology during disease progression since CXCL9, CXCL10 and CXCL11 have 
also been detected in the CSF of patients (Mellergard et al., 2010).  
The detection of CXCR5+ cells could indicate the presence of B cells (Sorensen et al., 
2002a) or, as we reported co-expressed with CD4, of follicular helper t cells (Fazilleau et al., 
2009). This observation would require further investigations to quantify their contribution to 
the inflammation within the MS brain and particularly to determine their relationship with the 
presence of ectopic lymphoid-like follicles reported in the meninges of the progressive MS 
brain (Magliozzi et al., 2007). Interestingly, the concentration of CXCL13, the ligand for 
CXCR5, has been reported to be significantly increased in patients with RRMS, PPMS and 
SPMS (Sellebjerg et al., 2009) suggestive that this chemokine axis is also central for the 
entry of B and T lymphocytes in the meninges and possibly for their organization in clusters 
showing the features of ectopic lymphoid follicles. 
I also reported the presence of CXCL12 in the lumen of meningeal blood vessels together 
with a spatially associated lymphocytic infiltration and cortical demyelination suggestive that 
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CXCR4 bearing lymphocytes could cross the BBB and entry into the meninges of the MS 
brain owing to this interaction. This observation is in agreement with a previous report 
showing the redistribution of CXCL12 from the perivascular to the luminal space also in WM 
lesion blood vessels (McCandless et al., 2008a). Within the CNS the expression patterns of 
CXCL12 and CXCR4 are widespread and include the cortex, the cerebellum, the meninges 
and the endothelium of the BBB. In addition, CXCR4 expression, which I reported expressed 
in GM lesions parenchyma, has been detected in various cellular types such as astrocytes, 
microglia, oligodendrocytes, neurons and endothelial cells of BBB (Jazin et al., 1997, 
McGrath et al., 1999, Krumbholz et al., 2006) where its co-expression with CXCL12 could 
also indicate a potential positive feedback mechanism.  
It has been shown that CXCL12 can also bind the receptor CXCR7 (Balabanian et al., 2005, 
Burns et al., 2006) which has been found expressed on the surface of B cells (Infantino et 
al., 2006, Sierro et al., 2007) and in CNS microvasculature of rat brain (Schonemeier et al., 
2008a, Schonemeier et al., 2008b). More recently, an EAE experiment has shown that 
CXCR7 scavenges CXCL12 and that this is an essential step for leukocyte entry via 
endothelial barriers. In addition, treatment with a CXCR7 antagonist ameliorated EAE, 
reduced leukocytes infiltration in the parenchyma and increased abluminal levels of CXCL12 
(Cruz-Orengo et al., 2011). It would be of interest to investigate the localization and/or the 
expression of CXCR7 in the inflamed CNS, in particular in WM and meningeal blood 
vessels, to verify the possibility of its involvement in leukocytes entry to the MS brain. On the 
basis of our observation, CXCL12 and its receptors are suggested as possible therapeutical 
target for MS. 
7.3.3 The proportions of lymphocytes subsets infiltrating perivascular 
spaces in WM and the meninges are similar in the MS brain 
My characterization of lymphocyte subsets forming meningeal and white matter perivascular 
inflammation revealed that the contribution of all the immune subsets to inflammatory 
infiltrates was similar between the two compartments. The only exception were MAIT cells 
which were more prevalent in the white matter, although it must be kept in consideration that 
their quantification was performed only on 9 MS cases instead of 21 cases. Furthermore 
cases with high meningeal inflammation always had florid lymphocytic extravasates in white 
matter lesions. This observation is in keeping with other MS pathology studies that have 
reported the correspondence of the levels of inflammation in the meninges and white matter 
perivascular spaces (Guseo and Jellinger, 1975, Howell et al., 2011). This evidence is 
indicating that the (re)activation of the immune response in the two compartments is not 
independent and that, although in different anatomical locations, the relative contribution of 
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different lymphoctyes subset corresponds. In regard to a relationship between immune cells 
in the meninges and in WM parenchyma, there is evidence that the same B cell clones are 
shared between the two (Lovato et al., 2011) and that common T cell clones can be found in 
multiple sites of the brain (Junker et al., 2007), suggesting that CSF flow through the 
meninges might play a role in their infiltration to different anatomical locations. Together with 
the finding of ectopic B cell follicles in the MS meninges (Magliozzi et al., 2007), these 
evidences seem to indicate that B cell maturation and T cells reactivation take place in this 
CNS compartment and then different clones migrate into the white matter first through 
systemic circulation and then extravasating at sites where the BBB is impaired and/or 
activated. Further investigations could be directed to the comparison of T cell clones in the 
meninges and in white matter lesions to verify and possibly confirming the observation on B 
cells. Even if I tried to perform such an experiment, the limitations in the molecular biology 
approach I had chosen could not be overcome in a reasonable time to collect enough 
significant data. 
Taken together with the hypothesis of the diffusion of pro inflammatory signals from the 
meninges to the cortical parenchyma, and the observation of lesions seemingly extending 
from the cortex to the white matter, the corresponding level of immune cells infiltrates in the 
meninges and in white matter could be interpreted as an evidence of an immunological link 
between these two apparently separated compartments. In this regard I hypothesize that the 
initial reactivation of immune cells in the meninges induces a “wave” of inflammation first to 
the cortical parenchyma that then diffuses to white matter inducing microglia activation, 
which in turn can trigger the endothelium of white matter blood vessels to up-regulate 
adhesion molecules allowing the infiltration of the effector B and T cells previously 
reactivated in the meninges.  My observations indicate the possibility that this is the 
sequence of immunopathological events in the MS brain although the limitations of our 
analysis on post mortem MS brain must be kept in consideration. This hypothesis would 
require further investigation using animal models to verify whether in immune cell 
reactivation within the meninges could trigger the formation of early cortical demyelination 
and, as a consequence, trigger the entry of further effector cells from the systemic blood flow 
to the CNS. 
7.4 The role of meningeal inflammation in disease 
progression  
My observations linked the presence of pro inflammatory immune cell subsets in the 
meninges with severe cortical pathology and disease progression by showing that meningeal 
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inflammation correlates with both of them. This implies that the neuropathological basis of 
MS disease progression could lie in the relationship between meningeal inflammation and 
grey matter pathology (Reynolds et al., 2011). Considering that my pathology observations 
describe a snapshot reflecting the final stages of the disease, their correlation with the 
clinical course allows us only in part to argue about the mechanisms of tissue damage 
accumulation over time. However, based on the assumptions that the initial activation of 
autoreactive immune cells takes places in the meninges and that later in the disease the 
immunologically specialized CNS is permissive for the development of a compartmentalized 
chronic immune response, I could hypothesize that the watershed between the relapsing-
remitting and the progressive phase is marked by two different and partially independent 
immunopathological mechanisms: an earlier one, characterized by acute inflammatory 
attacks to grey and white matter discrete locations, which would reflect the specificity of the 
neurological dysfunctions, and a later one characterized by a gradual and irreversible 
increase of meningeal inflammation driving the accumulation of widespread cortical damage, 
which would reflect the overall clinical progression. At the same time during this later phase, 
as no new inflammatory white matter lesions form, the activated effector cells from the 
periphery enter the CNS parenchyma where previous white matter lesions have determined 
a breach in the BBB.  I hypothesize that two possibly concurring events to the disease 
clinical turning point around the age of forty years (Confavreux et al., 2000, Scalfari et al., 
2010) could be: the failure to repair the damage done and the progressive 
neurodegeneration that in MS appears always to occur on a background of tissue 
inflammation. 
7.4.1 Detrimental impact of meningeal inflammation on the MS 
clinical course 
The survival curves comparing cases with high versus low meningeal inflammation for 
disease milestones such as, age at onset, age at wheel chair, time from wheelchair to death, 
age at death and disease duration, revealed a trend of the cases with high meningeal 
inflammation to reach all these disease time points faster. In particular it is the age at death 
the measure that almost reaches statistical significance in accordance with previous analysis 
showing that in general a shorter duration of illness is associated with severity of 
inflammatory infiltrates in the meninges (Guseo and Jellinger, 1975, Howell et al., 2011). 
These findings are supportive of the idea that an increased intensity of the pro-inflammatory 
environment within the meninges is linked with an earlier progression to death in the final 
stage of the disease. 
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7.4.2 The extent of white matter lesions correlates with disease 
progression more than cortical lesion load 
When I tested the correlation between lesion load in white and grey matter with disease 
progression milestones I found that all of them, except age at onset and time from 
wheelchair to death, negatively correlated with WML, but not with GML. This data suggest 
an association between disease progression and white matter pathology rather than with 
grey matter one as I would have expected. However, there is now wide agreement that MS 
progression depends on accumulated axon degeneration and in order to provide a broader 
and more comprehensive account of the disease pathogenesis the relative contribution of 
acute and chronic axonal loss, together with their dependence on inflammatory processes 
within the CNS, must kept in consideration (Compston and Coles, 2008). Although I did not 
investigate these aspects of the MS pathology in our cases, it has been observed that the 
presence of diffuse pathological changes and tissue damage unrelated to focal WM lesions, 
such as in normal appearing white matter as well as a more severe cortical pathology 
(Kutzelnigg et al., 2005, Frischer et al., 2009), are also likely to play an important role in the 
accumulation of motor, sensory and cognitive impairment characteristic of progressive MS 
(Reynolds et al., 2011). It has been shown that in white matter it is axonal loss that 
correlates with parenchymal inflammation, such as CD8+T cells and macrophages, and 
demyelination (Bitsch et al., 2000). In addition, axonal injury within inactive white matter 
lesions correlates well with the degree of residual inflammation and also of microglia 
activation (Kornek et al., 2000) 
In agreement with this, my findings did not reveal a correlation between inflammatory 
infiltrates and demyelination in WM, but a correlation of the latter with disease progression. 
This supports that axonal loss together with demyelination in white matter might be the 
substrate for progression. Further investigation in MS pathology could be aimed at a global 
quantification of axonal loss analyzing in parallel WM and spinal cord to test if this measure, 
rather than demyelination alone, could reflect more closely the severity of disease 
progression. In fact, axonal damage and loss, clinically presenting as neurodegeneration, 
might be more related to the effect of multiple lesions along the neuraxis by means of 
Wallerian and retrograde degeneration (Lassmann, 2009). In order to verify this possibility 
further studies should aimed at verifying the possible correlation between axonal loss in WM 
and neuronal loss in GM with clinical progression.  
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7.4.3 B and T cell subsets in the meninges correlate with an earlier 
age at death 
Interestingly all the immune cell subsets I quantified in the meninges negatively correlated 
with the age at death with the exception of CD8+CD161+ cells which instead almost reached 
statistical significance in the correlation with the time from wheelchair to death. Notably the 
strength of linear correlation was higher for CD3+T cells than for CD20+ B cells, and among 
CD3+ T cells it was stronger for CD8+ T cells than for CD4+ T cells. Taken together these 
observations indicate that meningeal inflammation plays an important role in driving disease 
progression and that it might particularly affect its later stages. This is observation is in 
keeping with the emerging hypothesis that during MS clinical course, the formation of GM 
and WM lesions might relate to different pathological mechanisms. I might in fact speculate 
that, on the basis of MRI studies showing lack of new gadolinium-enhanced focal lesion in 
white matter during progression, during progression GM pathology could accumulate 
independently from white matter lesions. If this was the case then, also the diffuse 
pathological changes occurring in normal appearing white matter could be explained by the 
presence of neurodegeneration affecting in general the whole cortex. In support of this 
hypothesis our findings have first linked together the presence of meningeal inflammation 
with an extensive cortical demyelination and then showed that the density of B and T cells 
subsets in the meninges negatively correlated with age at death, therefore implying that an 
increasingly secluded immune response in this compartment could drive a more severe 
accumulation of GM demyelination in particular during the last stages of progression.   
7.5 Final conclusions 
The work presented in this thesis contributed to a detailed characterization of the immune 
cell subsets forming meningeal inflammation. The assessment of the relationship between 
this pathological finding and cortical pathology revealed that the presence of pro-
inflammatory CD161 expressing lymphocytes is linked with a more severe microglial 
activation and GM demyelination. Furthermore I showed that the density of meningeal 
inflammation can affect the later stages of disease progression. These findings support my 
hypothesis of a detrimental role of meningeal inflammation in cortical pathology during the 
progressive phase of the disease. Taken together these evidences suggest considering the 
development of new therapeutical strategies to treat progressive MS by targeting the 
immune response occurring within the meninges. 
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